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Introduction
Acute lower respiratory tract infections (LRTI), including pneumonia and bronchiolitis, 
are the leading cause of childhood hospitalisation and mortality in children between 
two months and five years of age.1-3 The burden of LRTI is high especially in developing 
countries. One of the millennium goals was to reduce under-five mortality by raising 
political awareness, implementation of health care programs, expanding vaccine 
coverage, improve healthcare systems, and focus on sociodemograpic factors.1,4 
These, and other actions resulted in more than 50% reduction in deaths between 1990 
and 2015. Despite this achievement, it has however been estimated that LRTI still 
causes 1.4-2 million deaths each year and remains the major reason for childhood 
hospitalization.1,5 Well known bacterial pathogens causing LRTI in children include 
Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus and 
Bordetella pertussis. The incidence of bacterial LRTI has substantially decreased as a 
result of vaccination programs. However, studies using multiplex PCR techniques show 
that most cases of LRTI are caused by viruses, especially in children under five years of 
age. Jain et al. reported that 1472 (66%) of 2222 children with a radiologically confirmed 
community acquired pneumonia had a viral infection, whereas only 175 (8%) of the 
children had a confirmed bacterial infection.6 Similar findings were recently published 
by Berg et al. in a cohort of patients with a high coverage of pneumococcal vaccination.7 
The most commonly detected virus is respiratory syncytial virus (RSV) followed by 
rhinovirus, human metapneumovirus, parainfluenza virus and influenza virus. The two 
recent studies of Jain et al. and Berg et al. highlight the importance of viral LRTI in 
children and the need for a better understanding of the pathophysiology of these 
infections in order to develop improved treatment strategies. This thesis presents epi-
demiological, diagnostic, clinical and laboratory (translational) studies on childhood 
infections by two major respiratory viruses: RSV and influenza virus. 
Influenza virus
Influenza virus can cause severe respiratory disease in young children under 5 years of 
age. Influenza increases the risk of hospitalization in this age group (<5 years of age) 
12-fold compared to the risk in children aged 5-17 years. 8 Although respiratory 
symptoms form the most important clinical presentation of influenza infections, 
influenza is also associated with muscle pain, malaise and neurological symptoms. 
Additionally, gastro-intestinal symptoms are often seen in children.9,10 The exact burden 
of disease caused by influenza is difficult to estimate, since influenza causes a broad 
range of clinical symptoms and seasonal outbreaks overlap with those of other 
respiratory viruses such as RSV. In addition, viral testing is not routinely performed. 9,11,12 
Most children have encountered influenza A virus before the age of 6 years. 13,14 Average 
hospitalization rates in children are 0.4-1.5/100,000 (95% CI 0.2-1.9). However, in 
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children younger than 6 months the hospitalization rate can be as high as 100/100,000, 
whereas emergency room visits vary from 6-27 per 1000 children (95% CI 4-33).9 
Healthcare costs, morbidity and mortality caused by influenza can be reduced by 
vaccination. Circulating influenza strains change rapidly during replication, which is 
called ‘antigenic drift’. When adaptations in the hemagglutinin gene accumulate, the 
virus is no longer recognised by the human immune system.15 This allows the virus to 
evade the antibody response raised by vaccinations and by previous exposure to 
influenza leading to re-infection. Every year, minor changes in the hemagglutinin and 
neuraminidase genes of influenza virus are analysed to determine the vaccine 
composition of the following year. When the seasonal prediction of the genetic makeup 
of the virus is correct, vaccines are effective and protective.16-19 Three different vaccine 
types are currently available for children: a live attenuated influenza vaccine (LAIV) and 
a trivalent or quadrivalent inactivated influenza vaccine (TIV or QIV). Unfortunately, there 
are no vaccines available for children under 6 months of age, the age group with the 
highest risk for severe disease. There is an ongoing discussion on the vaccination 
strategy against influenza in children. Most European countries, including The Netherlands, 
use a risk group based approach.20 However, risk groups are not well defined and data 
are often extrapolated from adult studies and not confirmed in studies in children. 
Moreover, a substantial proportion of hospitalized infants with influenza was previously 
healthy.21 Currently a growing number of countries switched to vaccination of all 
(healthy) children to protect the population as a whole via herd immunity, and decrease 
the burden of disease on the healthcare system.22,23 In the USA, Canada and England 
the ACIP, NACI and JCVI advise to vaccinate all children.24-26 Finland, Austria, Switzerland, 
Malta, Slovenia, Slovakia, Poland, Estonia and Latvia recommend seasonal influenza 
vaccination for healthy children, although they differ in their selection of age categories.20 
In countries which recommend vaccination, the coverage among both healthy children 
and patients with an underlying condition remains low. For instance in the US 85% of 
the population is advised to be vaccinated. However, in practice only 50% of high risk 
patients is vaccinated and 27-45% of all children is completely vaccinated.27,28 In the 
Netherlands only risk groups are vaccinated with a vaccine uptake between 52-70% in 
the at risk population.20 
Respiratory Syncytial virus 
Respiratory Syncytial virus (RSV) is the most frequently detected virus in children with 
LRTI 29 and in those requiring hospitalisation.30 Infection usually starts as a common 
cold, but approximately 1/3 of patients will develop a lower respiratory tract infection 
with difficulties in breathing (nasal flaring, thoracic retractions, tachypnea, hypoxia) and 
feeding problems in the youngest.31 By the age of 1 year 65% of infants have been 
infected with RSV of which 2-3% needs hospitalisation.32 At the age of 2 years virtually 
all children have at least encountered RSV once.33 Annual hospitalisation rates are 
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25-40 per 1000 infants in children under 1 year of age and 1.8 per 1000 children aged 
1-5 year.34 The course of disease of RSV in young infants is unpredictable. Patients can 
quickly deteriorate from mildly ill to becoming respiratory insufficient. This leads to 
frequent hospitalisation in very young infants for observational purposes. Risk factors 
for severe disease can be classified as virus specific, environmental and host specific.31 
RSV has adapted to the human host and evades and alters the immune responses 
resulting in an insufficient induction of long lasting immunity. In a recent meta-analysis 
Shi et al. confirmed the presence of previously well known environmental and host 
specific risk factors for the development of severe disease such as prematurity, low 
birth weight, siblings, maternal smoking, history of atopy, no breastfeeding, crowding 
and being male.35 Age is considered the most important risk factor. This is a 
consequence of a more immature immune system, smaller airways and less energy 
levels combined with less effective coughing in young children.36 Host specific risk 
factors include chronic diseases such as congenital heart or lung disease, which 
diminish an adequate broad immune response to RSV infection. Patients with immuno-
deficiency defects in either innate or adaptive immunity also have an increased risk for 
(severe) infection.36 However, more than half of the patients admitted to the ICU with 
severe RSV disease was previously healthy.31,37 Several investigators have tried to 
develop clinical prediction rules (CPRs) for children with RSV infections or bronchiolitis. 
These CPRs have different outcomes such as safe discharge from the emergency 
room, need for hospital admission or the prediction of the need for ICU admission. 
More than a hundred clinical prediction rules for children have been published but only 
few are used in clinical practice.38 Maquire et al. and Ferrero et al. discuss the reasons 
why CPRs for children are not used in daily practise. First of all, many prediction rules 
use subjective criteria resulting in a large inter-observer variability. Validation of 
prediction rules in children is more difficult than in adults due to the relatively small 
numbers of affected children and rare outcomes. Moreover, many clinicians seem to 
expect a 100% outcome, whilst CPRs are only used as a tool to improve clinical decision 
making and increase the sensitivity of clinical judgement.38,39 Validated CPRs are 
available for children with meningitis and pneumonia. These decrease the use of 
unnecessary antibiotics with 52 and 55.6%, respectively. 40-43 Validation of CPRs for 
RSV is often missing, or appears problematic due to subjective criteria.44,45 
To date, it is not known how immune responses against RSV develop in time and where 
in this process the course of disease is being determined. However, the early innate 
immune response is thought to play a major role in the pathogenesis.36,46 Severe 
bronchiolitis is associated with airway obstruction caused by sloughing and apoptosis 
of airway epithelium, oedema of bronchioli, mucus production and infiltration of the 
airways with neutrophils and lymphocytes.47,48 RSV has cytopathic effects, but the 
immune response is also thought to play an important role in the pathogenesis.46,48 It 
remains a challenge to study the course of disease in these very young children, 
especially since the site of infection (the lungs) is difficult to sample. Alternatively, more 
research is necessary to study the inflammatory response at the level of the nasal 
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mucosa. The nasal mucosa forms the initial site of infection, and may therefore also be 
a factor to influence disease severity. In the last decade new techniques emerged to 
study the host response during infection. These allow to make a differentiation between 
viral and bacterial infections by a characterization of the transcriptional (RNA) host 
response against these pathogens.49-51 This response appears to be so specific that it 
even allows identification of the individual pathogen causing the disease. Mejias et al. 
successfully explored the use of host transcriptome analysis to develop a scoring 
system for severity of disease called the molecular distance to health.52 
We conducted and describe in this thesis an observational cohort study, called Venturius, 
within the Virgo-consortium (www.virgo.nl). In this study we compared patients with 
mild disease (no need for supplemental oxygen) admitted for observation or sent home 
after emergency department visit with patients admitted to the hospital with moderate 
disease (need for supplemental oxygen) and with severe disease (need for mechanical 
ventilation on the ICU). The study design is depicted in figure 1.
Figure 1.1 Study design Venturius study. Patients presenting at the emergency room from one 
of the two hospitals in Nijmegen with signs and symptoms of a viral RTI were asked to participate 
in this study. After parental consent was obtained samples (6 ml blood, nasopharyngeal aspirate 
and saliva) were collected within 24 hours after presentation in the hospital. The children were 
retrospectively allocated to one of three severity groups. Patients admitted to the ICU from the 
Radboud university medical center in Nijmegen or the Sophia Children’s Hospital in Rotterdam 
were also asked to participate and were included within 24 hours after admission. Recovery 
samples were taken after 4-6 weeks. A healthy control group consisted of healthy infants who 
needed surgery.
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Aim of this thesis
The aim of this thesis is to identify risk factors and immunological determinants that are 
important in the development of severe viral respiratory tract infections in young infants.
Objectives of this thesis
- To identify risk groups for a severe course of influenza infection in children. 
- To discover and study biomarkers that reflect the course of disease and provide 
insight in the pathophysiology of RSV infections. 
- To explore factors at the nasal mucosa that influence the immune response against 
RSV. 
Outline of the thesis 
In the first part of this thesis we focus on the emergence of pandemic H1N1 influenza 
virus. Many new viruses have been discovered in clinical specimens since the 
introduction of molecular techniques to identify nucleic acid sequences of viral DNA or 
RNA. In Chapter 2 the clinical features of novel respiratory viruses including the H1N1 
virus, which emerged during the last decade are described. pH1N1 caused a major 
outbreak in The Netherlands In the respiratory season of 2009-2010. A description of 
the first children hospitalized with pH1N1 in two Dutch hospitals is presented in Chapter 3. 
During this pandemic, influenza vaccination was recommended for all children and 
pregnant women. This resulted in a public debate on the benefits of influenza vaccination 
and the scientific, economical and ethical grounds on which this decision was made. In 
Chapter 4 we studied the course of disease of influenza infection in a nationwide 
retrospective study on the clinical characteristics of hospitalized children. In this study 
we focused on the risk factors of severe disease. In Chapter 5 the arguments in favor 
of routine influenza vaccination for children are weighed against the criteria to introduce 
a new vaccine into the Dutch national immunization program.
The second part of this thesis describes studies on infections by the respiratory 
syncytial virus. Because the course of disease is difficult to predict in young infants 
with a RSV infection, there is a need to detect novel plasma or mucosal markers for 
severe disease. In Chapters 6 and 7 inflammatory proteins were measured in the 
plasma of children with RSV infection and levels were correlated with disease severity. 
In severe bacterial infections and sepsis, the expression of surface markers on 
circulating leukocytes is correlated with disease severity and immune paralysis. These 
markers have not yet been tested in children with RSV infections. In Chapter 8 we 
studied the expression of surface markers on circulating monocytes of patients with 
non severe or severe RSV infections and compared the data with those from cells 
derived from recovered and healthy infants. Furthermore, we tested the effect of LPS on 
monocytes of these patients to establish the presence of immunoparalysis. Surface 
marker expression and protein production are partially regulated at the transcriptional 
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level. We therefore performed in Chapter 9 micro-array transcriptome studies on 
peripheral blood mononuclear cells of children with infections by RSV. In these 
experiments we wanted to find biomarkers for a severe course of disease. In Chapter 
10 we describe a transcriptome analysis performed on whole blood and used the data 
to further optimize the statistical methods in order to detect a combination of biomarkers 
to predict disease severity. In Chapter 11 a different analysis was used on the same 
data, based on modules associated with specific cell-type activation profiles. We 
intended to identify cell subset populations involved in the pathogenesis of severe RSV 
disease. In addition we used ‘distance to health’ measurements to predict disease 
severity. 
The last part of this thesis focuses on studies of nasal mucosal samples. The nasal 
mucosa is the primary site of initial RSV infection. We hypothesized that crucial steps in 
the development of and susceptibility for severe disease are initiated at the mucosal 
level. We first studied the host response by studying gene expression in cells derived 
from nasopharyngeal washes during infection. In addition, we investigated the 
composition of bacteria residing in the nasal cavity (microbiome) the level of maternal 
antibodies. In Chapter 12 we describe transcriptional markers, that reflect the level of 
disease severity. Presence and quantity of frequent colonizers of the respiratory 
mucosa was determined in the nasopharynx of children with and without RSV infection 
and correlated with inflammatory parameters and disease severity, as described in 
Chapter 13. Immunoglobulin levels present at the nasal mucosa were measured and 
these levels were correlated with the viral load and inflammatory proteins in the nose 
(Chapter 14). Finally, in Chapter 15 all studies are summarized, discussed in broader 
perspective and new ideas for future studies are proposed. 
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Abstract
Acute respiratory viral infections (ARVI’s) are the most common infectious disease in 
humans. With the appearance of molecular techniques the recovery of viruses has 
dramatically increased. Nowadays virologists can quickly discriminate virological 
families and related viruses from emerging viruses and consequently identify novel 
viruses. Many new respiratory viruses have been identified in children in the past 15 
years. In this review we shortly discuss novel respiratory viruses and their pathogenic 
role in pediatric respiratory disease. Advantages and drawbacks of the technique and 
our current knowledge will be discussed. We will conclude this review with a general 
discussion on the future role of molecular diagnostic virology in the clinic.
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Introduction
General (Respiratory Viruses in Pediatrics)
Acute respiratory viral infections (ARVI’s) are the most common infectious disease in 
humans. They occur more frequently in children than in adults (6.1 episodes per year 
under the age of 1, 3–6 episodes per year between the age of 1–5 and 2.4 episodes per 
year between the age of 15–19). Disease severity depends on age, underlying condition 
and type of virus. ARVIs account for huge numbers of doctor’s visits and days lost from 
work and school. They are a leading cause of global mortality and morbidity in children. 
Moreover, respiratory viral infections are an important driver of unnecessary usage of 
antibiotics. Unfortunately prevention and treatment of the majority of respiratory virus 
infections is not possible with the exception of influenza.1
Although much research has been done on the epidemiology and burden of viral 
respiratory tract infections the size of the problem is underestimated. Due to the lack of 
routine testing for (multiple) viruses and the limitation that a majority of infected patients 
will not visit a doctor.
General Introduction Molecular Techniques (Discovery Novel Viruses)
With the appearance of molecular techniques the recovery of viruses has dramatically 
increased. Before their use approximately 50–80% of the viral tests remained negative.2 
Due to the introduction of PCR and the discovery of novel viruses this proportion 
decreased to 3–15 %. However, such recovery rates are largely dependent on the 
selection of the patient group.3-5 The combination of high sensitivity, multiplex options 
and quantification was essential for some of the new insights in viral epidemiology. This 
could not have been achieved with conventional viral diagnostics such as culture and 
immunefluorescence assays (FDA).
The identification of respiratory viruses in a clinical context can also guide diagnostic 
and treatment strategies. Bonner et al. revealed that a known viral aetiology of disease 
results in decreased use of additional tests such as X-rays or blood examination, shorter 
hospital admission and less frequent use of antibiotics.6 However, molecular diagnostics 
have also created new dilemmas. For example, the identification of respiratory viruses in 
asymptomatic children, the occurrence of many viral co-infections, concerns about the 
pathogenic capacity of certain viruses and the value of quantitative measurements.
General Introduction on Emerging Viral Diseases
Some of the advantages of the new genetic (e.g. sequencing) and molecular techniques 
became clear during outbreaks of novel emerging viruses. Emerging viruses can be 
classified as (1) previously unknown viruses or (2) previously known viruses that have 
significantly increased in incidence.7 Nowadays virologists can quickly discriminate 
virological families and related viruses from emerging viruses and consequently identify 
novel viruses.
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The introduction of molecular diagnostics in medical virology has led to the identification 
of many new respiratory viruses in children in the past 15 years (Table 2.1). However, the 
pathogenicity of these viruses is not always clear and the clinical relevance is often 
poorly understood. Fredricks and Relman proposed seven rules which are necessary 
to demonstrate the causative relationship between a virus and disease. These rules are 
based on Koch’s postulates and were adapted for nucleic acid based detection methods, 
location of the pathogen and quantification (Table 2.2).8,9 These rules can help to interpret 
research on the role of novel respiratory viruses in disease and guide future research. It 
should also be stated that the clinical relevance is in some cases apparent, without 
extensive research to fulfil all requirements.
In this review we briefly discuss novel respiratory viruses and their pathogenic role in 
pediatric respiratory disease. We will conclude this review with general discussion on 
the future role of molecular diagnostic virology in the clinic.
Henipavirus (1994–1998)
Hendra Virus
The Hendra virus was first detected in a disease outbreak in 1994. It initially presented 
with a new respiratory disease in horses that was transmitted to two persons one of 
them died.10 The virus belongs to the genus of Henipavirus within the family of the 
Paramyxoviridae family. It was initially named morbillivirus and later renamed Hendra 
virus (HeV) after the suburb where the outbreak occurred.11,12 The virus itself is not very 
contagious. It spreads through direct contact between horses or during intensive 
contact between humans and severely ill horses. The animal reservoir appears to be 
the Flying-fox, in this population the Hendra infection is largely subclinical. The breading 
Table 2.1 Emerging viruses from the last 2 decades
Family Virus Year of discovery
Hendra-/NipahV Paramyxovirus 1995
AIV’s Influenza virus 1997
hMPV Paramyxovirus 2001
SARS-CoV Coronavirus 2003
HCoV-NL63 Coronavirus 2004
HCoV-HKU1 Coronavirus 2005
HBoV Parvovirus 2005
HPeV4 Parechovirus 2006
HPeV5 Parechovirus 2006
HPeV6 Parechovirus 2007
KIV/WUV Polyomavirus 2007
H1N1V Influenza virus 2009
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season of Flying-foxes is a risk period for spread and the human risk group is defined 
as people with close and intensive contact with horses. Up till now fourteen outbreaks 
have been reported. 13 In five of these outbreaks humans were involved, resulting in five 
deaths. So far, only two persons survived an infection.
The case fatality rate (CFR) is over 50 %.13 HeV in humans causes, after an incubation 
period of 5–21 days, a severe influenza like disease (fever, myalgia and headache) 
which can progress to pneumonia, respiratory failure and death.10,14 An infection can 
also result in encephalitis with headache, fever and drowsiness. The encephalitis can 
occur after initial recovery from the illness. The Hendra virus genome is readily detected 
in several materials, e.g. blood, urine, nasal- and oropharyngeal swabs by RT-PCR. 
Next to this standard detection method the virus can be cultured in several cell lines, 
where it forms syncytia upon infection. ELISA serological tests are used for screening, 
however their diagnostic sensitivity is not yet established. Immuno fluorescense assays 
and serum neutralization methods can also be used.13,15
Nipah Virus
In 1998 and 1999 two large outbreaks of respiratory disease in pigs and humans 
occurred. In Malaysia and Singapore 106 people died.16 The causative agent had large 
similarities to the HeV and is the second member of the genus of Henipavirus within the 
Paramyxoviridae family. It was named Nipah virus (NiV) after the location of the first 
Table 2.2 Koch’s postulates adapted for viral infections 8,9
A nucleic acid sequence belonging to a putative pathogen should be present in most cases  
of an infectious disease. Microbial nucleic acids should be found preferentially in those organs 
or gross anatomic sites known to be diseased, and not in those organs that lack pathology
Fewer, or no, copy numbers of pathogen-associated nucleic acid sequences should occur in 
hosts or tissues without disease
With resolution of disease, the copy number of pathogen-associated nucleic acid sequences 
should decrease or become undetectable. With clinical relapse, the opposite should occur
When sequence detection predates disease, or sequence copy number correlates with 
severity of disease or pathology, the sequence-disease association is more likely to be a 
causal relationship
The nature of the microorganism inferred from the available sequence should be consistent 
with the known biological characteristics of that group of organisms
Tissue-sequence correlates should be sought at the cellular level: efforts should be made to 
demonstrate specific in situ hybridization of microbial sequence to areas of tissue pathology 
and to visible microorganisms or to areas where microorganisms are presumed to be located
These sequence-based forms of evidence for microbial causation should be reproducible
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human case.17 This virus had already caused respiratory disease in pigs until late 1996. 
Like HeV it shares the bat as a natural reservoir. NiV virus is very contagious among 
pigs and spreads through the respiratory route or directly by the transport of infected 
pigs. Initially humans became infected via direct contact with pigs, although food borne 
transmissions were also reported. Initially the case fatality rate was 38.5 %.14,18 Since the 
initial outbreak almost yearly new outbreaks emerged in Bangladesh and India causing 
fatal encephalitis in humans. Notably, the CFR’s of these outbreaks increased to 92 %. 
Also the transmission changed: starting from pigs, soon cows could transmit the virus. 
Later human to human and nosocomial transmission was demonstrated.19-21 It has been 
hypothesized that there were multiple introductions of viruses in the human population, 
explaining the unique genetic signature of isolated viruses nowadays.18 These genetic 
differences may be the reason for the increase in CFR and differences in clinical 
manifestations and transmission. The clinical manifestation of a Nipah infection differed 
per outbreak. Incubation periods differ from an average of 2 weeks in Malaysia to 
1 week in Bangladesh. The infection can be asymptomatic, but often starts with 
influenza-like symptoms of fever, headache, myalgia, vomiting and sore throat. Patients 
can recover or develop signs of encephalitis or sometimes atypical pneumonia or acute 
respiratory distress. In severe cases the encephalitis includes the brain stem or 
progresses to a coma within 24–48 h.18,19,22 Around 20% of the cases are left with 
residual neurological symptoms, including personality changes. In comparison with 
outbreaks in Malaysia and Singapore the Bangladesh and Indian patients experienced 
more profound respiratory symptoms with case rates of 14, 27, 70 and 51 %, 
respectively.19 A Nipah infection can be diagnosed in serum urine and cerebrospinal 
fluid (CSF) by RT-PCR.23 Also culture in cell-lines, ELISA for anti-HeV IgG and IgM in 
serum and CSF, serum neutralization assays or immunofluorescence assays are 
used.18,19,24,25
Patients with both Hendra and Nipah virus infections are treated supportive, antiviral 
therapy is not effective.22 Prevention is based on careful hygiene, quarantine and safe 
disposal of animal carcasses.13,14 Currently, there are no vaccines available. However, 
several therapeutic agents seem effective in vitro and in some animal models .18
Avian Influenza Virus (1997)
The first cases of avian influenza virus (AIV) infection were reported in 1997 in 
Honk-Kong.26 This influenza A (H5H1) originated completely from strains circulating in 
wild birds and poultry.27 The avian influenza virus undergoes rapid genetic and antigenic 
evolution reflected by the occurrence of different clades with distinct phenotypes.28,29 
The majority of human cases had direct contact with poultry or could be related to 
outbreaks in wild birds.20 There is limited transmission from human to human, although 
some epidemiological studies suggest it is possible.30 The median age of patients is 
around 18 years and the mortality rate is extremely high between the age of 10 and 19 
years (61 %). Yearly H5N1 outbreaks in humans have been reported in Asia, Africa and 
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Eurasia.31 These epidemics are all related to outbreaks of avian influenza in wild birds 
or poultry during the colder seasons.32,33 The incubation period of H5N1 is estimated to 
be 2–7 days.34 The disease typically manifests as a severe pneumonia which often 
progresses to respiratory failure and death within 10 days (case fatality rate up to 90 % 
in children). It appears that in children cases may occur without pneumonia. Detection 
of viral RNA by (RT-) PCR is the best method for the diagnosis of H5N1, preferably using 
throat swabs.35 Because of genetic variably of the virus, primers need to up-dated 
frequently. The available immune-assays for detection of H5N1 are not sensitive enough 
for clinical purposes and cannot differentiate between human and avian subtypes of 
influenza A. Seroconversion after 2–3 weeks can be used to confirm H5N1 infection 
and can be used for epidemiological studies.35 Early treatment with oseltamivir is 
recommended based on some evidence that it increase survival rates.36 There are 
differences in susceptibility to oseltamivir between the different clades of H5N1 
circulating in different parts of the world. Combination of oseltamivir with amantidine 
can be given if the circulating H5N1 is susceptible to both agents. Currently, it is possible 
to produce vaccines that inactivate H5 influenza A strains. However due to the circulation 
of different clades and the rapidly changing antigenicity of H5N1 the need for the 
development of a new vaccine remains.34,37
Metapneumovirus (2001)
The human metapneumovirus (hMPV) was first discovered in the Netherlands in 2001 
from a databank of samples from children with respiratory tract infections.38 hMPV 
belongs to the genus metapneumovirus within the family of Paramyxoviridae. It is related 
to respiratory syncytial virus, both belonging to the pneumoviridae sub-family.
In both retrospective and prospective studies it has been shown that hMPV can be 
detected in 3.9–14.8 % of respiratory samples from children with respiratory disease.39 
This wide range reflects differences in the tested populations and the level of care. Co- 
infections with other viruses occur in 15–30 %.40-42 hMPV is detected in up to 4 % of 
nasopharyngeal aspirates from healthy children, although percentages of less than 1 % 
are also frequently published.43 Serological studies showed that all children by the age 
of 5 years had been in contact with the virus and that it has been circulating in the 
human population for over 50 years.38 It has a seasonal occurrence with a peak 
incidence just after the influenza and RSV season.43 Spread is thought to be via direct 
or close contact with respiratory secretions from an infected person with an incubation 
period of 3–5 days. Reinfections occur frequently in children, although symptoms are 
less severe.44 Symptoms associated with hMPV infections are comparable with RSV 
(see Table 2.3) hMPV infections are, after RSV, the most frequent cause of bronchiolitis 
in young children and account for 5–15 % of all hospital admissions.45 Hospitalization 
rates are highest among 6–12 month old children, remarkably older than for RSV.46 
There is an association between severe hMPV infection (bronchiolitis) and the 
development of wheezing in childhood.47
Processed on: 1-3-2017
508516-L-bw-Ahout
30
Chapter 2
hMPV can only be cultured in specific cell lines under specific conditions and is time 
consuming; therefore it has no role in a clinical setting. Real time PCR is the most 
sensitive test for hMPV detection in NPA and swabs and is therefore the common 
method in clinical and research settings.48 RT-PCR also provides semi-quantitative 
information of the viral load (Ct value), which can be used to monitor treatment in a 
research setting.49 Immunofluorescence assays are available for rapid detection of the 
virus in respiratory specimens; however, these tests are less sensitive than RT-PCR. 
Serology for hMPV has little additive value in the clinic because most children are 
seropositive in early childhood. Currently no vaccines against hMPV are available, 
though several candidates are being pursued.45 Ribavirin, antiviral therapy, is effective 
in vitro against hMPV, though clinical data are sparce. Currently new therapies such as 
fusion inhibitors and siRNA’s are being tested in murine models.45
Coronavirus (2003–2005)
Human corona viruses related to respiratory disease, 229E and OC43, have been 
known since the 1930s. They were recognized as the second most common cause of 
the common cold in humans.50-52 A new strain of human coronavirus was identified in 
2004 from a respiratory sample of a 7 month old infant with bronchiolitis and named 
NL63 (HCoV-NL63).53 The HCoV-NL63 belongs to the genus Coronavirus within the 
family of Coronavidae. In retrospective cohort studies HCoV-NL63 have been identified 
in 1.7–9.3 % of respiratory samples from children with respiratory symptoms and occurs 
worldwide.39 The virus is often found in combination with other respiratory viruses (57 
Table 2.3 Symptoms and diagnosis of hMPV mono infections in literature
Symptoms/diagnosis Spread in literature (%) a 
Feverb 36-80
Cough 67-99
Rhinitis 72-90
Wheezing 10-73
Respiratory failure 8
Oxygen 90% 32-85
Pharyngitis 24-66
Bronchitis 1-68
Bronchiolitis 11-51
Pneumonia 3-65
Otitis media 16
a Heikkinen et al. 121; Aberle et al. 122; Mullins et al. 123; Chen et al. 124; Manoha et al. 125; Williams et al.126; Bosis et al. 127 
 b Different definitions varying from > 37.5 to > 39 °C
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%).54,55 Peak incidence is found in the winter months and the incubation period is 
estimated 2–5 days.56,57 HCoV-NL63 is associated with mild upper respiratory tract 
symptoms and less frequent with severe lower respiratory tract symptoms such as 
bronchiolitis.58 Some studies have reported an association with croup.55,59 HCoV-NL 
can be detected in respiratory specimens by RT-PCR which is the first choice for 
diagnosis. Immunoassays are available for rapid detection and distinction of different 
HCoV strains.60 Different cell-lines are permissive for viral culture and used in a research 
setting. Currently no anti-viral treatment against HCo-ViNL63 is available, although 
several inhibiting compounds have been identified.61
A second novel human coronavirus was identified in 2005 in a 71-year-old man with 
pneumonia in China and named HKU1 after the Hong Kong University where it was 
found.62 In a retrospective cohort studies the HCoV-HKU1 was identified in 1–3.1 % of 
respiratory samples in which no other virus was detected, from children with upper and 
lower respiratory symptoms with a higher incidence in children younger than 6 months.39 
The peak incidence of HCoV- HKU1 is in spring, early summer and winter with an 
incubation period of 2 days.63 HCoV- HKU1 is mainly associated with upper respiratory 
tract symptoms in children and occasionally with pneumonia and bronchiolitis.64 The 
first choice of assay for detection in respiratory specimens is RT-PCR. Coronaviruses 
exhibit substantial genetic variability hampering the development of pancorona primers 
and therefore specific primers for each strain have to be used.65 There is no specific 
anti-viral therapy available against HCoV-HKU1.
Human Bocavirus (2005)
Human bocavirus (HBoV) belongs to the genus Bocavirus within the family Parvoviridae 
(and is closely related to the bovine parvovirus and canine minute virus). This virus was 
identified in 2005 by nucleic acid amplification (PCR) in respiratory tract specimens 
from Swedish children with lower respiratory tract infections.66 In this study HBoV was 
detected in 3.1 % of hospitalized children below the age of three. Other studies detected 
HBoV in 3–19 % of children with respiratory symptoms depending on the sample type 
used (NPA and BAL higher, nasal swab lower) and the age of the patient (higher in 
younger children).67,68 However, HBoV is frequently found in asymptomatic children (up 
to 40 %) or in combination with other viruses (up to 80%) in symptomatic children.39 
Based on these findings it is still unclear whether HBoV has a pathogenic role in 
respiratory disease. One study performed in a PICU suggests that the viral load (high 
titres) of HBoV may indicate a pathogenic role in (severe) respiratory disease.69 HBoV 
has been associated with wheezing in asthmatic children.70 In general HBoV infection is 
marked by relatively mild symptoms of the upper respiratory tract such as cough, 
rhinorrhea and fever. In rare cases it has been associated with lower respiratory tract 
infection and even respiratory insufficiency.71 Detection of HBoV is by RT-PCR and the 
virus can be detected in respiratory as well as gastrointestinal specimens.72 Diagnostic 
seroresponses can be used to establish the specific immune response against HBoV 
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during infection, although the clinical relevance is unclear.73 HBoV can only be cultured 
on ciliated primary human epithelial cell-lines, and therefore viral isolation is only used 
in experimental settings.74 Treatment of HBoV infections is mainly supportive and no 
specific anti-viral treatment against HBoV is available. Currently there is not enough 
epidemiological evidence to drive vaccine development against HBoV.
Parechovirus (2006–2007)
Human parechoviruses (HPeVs) belong to the genus Parechovirus of the family 
Picornaviridae. The first HPeVs, serotype 1 and 2, were identified 50 years ago during a 
summer diarrhoea outbreak in American children.75 With the introduction of molecular 
techniques many new serotypes of HPeVs have been identified in the past 15 years in 
the stool or NPA of children with gastrointestinal and respiratory disease, and in the 
cerebrospinal RT-PCR is only available for HPeV1-3.87 Currently amplification and 
nucleotide sequencing is used to identify specific genotypes in a research fluid of 
children with meningitis and sepsis-like illness (see Table 2.4).76-79 Every HPeV serotype 
has its specific epidemiological and clinical features.
All HPeVs infections are very common in children under the age of 1 year and most data 
are available on HPeV1 and HPeV3.80 The median age of infection with HPeV1 is 6.6 
months, whereas HPeV3 infections occur at a younger age of 1.3 months. There is also 
seasonal variability in occurrence, HPeV1 in late summer and early winter season, and 
HBeV3 mostly in summer. HBeV serotype 5 and 6 have also been associated with 
respiratory tract symptoms.81-84
Most HPeVs have are common causes of asymptomatic infection in early childhood 
and are often found in combination with other viruses, so that the relation with respiratory 
disease is hard to establish.80 While the association of HPeV3 with encephalitis, 
meningitis and neonatal sepsis is widely accepted,85 for most other serotypes the 
relationship with disease and specific symptoms is less clear (see Table 2.4).86
A viral neutralisation assay or culture are time-consuming and not suitable for severe 
disease such as sepsis and meningitis. Detection by setting. The specific antibody 
response can be used to demonstrate involvement of HPeV in disease if the virus itself 
cannot be detected. No antiviral treatment against parechoviruses is currently available 
and only supportive care is given.
Polyomavirus (2007)
In 2007 two new members of the Polyomaviridae family were discovered in samples of 
patients with respiratory disease. The first of these new polyomaviruses was identified 
during a large scale molecular virus screening project in respiratory samples from 
children and named after the Karolisnka institute where it was discovered (KIV).88 The 
second was identified in a nasopharyngeal aspirate of a 3-year-old child with pneumonia 
and named Washington University virus (WUV).89 Seroprevalence studies show KI in 66 % 
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and WU in 79 % of paediatric sera.46,90 The virus has been detected in 1–5 % respiratory 
samples worldwide in respiratory samples of young symptomatic children.91-93 However, 
in 70–80 % of the cases there was a co- infection with other respiratory viruses, and KIV 
and WUV have been described in asymptomatic HSCT patients.94 Based on these 
results it is difficult to assign symptoms and pathogenicity to both of them and more 
epidemiological evidence is needed. In most studies the viruses have been associated 
with both upper and lower respiratory tract infections in children. Detection of WUV and 
KIV in respiratory samples can be undertaken by RT-PCR. Thus far there is no indication 
for treatment of either of these viruses nor vaccine development.
Influenza A H1N1 Virus (2009)
In late march 2009 a novel influenza A (H1N1) virus was identified in America. This virus 
was subsequently recognised as the cause of an outbreak of respiratory illness in 
Mexico.95 The novel flu virus showed reassortment of swine, avian and human strains, 
and appeared to be very infectious between humans.96
After the initial detection several other countries reported H1N1 infections. In June 2009 
the WHO declared a pandemic with spread over at least two continents. At the start of 
the pandemic the virus appeared to be very virulent with a high mortality rate, especially 
in young adults and children.97,98 However, in the Northern Hemisphere the virus 
behaved more like a seasonal influenza virus. H1N1 disease had the highest attack rate in 
young children causing relatively mild disease.99,100 The pH1N1 was able to outcompete the 
seasonal flu so that, in the influenza season 2009–2010, over 99 % of the influenza 
positive isolates in Europe and America were pandemic H1N1 influenza A.101
In general the symptoms resembled those of other winter viruses: fever, cough, sore 
throat, myalgia and headache. Symptoms at presentation for hospitalised patients are 
Table 2.4 HPeV, discovery and clinical associations
HPeV type Known since Clinical associations
HPeV1 1956 Mild gastrointestinal and respiratory symptoms, bronchiolitis, 
pneumonitis, otitis media.
HPeV2 1956 Mild gastrointestinal and respiratory symptoms, (rare) neonatal 
sepsis, meningitis, encephalitis
HpeV3 2004 Neonatal sepsis, meningitis,encephalitis (transient paralysis)
HPeV4 2006 Fever, mild gastrointestinal and respiratory symptoms
HPeV5 2006 Fever, mild gastrointestinal and respiratory symptoms  
(sepsis, Reye’s syndrome)
HPeV6 2007 Fever, mild gastrointestinal and respiratory symptoms  
(paralysis, Reye’s syndrome)
HPeV8 2009 Enteritis
HPeV10 2010 Gastro-enteritis
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shown in Table 2.5. Spread occurs up to 8 days after the start of symptoms, although 
this may be prolonged in the immunocompromised and children.102
H1N1 infection can be diagnosed by RT-PCR on respiratory samples and this appears 
to be the most sensitive method. In case of high suspicion of H1N1 infection with a 
negative PCR result, the virus can be cultured or infection proven by documenting 
seroconversion.103-105
During the pandemic of H1N1 were treated with oseltamivir (Tamiflu®) and zanamivir. 
This treatment reduced the duration of symptoms, the occurrence of otitis media and 
progression into severe disease, especially when administered early in the course of 
disease.106 Also the prophylactic use of anti viral agents is effective in reducing the 
occurrence of H1N1 infections in exposed individuals. However, oseltamivir and multi 
drug resistant viruses are emerging.107 In several countries children have been 
vaccinated.108,109 H1N1 vaccination induced an effective and long lasting humoral immune 
response.108-110 The vaccine seemed to reduce the risk of infection and decreased 
severity of disease in children, however because of the rapid spread of the H1N1 
pandemic most people were vaccinated during the pandemic making efficacy studies 
complex.111,112
Discussion on Molecular Diagnostics of Respiratory Viruses and 
Their Clinical Use
In this review we have discussed newly identified and emerging viruses from the past 
2 decades. These viruses could be subdivided in three categories, based on the 
evidence for their pathogenicity in respiratory disease in children. First, emerging 
viruses causing epidemics with high mortality, such as AIV, Hendra and Nipah virus, 
were clearly associated with a pathogenic role in disease. These epidemic-causing 
viruses are often of zoonotic origin (transmission from animals to humans). The second 
group comprises viruses that fulfil the modified Koch’s postulates.8,9 Most novel 
respiratory viruses are not completely characterised according to the postulates due to 
the extensive and costly research needed to achieve this. In this perspective hMPV is 
unique among the recently discovered respiratory viruses, because all criteria have 
Table 2.5  Symptoms of H1N1
Presentation Literaturea (%)
Fever (> 38 °C) 81–94
Cough 69–82
Gastro-intestinal symptoms 8–32
Rhinorrhea 31–62
Diarrhea 8–23
Wheezing 12–25
a Libster et al.97, Hackett et al. 128, Jain et al.129
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been fulfilled.38,113 Third are viruses that were found during screening for new respiratory 
viruses in respiratory samples with molecular techniques, such as human bocavirus, 
the novel polyomaviruses, parechoviruses and some coronaviruses.114 For most of 
these viruses their pathogenic role as an important respiratory pathogen is less clear. 
Although these viruses are present in respiratory samples of children with respiratory 
disease however, they are also often present in asymptomatic children or found in 
combination with other viruses. Many studies were performed retrospectively, or without 
the proper control cohorts of asymptomatic children. In epidemiological studies based 
on seroconversion it is apparent that a first encounter with these viruses occurs early in 
childhood without (severe) respiratory tract infections. Especially in this last category of 
viruses, in which the association with respiratory disease is less clear, large prospective 
epidemiological studies are needed to further specify the pathogenicity and health 
burden of these viruses in children.
The highly sensitive molecular techniques for identification and detection of novel 
viruses are a powerful tool for epidemiological studies, especially when used in 
multiplex platforms. Their ability to quantify the viral burden in infection may be used as 
additional information in determining the role of a virus in respiratory disease. For some 
viruses a positive correlation between viral load and disease severity is described.69 115 
However whether viral load correlates with disease severity in general remains a point 
of debate. Viral load appears to be lower in viral- viral co-infection compared to viral- 
mono-infections, the mechanism behind this and the clinical relevance requires further 
investigation.116,117 Studies show that viral load decreases during the course of disease, 
and this can be used as marker for the therapeutic effect of anti-viral compounds. 
A drawback of the high sensitivity of molecular diagnostics is that PCR signals remain 
positive after recovery from an illness, sometimes even for several weeks. Because 
young children have frequent viral infections of the upper respiratory tract, the value of 
a positive PCR test can be limited.
Interaction of viruses with bacteria present in the nasopharynx can result in enhanced 
disease severity. This is well known for influenza and Streptococcus pneumoniae, and 
other respiratory bacteria.118 How other (novel) respiratory viruses interact with bacteria 
and how this leads to enhanced disease is less well known. In studying the pathogenicity 
of viruses these interactions should be taken into account and implemented in new 
epidemiological studies. In this context ‘old’ viruses, like rhinovirus, can be seen in a 
new perspective and the causality with severe respiratory disease should be re-
evaluated.118-120
The introduction of molecular detection of viruses has led to the discovery of many new 
human respiratory viruses and improvement in diagnostics. Novel molecular techniques, 
like sequencing of the complete virome, will offer new insight in viral infections but also 
new challenges in proving causality in human disease.
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Abstract
A discrepancy has been noted in the severity of the clinical course of H1N1 infections 
between countries of the Northern and Southern Hemisphere. In this article, we retro-
spectively review our experience with respect to the clinical epidemiology of H1N1 
infections in children admitted to a our university hospital. The largest part of the 24 
admitted children with proven HiN1 infection was aged > 5 years (71%) and had a 
severe course of disease (47%). A remarkable high percentage of underlying diseases 
was noted in these hospitalized children (79%), with most frequent congenital heart 
disease, followed by chronic lung disease, malignancies and/or immunodeficiency. 
However, most acute life-threatening presentations of disease occurred in previously 
healthy children under the age of 3 years.
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Introduction
The new Influenza A (H1N1) virus caused an epidemic in the Netherlands from 23 
October till 24th of  2009.1,2 A pandemic of influenza A viruses can occur after an antigenic 
shift. Influenza viruses are recognised by the immune system by heir hemagglutinin (H) 
and neuraminidase (N) – antigen. Replacement of the influenza A antigen can occur 
when several influenza strains infect one single host. Such acute and large changes in 
the genomic backbone of the virus is called antigenic shift and mostly occurs in the H 
antigen. In June 2009 the World Health Organisation (WHO) declared the New Influenza 
A (H1N1) pandemic.3 After the initial identification of the novel Influenza A H1N1 virus in 
infected Mexican patients, the virus spread rapidly. Characteristic aspects of this 
pandemic were the fast spread of the virus and quick notifications on the course of 
infections in the Southern Hemisphere trough scientific reports and other media. The 
information from the Southern Hemisphere reached the Netherlands in the summer and 
raised many concerns. The National Institute for public health and the environment 
(RIVM) and the Ministry of health, welfare and Sport (VWS) introduced policy measures 
after consultation with national and international experts. In addition to public information 
and education to professional organizations, increased hygiene and isolation measures 
were introduced. In addition, large numbers of vaccines were purchased and guidelines 
were published on the use of Oseltamivir. Oseltamivir (Tamiflu) inhibits the action of 
neuraminidases and thereby influences the duration of illness.4-6 A recent meta-analysis 
on the use of neuraminidase inhibitors in children demonstrated that the use of 
Oseltamivir in children is safe.6 
The H1N1 vaccination campaign started on November 9th in Netherlands for predefined 
risk groups. The Health Council of the Netherlands advised to extend the vaccination 
campaign to children between 6 months and 5 years of age and to housemates of 
children less than half a year on 23 November 2009.1,2,7 It is now becoming clear that the 
H1N1 pandemic in the Southern Hemisphere resulted in a more severe course of 
disease than in the Northern Hemisphere.8-16 It is important to assess the morbidity and 
mortality as a result of the pandemic, especially since the clinical aspects of H1N1 
infections in children are still relatively unknown. This article describes the clinical 
epidemiology of H1N1 infections in children in a Dutch university medical center during 
the H1N1 outbreak in the autumn of 2009.
Patients and methods 
This is a retrospective study, although part of the information was prospectively 
collected. The demographic and clinical data (including medical history, vaccination 
status, course of disease and outcome) of 61 children from 0 to 18 years who were 
admitted with the suspicion of a H1N1 infection were gathered by means of a case 
report form (CRF). From all children a nasopharyngeal swab was obtained and tested 
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for the presence of H1N1 Influenza A virus by means of a ‘quantitative real-time reverse 
transcriptase polymerase chain reaction (RT-qPCR).17 Based on these results patients 
were divided into an H1N1-positive or-negative group. A further subdivision of these 
groups was based on severity of disease (mild, moderate and severe). Mild disease 
meant admission without need for supplemental oxygen therapy or tube feeding, patients 
with moderate disease needed supplemental oxygen or tube feeding and those with 
severe disease needed mechanical ventilation or died due to the H1N1 infection.
Results 
A total of 154 children with symptoms of flu (influenza-like-illness ) were tested for an 
Influenza A (H1N1) infection. Sixty-one children were admitted under the suspicion of a 
H1N1 infection. Of this group, 24 children (39%) tested positive for H1N1. Two children 
were not primarily admitted for the suspicion of an H1N1 infection. They were tested 
because of fever and respiratory complaints during pre-operative screening (n = 1) and 
during chemotherapy (n = 1). Demographic data and underlying conditions of the 
study populations are shown in Table 3.1. 
Two-thirds of the admitted children had an underlying medical condition. Congenital 
heart defects, asthma, malignancies and/or immune deficiency were the most common 
conditions. Reasons for admission of the H1N1-positive group were age (n = 4), 
underlying diseases (n = 5), and severity of clinical presentation (n = 15). A subdivision 
in age groups and severity of disease in H1N1 positive and negative children is shown 
in Table 3.2. 
Table 3.1  Demographic characteristics and underlying conditions in admitted children 
with (Note: more than one underlying disorders possible). 
Admitted children
n = 61 (%)
H1N1 +
n = 24 (%)
H1N1 -
n = 37 (%)
Average age in years (range) 5.3 (0.03 to 17.8) 7.9 (0.1 to 6.7) 3.8 (0.03 -17.79)
number of boys 37 (61%) 15 (63%) 22 (59%)
Underlying disease 40 (66%) 21 (79%) 19 (57%)
- asthma 8 (13%) 3 (13%) 5 (14%)
- congenital heart defect 6 (10%) 6 (25%) 0
- Immune suppression / malignancy 7 (12%) 2 (8%) 5 (14%)
- syndrome 3 (5%) 2 (8%) 1 (3%)
- Metabolic / Diabetes 3 (5%) 1 (4%) 2 (5%)
- Preterm birth 3 (5%) 2 (8%) 1 (3%)
- Other 10 (16%) 5 (21%) 5 (14%)
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In November there was a peak in admissions, that same month the first H1N1 
vaccinations were administered to patients in risk groups. Vaccinations for children 
aged between 6 months and 5 years started 2 weeks later. Between August and 
October 2009 5 children with a H1N1 infection were admitted and in December there 
were 3 children. One patient was vaccinated a week for presentation in the hospital and 
the parents of a neonate were vaccinated before the week before the child got ill.
Symptoms 
H1N1-positive children often experienced fever (83%), cough (71%) or a combination of 
these 2 symptoms (63%), see Table 3.3. Over 40% of the children experienced gastro-
intestinal complaints, diarrhoea (38%) was reported more often than vomiting (21%). 
They were always accompanied by coughing and/or fever. Two children (8%) presented 
after a resuscitation situation at home, 1 child (4%) had a circulatory insufficiency at the 
emergency room. Four children (17%) developed a respiratory or circulatory insufficiency 
later in the course of disease and were transferred to our hospital. In total, 29% (n = 7) 
of the children needed mechanical ventilation. 
Co-infections 
Fifteen out of the 24 children (63%) were tested for co-infections. In 9 of these 15 children 
(60%) a co-infection was found, 5 viral co-infections were identified (respiratory syncytial 
virus (RSV), adenovirus, rhinovirus, bocavirus, norovirus) and in five children a bacterial 
co-infection was detected (Streptococcus pneumoniae (sputum), Streptococcus pyogenes 
(empyema), Acinetobacter baumannii (blood), enterococcus faecium (blood, urine) and 
Staphylococcus ugiant (blood). In 7 of these children with a proven co-infection the 
course of disease was severe of which 2 patients died. 
Course of disease
The average duration of hospitalization for H1N1 positive children was 6 days (1-23 
days). Two children with a severe and complex course of disease due to an underlying 
illnesses were admitted for more than a month and were not included in the average 
length of stay. All children were treated with Oseltamivir. Antibiotics were prescribed in 
Table 3.2  Age distribution in relation to the severity of disease in H1N1-positive and 
-negative patients.
Total 0-1 years 1-2 years 2-5 years 5-19 year
Disease 
severity
H1N1 + H1N1 - H1N1 + H1N1 - H1N1 + H1N1 - H1N1 + H1N1- H1N1 + H1N1-
Mild 13 30 3 9 1 3 0 11 9 7
Moderate 3 5 0 1 0 0 0 3 3 1
Severe 8 2 1 0 0 0 2 1 5 1
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54% of the patients. When looked at severity of disease, 15% of the children with a mild 
course of disease and all patients in the moderately and severely ill group received 
antibiotics. The percentage of seriously ill children was relatively higher among older 
children (5 out of 17 group> 5 years). Patients in the youngest age group were often 
admitted for observational purposes. All patients with H1N1 infections in the age group 
of 2-5 years experienced a severe course of disease.
Outcome
Four patients (17%) deceased. Two patients, both younger than 4 years, died in the ICU 
after resuscitation at home. In one of them both a bacterial and a viral co-infection was 
detected. Another deceased patient refused intensive care treatment due to his underlying 
disease and with the consent of his parents and physicians this was accepted. The fourth 
patient, where there was also a viral co-infection, died due to his underlying disease 
during an H1N1 infection. The last 2 patients were both older than 5 years.
Discussion
The H1N1 epidemic caused an increase in consultations and admissions that peaked 
in November 2009. In particular the confrontation with resuscitations of young, 
previously healthy children in the home setting caused concerns. This led to a low 
threshold for admission of children <5 years of age with the suspicion of H1N1 infection. 
In retrospect the severity of disease due to H1N1 was relatively mild, although there are 
some notable observational done.
Table 3.3  Clinical symptoms at presentation of children admitted with an suspected  
H1N1 infection
Admitted  
 n = 61 (%)
H1N1 + 
n= 24 (%)
H1N1 - 
n = 37 (%)
Fever 46 (75%) 20 (83%) 26 (70%)
Fever and respiratory symptoms 32 (52%) 15 (63%) 17 (46%)
Cough 31 (51%) 17 (71%) 14 (38%)
Gastrointestinal symptoms 10 (16%) 10 (42%) 4 (11%)
Vomiting 7 (12%) 5 (21%) 2 (5%)
Diarrhoea 12 (20%) 9 (38%) 3 (8%)
Respiratory / circulatory failure 8 (13%) 7 (29%) 1 (3%)
Fever without respiratory symptoms 6 (10%) 2 (8%) 4 (11%)
laryngitis subglottica 5 (8%) 1 (4%) 4 (11%)
Upper Respiratory symptoms 1 (2%) 0 (0%) 1 (3%)
Other 13 (21%) 4 (17%) 9 (24%)
Processed on: 1-3-2017
508516-L-bw-Ahout
49
H1N1 infections in Dutch children. Impressions from a university clinic
3
Of all admitted children with a H1N1 infection the majority were older than 5 years of age 
(17 of the 24 children, 71%) and it was especially in this age group that there was a 
serious course of disease (8 of the 17 children, 47%). A Canadian study in which 58 
children with H1N1 infection are described, shows a similar distribution in terms of age 
distribution and severity of disease. Sixty-four percent of the children with H1N1 infection 
was older than 5 year, a significant difference with respect to the children who were 
before them in 5 years recorded with a seasonal Influenza A infection.18 Initial reports 
from the United Kingdom show a similar distribution, where 12 of the 13 children who 
were included in intensive care with H1N1 was older than 5 years of age. 9,11
The Dutch data collected by the National Institute for public health and the environment 
(RIVM) showed that the number of admissions per 100,000 is highest for the age group 
0 to 5 years (62.7).1,2,7 The proportion of children under 6 months of age in this whole 
group is 33%. This percentage might be positively influenced by the advise to admit 
children <3 months during treatment with Oseltamivir. The number of admissions to 
intensive care units per 100,000 for the age group 0-5 years is equal to the number of 
ICU admissions for 5 to 14 years old (1.73 and 1.71, respectively) while the mortality in 
the youngest age category is higher per 100,000 (0.54 vs. 0.45, respectively). When we 
look at absolute numbers, more young children from 0 -4 years (581 vs. 384) were 
admitted to the hospital, but twice as many children aged 5 to 14 years needed 
admission to the ICU (32 vs. 16). Finally more children deceased in the age group 5 to 
14 years (9 vs. 5).1,2,7 
A number of exceptionally serious manifestations of H1N1 infections in previously 
healthy children were observed. Two children needed to be resuscitated at home, 
another arrived in circulatory shock at the emergency room. These three children were 
all 3 years old or younger, and represented 43% of all admitted children in the age 
group < 5 years of age; the other children from this age group (n = 4) were only 
admitted for observational purposes. In the study of Libster et al. a death rate of 5% is 
found this is significantly lower than the 17% mortality rate in our population. The number 
of ICU admissions (33 versus 19%) and the number of children that needed mechanical 
ventilation (23 versus 17%) is also higher in our population.10 Miroballi et al. showed a 
similar rate of ICU admissions in New York, but they described a lower percentage of 
mechanical ventilated children and a lower mortality rate of 1%. 14 This might be due to 
the academic setting of the hospital resulting in a bias that results in more children with 
significant comorbidity. Further the hospital functions as tertiary referral centre for the 
region. 
The incidence of fever (83%) and cough (71%) as presenting symptoms of H1N1 
infections in children is similar to the symptoms found in the literature (respectively 
84-92% and 69-91%).9,10,19
However, there are also striking differences between our study and previously published 
studies concerning the presence of rhinitis and upper respiratory tract symptoms 
(ranging from 31-77% vs. 0% in our study group) and the occurrence of gastro-intestinal 
complaints (ranging from <10% to 37% versus 42% in our study). 9-11,19
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The influence of co-infections in the course of disease and the outcome is not yet clear. 
Libster et al. mention a (suspected) bacterial pneumonia in 10% of the children with a 
H1N1 infection, of which 16% developed an empyema. In 7% of the tested children (n = 147) 
a positive blood culture was found and 19% had a viral co-infection, usually RSV (89%).
Four children with a proven co-infection deceased in this group.10 Miroballi et al. found 
no viral co-infections and 3.5% bacterial co-infections. 14 These two studies show no 
increase in mortality based on the presence of a co-infection.10,14
In our study, children with H1N1 infections were not routinely tested for co-infections. 
Ultimately, 63% of the hospitalized children were tested for co-infections. The choice to 
perform diagnostics in children was based on the clinical parameters of the individual 
patient. Seventy-five percent of the patients with a severe course of disease had a viral 
or bacterial co-infection, also in 2 of the 4 deceased children a co-infection was 
demonstrated. Based on these small number of patients it is not possible to make a 
statement about the impact of co-infections in the course of disease. 
Underlying medical conditions are a main risk factor for hospitalization and death due 
to influenza infections. Over 70% of the admitted children with a H1N1 infection had an 
underlying disease (chronic lung disease, immune deficiency, cardiac and neurological 
diseases). Other studies published lower percentages (40.3% and 34%) of underlying 
diseases in comparable paediatric populations.9,11 The function of our hospital as a 
tertiary referral centre as previously mentioned might explain the differences in the 
percentage of children with an underlying medical condition. In our study there was no 
difference in mortality observed in patients with and without an underlying disorder. 
Fifty percent (2 out of 4 deceased children) had an underlying condition. In an Argentine 
study the presence of a complex underlying disease was significantly more frequent in 
a group of children who died due to an H1N1 infection in the intensive care.20
Conclusion
The description of the clinical epidemiology of H1N1 infections in Dutch children 
admitted to our university hospital revealed a number of striking observations: 1) most 
children admitted with a H1N1 infection were older than 5 years of age (71%); 2) in this 
age group the course of disease was more often severe (47%); 3) a remarkably high 
percentage of the children with H1N1 infection had an underlying disease (79%); in 
particular congenital cardiac disorders were found, but also asthma, malignancies and 
/ or immune deficiency were frequent; 4) the most acute (life threatening) presentations 
occurred in previously healthy children under 3 years of age.
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Abstract
Background: the influenza H1N1 pandemic of 2009-2010, provides a unique 
opportunity to assess the course of disease, as well as risk factors for severe disease 
in Dutch children (<18 years) hospitalized with influenza- virus infections. 
Methods: retrospective national chart study on children admitted to a Dutch hospital 
with a RT-PCR confirmed H1N1 infection during the 2009-2010 pH1N1 outbreak. 
Results: 940 patients (56% boys), median age of 3.0 year [IQR 0 - 9 years] were 
enrolled. The median duration of hospitalization was 2.0 days [IQR 1-4 days]. Of these 
children, 63% received antiviral treatment, 24% needed supplemental oxygen, 7% were 
admitted to the ICU and 5% needed mechanical ventilation. Staphylococcal aureus was 
the most common bacterial co-infection. Fifteen patients died (1.6%), five were 
previously healthy. After multivariable analyses risk factors associated with intensive 
care admission were pre-existent heart and lung disease. Risk factors for mortality were 
neurologic conditions and an oncologic medical history. At least 1 vaccination was 
administered to 66 patients at the peak of the pandemic. One third of these children 
(n=23, 35%) were hospitalized within 1 week. We did not observe a clear effect of 
vaccination due to the limited number of patients with a known vaccination status and 
due to the introduction of vaccines at the peak of the pandemic. 
 Conclusions: This study presents a nationwide overview of Dutch hospitalized children 
during the 2009 H1N1 pandemic and reconfirms known risk groups for severe influenza 
infections. Most of the acute and severe presentations occurred in previously healthy 
children. 
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Introduction
The 2009-2010 influenza A (H1N1) outbreak offered a unique possibility to assess the 
impact of infection with this pandemic virus in terms of clinical features and disease 
outcome in children. The early detection of H1N1, the rapid worldwide dissemination of 
information and the expectation of a severe course of disease raised concerns about a 
global outbreak with substantial morbidity and mortality in the Netherlands.1,2 The 
absence of herd immunity due to antigenic shift of the virus increased the risk for severe 
disease in the population and particular in risk groups for influenza who would not be 
protected by the seasonal influenza vaccine. In retrospect, only the elderly appeared to 
have some pre-existing immunity.3 The fear of a severe pandemic resulted in a 
nationwide protocol using RT-PCR in adults and children with (severe) manifestations of 
influenza-like illness, as defined by the WHO.4 To date the course of disease in pH1N1 
infections has been described by many investigators. However, data on children remain 
underreported, while children comprise more than half of all infected patients worldwide 
during this pandemic.5. We therefore evaluated disease characteristics in the 2009-2010 
influenza A (H1N1) pandemic among all hospitalized children in the Netherlands in 
order to increase our understanding of the clinical features of hospitalized children, to 
assess the presence of risk groups for severe disease and to study protection provided 
by H1N1 vaccination.
Methods
A retrospective nationwide analysis of clinical case records was performed of RT-PCR 
confirmed H1N1-infected children (<18 years) admitted for at least one night to Dutch 
hospitals between August 1, 2009 and August 1, 2010. Diagnostic RT-PCR was carried 
out in the participating hospitals in The Netherlands, with a protocol standardized and 
approved by the National Influenza Center.4 Children who tested positive for Influenza 
A, but not for pandemic influenza H1N1 were excluded. Children who tested positive, 
but were admitted for another reason, e.g. elective surgery, were also excluded. 
Approval of the local medical-ethical committees was obtained from each hospital. 
Clinical files were studied by one of the investigators (RP, ML, IA or GF). In situations of 
doubt regarding interpretation of data, a second investigator was consulted and a 
shared decision about interpretation was recorded. Clinical, laboratory, and radiological 
data were obtained and abstracted into a clinical record form. For chronically ill patients 
with prolonged hospitalization due to other causes than pandemic influenza H1N1, the 
symptomatic respiratory period was used to determine duration of hospitalization.
Data were entered into a database by one investigator (MB) and subsequently checked by 
another (IA, RP, or ML) to exclude errors. Data are presented as numbers (percentages) 
or median with inter-quartile range (IQR). Clinical symptoms, treatment, and medical 
history were compared among different age groups (<6 months, 6-24 months, >2 years) 
Processed on: 1-3-2017
508516-L-bw-Ahout
56
Chapter 4
with Kendall’s Tau statistics for trend analysis. Kruskall Wallis, Chi-square and Mann 
Whitney U-test were used to test for differences between groups. Gestational age was 
missing in 221 (24%) of the cases. Therefore, analyses were repeated in patients in 
whom the preterm status was known. For all other variables the percentage of missing 
data was <10%. Binary logistic regression analysis was used to identify risk factors that 
were associated with a binary outcome measure, e.g. mortality, ICU admission, or prolonged 
hospitalization of > 7 days. We calculated both unadjusted and adjusted odds ratios 
(ORs) with 95% confidence intervals (CIs) with the latter including all other potential risk 
factors. All data were analyzed using SPSS version 22 (SPSS Inc., Chicago, IL, USA).
Results
Seventy-five of the 91 hospitals throughout the Netherlands participated in this study 
(82%), including all tertiary centers and all large teaching hospitals. Four hospitals 
intended to participate, but did not have eligible patients. Seventeen hospitals refused 
to participate. Reasons for non-participation were: ‘’too much effort for only a few 
patients’’ (n=14), logistical problems (n=2) or because they did not test for H1N1 
specifically (n=1). An average of 12 patients [range 0-69] were included per hospital 
(Figure 4.1). From 62 hospitals, information regarding the total number of positive H1N1 
RT-PCRs was available, resulting in a hospitalization rate of 35% (731 hospitalizations 
among 2065 H1N1 positive samples). 
In this study 940 patients were included. The hospitalization rate was 28.4 per 100.000 
(940 / 3,312,432). The highest rate of admissions was seen in week 46 with 188 
hospitalized children (Figure 4.2a). The number of children admitted to the ICU showed 
a peak in week 45. The age distribution of these patients is shown in Figure 4.2b. The 
largest number of admissions was documented in infants below 1 year of age (140.9 
per 100,000), followed by infants 1-2 years of age (60.5 per 100,000). The number of 
admissions in older children remained almost equal for children up to 7 years of age 
(between 20-30 per 100,000) and decreased in those older than 7 years (<15 per 
100,000). The incidence of hospitalization (including ICU admission) was 57.4 per 
100,000 in 0-4 year old children, 17.6 per 100,000 in 5-14 year old children and 9.80 per 
100,000 children in children aged 15-18 year.
The majority of children with influenza H1N1 infection had fever (89%, defined as 
temperature >38 ̊ C), followed by cough (71%). The proportion of cough appeared to 
increase per age group from 61% to 75% (p<0.01). Almost one third of patients 
experienced dyspnea. The presence of dyspnea increased with age. Gastrointestinal 
symptoms were more frequently seen in patients between 6 months to 2 years of age 
as compared to infants below 6 months and above two years. Neurological complications 
were diagnosed in 10% of patients, especially in those between 6 months and two 
years of age (15%). This was significantly higher compared to both other age groups 
(Table 4.1A).
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The most common co-morbid condition was wheezing or asthma, followed by neuro-
muscular conditions and prematurity at birth. The frequency of co-morbidity increased 
with age (Table 4.1B). Positive bacterial cultures were found in 6% of all admitted 
children (59 positive out of 940 patients), although only 36% of the patients were tested 
for a bacterial co-infection (338/940). In the patients that were tested 17% had a bacterial 
co-infection (59/338). Staphylococcal co-infection was most frequently detected (in 13 
out of 59 positive patients, 22%), followed by E. Coli (n=4The majority of patients 
received antiviral therapy (63%). Eight patients received zanamivir. Reasons to give 
zanamivir or to switch from oseltamivir to zanamivir were liver failure, last resort since 
Figure 4.1 Regional representation of participating hospitals and number of children included 
per site. The red / dark circles represent general hospitals and the light circles are the academic 
medical centres (n=8). The size of the circles represents the number of included patients per site.
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patient deteriorates (n=5). Frequently noted reasons to abstain from antiviral treatment 
were: duration of symptoms >48 hours or mild course of disease. Oseltamivir was the 
only treatment of which the frequency decreased amongst the age groups (Table 4.1B). 
All other treatment modalities, including oxygen and antibiotics were significantly more 
applied in older patients. Eighty-seven patients (9%) were hospitalized longer than a 
week. Longer hospitalizations were more often seen in the older age groups. Sixty three 
patients (7%) were admitted to the ICU, 18 (3%) were previously healthy and 5% needed 
mechanical ventilation. Six patients were treated with ECMO. In this study a total of 
Fig 4.2a Number of hospitalizations per week. The height of the bar represents the number of 
admissions per week. Colours differentiate between healthy children and children with co-morbidity. 
Red dots represent the number of children admitted to the intensive care unit (right axis).
Fig 4.2b Age and gender distribution of admitted children. The height of the bar represents the 
number of admissions per age group. Colours differentiate between genders. Red triangles represent 
the number of children who died due to pH1N1 infections (right axis).
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fifteen patients died (1.6%). Eleven of them died in the ICU department. Five were 
previously healthy, including the two patients who received ECMO both were previously 
healthy, > 12 years old and suffered from a co- infection with Staphylococcus aureus. 
Two previously healthy patients (<5 years) died at home after resuscitation. One had an 
adenovirus co-infection, the other had a positive sputum sample for Staphylococcus 
aureus with bilateral consolidations on the chest X-ray. This patient died as a consequence 
of brain edema and encephalitis. The fifth previously healthy patient (<15 years) died of 
a bacterial co-infection. The chest X-ray showed bilateral consolidations. None of the 
patients who died were below 6 months of age. Patients younger than 6 months were 
less likely to need supplemental oxygen or tube feeding while they were more often 
treated with antiviral medication compared to both other age groups (Table 4.1B). 
In week 46 the H1N1 vaccine became available for risk groups. At that moment the 
H1N1 pandemic was at its peak (Figures 4.2a and 4.2c). Two weeks later the vaccine 
indication was extended to household contacts of children < 6 months of age and all 
children up to 4 years of age. Sixty-six patients received at least 1 pH1N1 vaccination, 
one third (n=23, 35%) received the vaccine within one week of hospitalization. This 
resulted in 43 (partially) vaccinated infants. None of these children died. None of the 
patients with a bacterial co-infection was previously vaccinated with the pH1N1 vaccine, 
although 3 patients received a vaccine within a week before hospitalization; their 
positive blood sample appeared to be contaminated. Six were admitted to the intensive 
care and three needed mechanical ventilation. Since this is a retrospective chart study 
we were unable to retrieve information on H1N1 vaccination status in many patients. 
Flowchart 4.1 shows the distribution of the hospitalized patients in time and the 
information regarding immune status. In Figure 4.2c the admission rates of children 
Figure 4.2c Number of hospitalizations per week in relation to start vaccination campaign. Frequency 
curves represent the total number of admissions per week (blue), the proportion of children with 
a co-morbid condition (purple) and number of previously healthy children (green). Vaccination 
started in week 46 for risk groups, in week 48 the target group was extended to all children between 
6 months and 4 years of age and household contacts of children below 6 months of age.
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with and without a vaccine indication in week 46 are shown separately, in this figure the 
number of hospitalizations in children of risk groups appears to decrease earlier and 
steeper compared to healthy children. 
Co-morbid conditions were analyzed to identify risk groups for a severe course of 
disease, defined as ICU admission, prolonged hospital stay of more than 1 week or 
mortality. Cystic fibrosis, Down syndrome and sickle cell disease could not be analyzed 
in the model since the number of patients with these conditions was too low (<20 
cases). Due to missing information regarding prematurity this risk factor was left out of 
the initial analysis. Results of these analyses are shown in Table 4.2A. Risk factors for 
prolonged hospitalization: any co-morbid condition (OR 1,9 95% 1.1-3.3), neuromuscular 
disease or psychomotor retardation (OR 2.3, 95%CI 1.3-4.2), malnutrition, including 
need for tube feeding (OR 2.3, 95%CI 1.1-4.7) and heart disease (OR 2.6, 95%CI 
1.2-5.9). Including age to the model did not influence these results. The same analyses 
were performed for need for ICU admission: pre-existing heart disease (OR 3.3, 95%CI 
143-8.0) and lung disease (OR 2.4, 95%CI 1.0-5.5) were identified as risk factors. After 
correction for age only heart disease (OR 3.0, 95%CI 1.3-7.2) remained a significant risk 
factor. Mortality was associated with a medical history of neuromuscular disease or 
psychomotor retardation (OR 4.3, 95%CI 1.5-12.4) and oncologic disease (OR 9.6, 
95%CI 1.9-48.4). Age was no risk factor in this outcome measure. When the same 
analysis was performed in a subgroup of patients in which pre-term status was known 
Flowchart 4.1  Description of cohort in relation to vaccine introduction of pH1N1 
vaccination.
940
patients 
n = 442
before
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8 patients
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(n=718), prematurity was not associated with one of the outcome variables from this 
study (Supplemental Table 4.1). 
The large proportion of previously healthy children (427 children, 45%) prompted us to 
further explore this group. The length of stay in the hospital was similar in healthy infants 
and patients with a medical history. Patients with a medical history did receive more 
antiviral (p<0.05) or antibiotic (p<0.01) treatment and were also more likely to need 
supplemental oxygen (p<0.001), tube feeding (p<0.01) or mechanical ventilation 
(p<0.05). Patients with a medical history had an OR of 1.4 (95% CI 1.4-1.6) of being 
admitted to the ICU (n=45/513, 9%) versus previously healthy infants (n=18/427, 4%). 
Four previously healthy patients died (0.9%) versus 11 (2.1%) patients with a medical 
history (NS). 
Discussion
In this study the H1N1 pandemic of 2009-2010 in the Netherlands was used to gain 
insight in the course of a pandemic influenza A infection in children, the effect of the 
vaccination campaign and to identify risk groups for severe influenza infections in 
children. This study is unique in its national design with a uniform diagnosis via RT-PCR 
and detailed insight in the course of disease. 
The epidemiological data in this study are similar to those in earlier studies from the 
Netherlands and Europe. This indicates that the national infectious disease notification 
system worked adequately.6 Steen et al. fount an infection attack rate of around 7.5% 
[4-11 95% CI] in the general population, with a higher attack rate of 35% in children aged 
5-19 years (25-45 95% CI) in a serological study.7 Van het Klooster et al. also show that 
hospital admission rates were highest in 0-4 year olds, followed by 5-14 and 15-24 year 
old children, then adults aged 45-54 and subsequently the age groups 25-34 years.6 
Many studies have documented the course of the pH1N1 infection.6,8-13 Compared to 
other studies the length of hospitalization in the Netherlands was relatively short 8,10,13 or 
similar.12 The percentage of ICU admissions was slightly lower (7% versus 8.8-27%) 13-19 
and the proportion of deaths slightly higher (2% versus 0.5 -3.0%) than in previous 
publications .14-16,20,21 Although American studies clearly show an excess in pediatric 
mortality during the winter of 2009/2010 compared to winters with seasonal influenza.22,23 
Approximately 50% of the patient in this study had significant co-morbidity, which is in 
agreement with other studies that reported percentages between 40-75%. 13-16,21,24,25 
The effect of the vaccination campaign was difficult to establish, since the introduction 
of the vaccine coincided with the peak of the pandemic. The vaccine uptake in the 
second round, starting in week 48, was 75% (n=588.750) for children between 6 months 
and 4 years of age and 63% for invited household contacts.26 As shown in figure 2c, 
there appears to be a steeper decline in the number of hospitalizations of patients with 
a co-morbidity from week 46 onward compared to previously healthy patients. The 
effect seems most evident in week 48, when healthy patients are more frequently 
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4
admitted to the hospital than patients with a co-morbid condition. However, in this week 
the number of hospitalizations was low. In our opinion the decline starts very early and 
based on this retrospective study with limited data on vaccination status it is not 
possible to draw a solid conclusions on the effect of vaccination. In serological or 
database driven studies positive effects have been described. 27-29 
Risk factors associated with intensive care admission in this study were pre-existent 
heart and lung disease. Other studies in which risk factors for a severe course of H1N1 
infections were identified had fewer inclusions, but found similar results. 9,11,13,21,30 
An Australian study added bacterial co-infection (OR 6.89 95% CI 3.2-15.1) 9 whereas 
Garcia et al. recognized obesity, premature birth and hematological disease as risk 
factors for severe disease.11 Stein et al. additionally found metabolic disorders to be a 
risk for intensive care admission.13 In this study risk factors for mortality were a 
pre-existent neuromuscular or psychomotor developmental disorder and an oncologic 
medical history. The increased risk of death due to influenza in children with a chronic 
neurological condition was also found in a study of Pebody et al. They report that 92% 
of the deceased children with an underlying condition had a neurodevelopmental 
disorder.31 
The limited number of co-morbid conditions like cystic fibrosis, metabolic disorders, 
Down syndrome and sickle cell disease in our study made it impossible to include 
these conditions in our analyses. This is an interesting finding by itself, since especially 
Down syndrome and diabetes are common diagnoses with a prevalence of 12 per 
10,000 births for Down syndrome and an incidence of 18.6 per 100,000/year diabetes 
cases, resulting in approximately 5400 and 6000 pediatric patients in the Netherlands.32,33 
This may suggest that children with these diagnoses were not more affected than the 
general population. In our study prematurity was not a risk factor for a severe course of 
disease. Gill et al. did find an association between prematurity and need for hospitalization 
for children up to two years of age in an emergency room study.34 In our study prematurity 
was only a risk factor for severe disease in a subgroup of children (< 6 months of age) 
(data not shown).
A large proportion of previously healthy children was admitted to the hospital. The 
majority was below 2 years of age and admitted for observation. However, five out of 
the 15 deceased patients were previously healthy and three of them entered the hospital 
after resuscitation at home. During our study we encountered at least two other infants 
who died outside the hospital. Since these children were not hospitalized they were not 
included. 6 Studies describe that 35-43% of deaths through influenza occur outside the 
hospital or in the emergency room. Death outside the hospital was more likely in 
children without high-risk medical conditions, as we also observed in this study.23,35 
Shrag et al. performed a surveillance study for influenza hospitalizations in America 
and described that 4 out of 6 paediatric deaths did not have a medical indication for 
influenza vaccination. Noteworthy, in their study they could not confirm that the presence 
of a medical history (vaccine indication) was associated with intensive care admission.17 
In this study stringent inclusion criteria were used. Due to the retrospective nature of this 
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study, missing data form a limitation. Especially data with regard to vaccination status 
and prematurity was difficult to find. Moreover, obesity as risk factor was impossible to 
assess, since especially length of children was rarely recorded. Furthermore, a limitation 
of our study is the lack of a control group. This would have enabled us to analyze the 
need for hospitalization as an outcome measure or would have helped us to correct for 
overrepresentations of conditions in our patient population.
We reported the clinical course of hospitalized Dutch patients with a uniformly RT-PCR 
diagnosed pH1N1 infections. H1N1 infections resulted in respiratory and neurological 
symptoms. However, some of the children presented with an acute or very severe 
disease entity with shock, resuscitation out of the hospital or necrotizing encephalitis. 
Most of these acute cases occurred in previously healthy children. In this study 
Staphylococcal aureus was the most common bacterial co-infection. Risk groups for a 
severe course of disease could be identified and overlapped with risk groups of 
seasonal influenza, although the proportion of healthy children was substantial. Due to 
the late introduction of the influenza vaccine no clear beneficial effect of vaccination 
could be observed. 
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Summary 
Seasonal influenza infections cause a high burden of disease for the whole community 
every year. Effective vaccines are available and used worldwide in adults and children. 
Discussion is ongoing as to whether influenza vaccination for children should be 
implemented in the National Immunization Program (NIP). Is there enough evidence to 
support routine influenza vaccination in children? In this review we briefly discuss the 
influenza viruses and the available vaccines. Subsequently, the current data available 
on influenza vaccination is reviewed and weighed against the Dutch criteria for the 
introduction of new vaccines into the NIP.
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Introduction
Influenza virus is a RNA virus belonging to the Orthomyxo- viridea which primarily infects 
the respiratory tract. Trans mission mainly occurs through aerosols created after 
coughing. However, the virus can also be transmitted via direct contact with nasal 
secretions (daycare centers and siblings) or faeces of animals (bird droppings and 
avian flu).1 Influenza occurs worldwide in winter epidemics, resulting in three to five 
million cases of severe illness and 250,000 to 500,000 deaths yearly.2 Some years, a 
new influenza A virus subtype emerges in which the hemagglutinin gene is not related 
to the circulating influenza strains. Influenza strains can acquire genes from influenza 
viruses that infect birds or pigs. These new strains of influenza viruses can spreads 
worldwide and cause a pandemic.3-5
In late March 2009 such a novel influenza A (H1N1) virus was identified in Southern 
America which showed reassortment of swine avian and human strains.6 This virus was 
subsequently recognized as the cause of an outbreak of respiratory illness in Mexico.7 
In June 2009 the WHO declared a pandemic. At the start of the pandemic the virus 
appeared to be very virulent with a high mortality rate, especially in young adults and 
children. 8 This information resulted in the decision to vaccinate people in the Northern 
hemisphere to protect them against this severe disease. However, in the Northern 
hemisphere the virus behaved more like a seasonal influenza virus. H1N1 disease had 
the highest attack rate in young children causing relatively mild disease.9 The pandemic 
H1N1 replaced the seasonal flu so that, in the influenza season 2009e2010, over 99% of 
the influenza positive isolates in Europe and America were pandemic H1N1 influenza A.10,11
There are three types of influenza viruses: types A, B and C, of which influenza A is the 
most virulent and causes more severe disease. Influenza A predominantly infects 
(aquatic) birds where extensive reassortment of genes can occur increasing the risk to 
form strains which can infect humans.12 This has led to pandemics in the past (H1N1, 
Spanish Flu 1918 and Swine Flu 2009; H2N2, Asian Flu 1957; and H3N2 Hong Kong Flu 
1968) and poses a continuous threat for new outbreaks. Due to the huge genetic 
variation of influenza A, different serotypes are known. Low cross protectiveness occurs 
throughout life and after vaccination.13,14 Influenza B is mostly restricted to humans and 
has a slow mutation rate leading to a low genetic diversity; only one serotype is known.13 
Throughout life people acquire a certain degree of protection against influenza B, 
although antigenic drift of the virus prevents full protection.15 Influenza C is less common 
then the other types and can infect humans, pigs and dogs. It most often causes mild 
disease in children and rarely outbreaks of severe disease.16
Currently two types of influenza vaccines are available, the trivalent influenza vaccine 
(TIV) and the live attenuated influenza vaccine (LAIV), both registered in the US and 
Europe. Both vaccines contain two type A influenza strains (H1N1 and H3N2) and one 
type B influenza strain.17,18 Due to the high mutation rate of the virus, the vaccine 
composition has to be adjusted every year based on the prediction from the World 
Health Organization about which strains of the virus are most likely to be circulating in 
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the next year.19 Both vaccines have been shown to be effective and are used in many 
national immunization programmes (NIP), although large differences in protection have 
been reported.20,21 LAIV has only been registered for vaccination of children older than 
2 years and adults younger than 50 years.22,23 Currently no vaccine for children younger 
than 6 months is available. Vaccination of pregnant women in 3rd trimester with TIV may 
protect young infants.24 There is the tendency to advice LAIV for pandemic influenza 
because it induces better protection if there is no preexisting immunity in the community 
against these strains.25
Influenza in children
Influenza infections lead to symptoms including fever, cough, nasal congestion, general 
malaise and muscle pain, also referred to as ‘the flu’ (Table 5.1).26 In children, the 
disease is often accompanied by gastrointestinal com- plaints such as vomiting and 
diarrhoea.27 In comparison to other respiratory viruses, influenza infection appears to 
have a more severe course of disease in children over 1 year of age, in whom infection 
may lead to viral pneumonia or secondary bacterial super infection.28-30 Further, 
influenza infection is associated with the development of otitis media in children.31
The annual incidence of seasonal influenza infection is 2-10% worldwide.2 Attack rates 
are highest in young children (20-30%). Before the age of 6 years most children have 
been infected at least once with influenza A.32-34 The annual burden of disease in 
children is difficult to establish and often underestimated. This is partly due to seasonal 
overlap with epidemics caused by other respiratory viruses35 and the diverse spectrum 
of clinical manifestations in children.27,36 The average annual hospitalization rate in 
children is 9/10,000 and higher in young infants (up to 100/10,000). The overall mortality 
due to influenza is very low, and is the highest in children below the age of 6 months 
(0.9/100,000). Pre-existing medical conditions, such as chronic diseases and the use of 
immunosuppression, increases the risk of a complicated influenza infection.27
Table 5.1 Symptoms of influenza infection in children.
H1N1 (%) 8,110-112 Seasonal influenza (%) 27,28,110
Fever 91 88
Cough 82 90
Rhinorrhea 65 83
Fatigue 63 71
Sore throat 49 42
Respiratory distress 35 35
Vomiting 22 28
Diarrhea 10 12
Convulsion 8 1
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Most children with an uncomplicated influenza infection are seen by the general 
practitioner, demanding high healthcare capacity during the respiratory season.37-39 
Further, children with flu have to stay at home resulting in absence at work of their 
parents. In this way influenza infection in children also affects the community indirectly. 
Influenza is rapidly disseminated in school children and children play an important role 
in transmission cycle during an epidemic.40,41 Vaccination of children therefore also pre- 
vents morbidity and mortality in the elderly.42
The Committee on Infectious Diseases of the American Academy of Pediatrics (AAP) 
publishes yearly the recommendations for the prevention and treatment of influenza in 
children.43 Regarding vaccination, they recommend annual TIV for: (i) All children, both 
healthy and with conditions that increase the risk of complications from flu, aged 6 
months to 18 years, (ii) household contacts and out-of-home care providers of children 
with conditions that place them at high risk or healthy children younger than 5 years, (iii) 
all healthcare professionals and (iv) pregnant women.
According to these recommendations, 85% of the US population should be vaccinated.44 
In practise, only 50% of high risk patients are vaccinated and 27% of all children in the 
US are completely vaccinated. Most of the children between the ages of 2 and 18 years 
are vaccinated with TIV (90%) and 10% with LAIV.45 In previous recommendations of the 
AAP only the youngest children should be vaccinated (TIV for children 6-23 months in 
2004 and 6-59 months in 2006).46 The evidence base to vaccinate older children up to 
18 years is poor.47
The European Centre of Disease Prevention and Control (ECDC) does not recommend 
routine seasonal flu vaccination in healthy children.18,48 Since 2007 TIV has been 
included in the NIP of Finland for children 6-35 months.49 During the 2009 H1N1 
pandemic, many countries in Europe decided to vaccinate young children, pregnant 
women, the elderly and high-risk patient groups (Figure 5.1).29 In The Netherlands, the 
policies regarding routine vaccination of the elderly led in 2012 to media commotion 
initiated by an article in the Lancet Infectious Diseases by Osterholm et al. and opinion 
articles by a general practitioner based on this article in the Geneesmiddelen Bulletin.50,51 
As a result of this commotion, uptake of influenza vaccines by the elderly, hospital 
employees and high-risk patient groups decreased, policy makers were taken to court 
and public concern about vaccination grew. The main arguments against vaccination 
were: (i) there are no randomized controlled trials with appropriate end-points in many 
high risk groups, (ii) there is no valid evidence from randomized studies that annual 
vaccination in the elderly and high risk patients is effective and (iii) 15 of the 36 studies 
on the effectiveness and efficacy of vaccination are sponsored by the pharmaceutical 
industry which raises issues of conflict of interest.52
Evaluation of influenza vaccinations against the Dutch criteria
In the second part of this review the current available data for influenza vaccination in 
children will be reviewed. The criteria to include vaccines in the Dutch NIP are used as a 
framework to evaluate whether influenza vaccination is justified in children (Table 5.2).53 
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Because data sometimes can be interpreted in different ways and new relevant studies 
on this subject are published every year, this review should be used as guidance to 
follow the ongoing discussion whether influenza vaccinations for all children should be 
implemented into the NIP as advised by the AAP. We will only refer to studies with lab-
oratory-confirmed influenza infection (RT-PCR or culture) to avoid an overestimation as 
seen in studies only using serology.54 
Disease burden and mortality of influenza in children
For children with influenza, medical attention is often sought at the general practitioner 
and outpatient clinics. Consultation rates vary between seasons and are age dependent. 
In general, children younger than 2 years are most frequently seen by GPs, with rates 
up to 1000/10,000 in seasons with a high incidence of influenza.27,38,39 Between the ages 
of 2-5 years, the GP visit rates decline to 30-150/10,000. Data for children older than 
5 years with laboratory confirmed influenza are not available, but it is likely that a further 
decline is seen in this age group.27
Frequently children are hospitalized due to influenza infection and this contributes 
considerably to the (limited) admission capacity of the pediatric wards. Hospitalization 
rates for children younger than 5 years are reported between 4 and 100/10,000 
depending on the season.27,28,37-39,55-60 Hospitalization rates due to influenza type B are 
lower.56 Hospitalization rates of young children, in particularly below the age of 6 
months, are the highest.27,55,57,58,60 Hospitalization rates of children between the ages 
5-16 years are relatively low and between 0.5 and 4/10,000.55,58,59
Table 5.2   Criteria used in the Netherlands to include a vaccine in the National 
Immunization Programme.53 
I The infectious disease causes considerable disease burden within the population, is 
serious for individuals and affects or has the potential to affect a large number of people
II Vaccination may be expected to considerably reduce the disease burden within the 
population
III Any adverse effects associated with vaccination are not sufficient to substantially diminish 
the public health benefit 
IV The inconvenience or discomfort that an individual may be expected to experience in 
connection with his personal vaccination is not disproportionate in relation to the health 
benefit for the individual concerned and the population as a whole
V The balance between the costs of vaccination and the associated health benefit 
compares favorably to that associated with other means of reducing the relevant disease 
burden
VI Relative to other vaccinations that might also be selected for inclusion, provision of this 
vaccination serves an urgent public health need at reasonable social cost
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Mortality due to influenza infection in children is rare in developed countries. Incidences 
have been reported up to 0.9/100.000.61 In the US (313.7 million people), 166 children 
died between 2004 and 2007 due to influenza infection. Only 6% of them were fully 
vaccinated. Bacterial co- infection was confirmed in 6-34% of these cases.62 Although 
mortality due to influenza is rare, young children below the age of 6 months are at 
highest risk.
Efficacy and effectiveness
The performance of a vaccine is assessed by its efficacy and effectiveness. Vaccine 
efficacy is defined as the relative reduction in influenza risk given ideal circumstances 
and 100% vaccine uptake. This is usually determined by a randomized placebo- 
controlled clinical trial. Vaccine effectiveness is defined as the relative reduction in 
influenza risk when a vaccine is used in routine circumstances in the community. This 
is measured in an observational studies that use medically attended, laboratory- 
confirmed influenza as primary outcome.63 Based on these definitions a meta-analysis 
was performed by Osterholm et al. to evaluate influenza vaccination in adults and 
children.50 In this analysis, 9 randomized controlled trials were included that evaluated 
Figure 5.1 Countries that have introduced national influenza A (H1N1) vaccination programmes.
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vaccine efficacy in children: 1 studied TIV and 8 studied LAIV. There was no efficacy of 
non- adjuvanted TIV in children aged between 6 and 23 months.64 For children aged 
between 2 and 18 years, no randomized controlled trials have been performed to date. 
LAIV vaccination in children between 6 months and 7 years was efficacious in all 
8 studies, although there was a considerable variation between the studies (57-93%).65-70 
The variation in efficacy of LAIV cannot be explained by differences in study design and 
is most likely attributed by seasonal variability and age groups included in the studies. 
No randomized studies have been performed to study the efficacy of LAIV in people 
aged between 8 and 18 years. Further, it should be noted that the incidence of influenza 
in a specific season is variable and unpredictable, therefore reducing the precision of 
vaccine efficacy measures during the mild seasons.71
The meta-analysis for effectiveness of vaccination for seasonal flu with LIV showed a 
large variation with overall moderate protection for children (10-84%).72-76 One study 
reported a high effectiveness of TIV with relative risk reduction for influenza A up to 
100% for children aged between 2 and 3 years.75 However, this was only shown during 
one season and as stated before, seasonal variation can have a major impact on these 
measurements. In two other studies it was shown that adjuvants increased the 
effectiveness of TIV in children aged between 6 and 72 months. A risk reduction was 
reached of 79% for children aged between 6 and 36 months (40% without adjuvants) 
and 92% for children aged between 36 and 72 months (45% without adjuvants).77,78
Overall it can be concluded that vaccination may lead to a considerable reduction of 
disease burden. However, efficacy in young infants is suboptimal and for those with the 
highest risk (younger than 6 months) no vaccine is approved. Furthermore, it should be 
noted that annual antigenic match for A/H3N2 subtypes (1991e2007) is relatively low 
(55-69%) and for B subtypes highly variable (38-100%).79 This will have major impact on 
the eventual effectiveness of vaccination. Therefore it is questionable if there is sufficient 
evidence and efficacy for inclusion of influenza vaccination in a NIP.
Adverse effects
Vaccination with TIV is associated with mild local reactions such as soreness or 
tenderness at the injection site. Fewer than 1% of adults immunized will also experience 
fever, chills, or a general sense of feeling unwell that lasts one to two days. These local 
reactions are not different between adjuvanted and non-adjuvanted TIV. Children are 
more likely to experience these symptoms. During the 2009 H1N1 pandemic influenza, 
more than 90 million people were vaccinated with non-adjuvanted TIV and adverse 
events have been monitored extensively due to public concerns regarding the safety of 
the vaccine. There were no adverse events associated with the use of this vaccine in 
children.80 The safety of the adjuvanted TIV (MF59) is comparable with non-adjuvanted 
vaccines in children.81,82 Increased incidence of Guillain-Barre´ has been reported for 
AS03 adjuvanted vaccines, but has been refuted in large observation studies.83-85 
Narcolepsy has been associated with the AS03 adjuvanted pandemic H1N1 vaccine in 
children and appears to be irreversible.86-89
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Vaccination with LAIV is associated with mild local symptoms such as rhinorrhea and 
nasopharyngeal congestion. Initially it was feared that LAIV in young children was 
associated with Bell’s palsy. However, this has not been observed in large cohort 
studies.90,91 It has been reported that LAIV is associated with wheezing in young children 
under the age of 2 years, although the incidence was not higher compared to TIV.92,93 
Only mild symptoms of rhinorrhea and headache are consistent in all studies.94
In animal models it has been shown that infection by seasonal flu induces hetero-sub-
typic protection (beneficial), whereas vaccination of mice and ferrets provides less 
protection against H5N1 compared to prior infection with seasonal flu.95,96 This could 
imply that vaccination reduces ‘natural’ protection against subsequent influenza 
infections. In contrast, for LAIV it has been demonstrated that CD4þCD8þ and gamma/
delta T-cells are induced which are relevant for hetero-subtypic immunity.97-100 Whether 
these immunological mechanisms play a relevant role on a population level and should 
be taken in account for vaccination policies needs to be further explored.101
In general it can be concluded that non-adjuvanted TIV and LAIV are only associated 
with mild adverse events. For children below the age of 2 years, data is limited and 
more studies are needed.
Number needed to vaccinate
The number needed to vaccinate to reduce overall disease burden can be expressed 
by prevention of outpatient visits, hospitalization or mortality. Lewis et al. included three 
studies for a meta-analysis and based on these studies it was calculated that 12-42 children 
aged between 6 and 59 months need to be vaccinated to prevent one outpatient visit.102 
To prevent one hospitalization, 1031-3050 children aged between 6 and 23 months and 
4255-6897 children aged between 24 and 59 months need to be vaccinated.102 No data 
are available regarding the number needed to vaccinate to prevent one death, due to 
the low mortality rates. These numbers indicate that an enormous number of children 
need to be vaccinated to reduce the burden of disease. It can be argued that vaccination 
of children may also prevent disease burden in the elderly by herd immunity and 
therefore the reduction of disease burden is higher.42 This was observed during the 
introduction of vaccination of school children in Japan and the US where morbidity and 
mortality rates due to influenza in the elderly decreased substantially.103,104 However, it is 
questionable whether it is ethical to vaccination children for this purpose.
Cost effectiveness
Prevention of influenza in children affects the consultation rate of healthcare workers 
and has an impact on the community, in terms of absence from school and parental 
work. This will directly result in cost reduction for healthcare providers as well as the 
community. In a sensitivity analysis from the healthcare provider perspective in Finland, 
it was calculated that vaccination was cost saving for all age groups. This was 
particularly evident in children aged 6-26 months.105 In this model, they used a moderate 
efficacy figure of 60% in account, which is feasible with current vaccines. These results 
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are comparable with calculations based on the situation in the US and the UK.106-108 The 
largest reduction cost (>50%) was achieved by prevention of otitis media in children 
younger than 3 years of age. In these models, the effect of childhood vaccination on the 
incidence of influenza in the elderly was not included and indirect cost savings might 
be much higher. These data indicate that vaccination of healthy children is cost effective.
In relation to other vaccines
The first five criteria discussed in this review assess objective measures of vaccine 
efficacy, effectiveness and necessity such as burden of disease, quality adjusted life 
years (QUALYs) and cost-effectiveness ratio. These criteria can be compared and 
guide healthcare policy regarding vaccination.109 However, both the financial resources 
and practical scope for including new vaccinations in the NIP are finite. Therefore 
priority should be given to vaccinations that serves the most urgent public health need, 
as measured by greatest public health benefit at reasonable individual and societal 
costs.53 This leads to a more subjective criterion: what is the most urgent or potentially 
most urgent public health need? No good criteria are currently available to compare 
vaccine candidates based on their urgency. As a result, in the final decision to include 
vaccines in NIP, politics are an important factor and public debate inevitable.
Conclusions
When the criteria of Houweling et al. are used to evaluate whether influenza vaccination 
of children should be implemented in the NIP, it is evident that not all criteria are met. 
Although currently safe and effective vaccines for children are available, they have not 
been tested in children under the age of 6 months, in which the burden of disease is the 
highest. Further, the number needed to vaccinate is enormous to prevent significant 
healthcare use and cost. Importantly, to have a significant benefit on a population level, 
high vaccination coverage is needed and therefore public support is mandatory.
The community can be critical on the subject of vaccination and discussions via internet 
and social media have a major impact. To maintain public support and high vaccination 
coverage in the NIP, inclusion of new vaccines should be based on scientific evidence. 
Based on the current-available literature, we conclude that sufficient evidence for 
universal influenza vaccination of healthy children is lacking.
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Abstract
Introduction: Respiratory viruses causing lower respiratory tract infections (LRTI’s) are 
a major cause of hospital admissions in children. Since the course of these infections 
is unpredictable with potential fast deterioration into respiratory failure, infants are easily 
admitted to the hospital for observation. The aim of this study was to examine whether 
systemic inflammatory markers can be used to predict severity of disease in children 
with respiratory viral infections.
Methods: Blood and nasopharyngeal washings from children < 3 years of age with viral 
LRTI attending a hospital were collected within 24 hours (acute) and after 4-6 weeks 
(recovery). Patients were assigned to a mild (observation only), moderate (supplemental 
oxygen and/or nasogastric feeding) or severe (mechanically ventilation) group. Linear 
regression analysis was used to design a prediction rule using plasma levels of CRP, 
SAA, PTX3, SAP and properdin. This rule was tested in a validation cohort. 
Results: One hundred and four children (52% male) were included. A combination of 
CRP, SAA, PTX3 and properdin was a better indicator of severe disease compared 
to any of the individual makers and age (69% sensitivity, 90% specificity). Validation 
in 141 patients resulted in 71% sensitivity, 87% specificity, NPV 64% and PPV of 90%. 
The prediction rule was not able to identify patients with a mild course of disease.
Conclusion: A combination of CRP, SAA, PTX3 and properdin accurately identifies a 
severe course of disease, especially in children under two months of age. 
Strengths and limitations of this study
- Identification and validation of novel markers to assess severity of disease in children 
with viral LRTI
- Combining biomarkers in linear regression model to optimize performance 
- Biomarkers and regression model adjusted for children under 2 months of age
- Other promising inflammatory markers, such as procalcitonin, were not included and 
could have further increased the clinical performance of test.
-  Study performed during admission hospital and ICU, validation needed in earlier 
stages of disease at ER and GP-office
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Introduction
Acute lower respiratory viral infections (LRTIs) annually result in hospitalisation of 
0.9-1.36% of a birth cohort.1,2 Eventually, 6 to 15% of these patients are admitted to the 
intensive care unit.1,3 Young age and prematurity are the most important risk factors for 
severe disease. This is reflected by the fact that over 50% of the children admitted to the 
ICU have no other risk factors besides young age.1,4,5
Infants under 2 to 3 months of age are easily admitted to the hospital due to a potentially 
rapid progression of disease. More than one third of all patients hospitalized with acute 
respiratory viral infections do not receive supportive care.5 However, 5% of the patients 
discharged from the emergency room require readmission at a later stage of the infection.6 
Therefore, there is a need for biomarkers that can predict the course of disease in 
infants with viral respiratory tract infections.
Currently, there are clinical prediction rules to predict safe discharge, length of hospital-
isation and ICU admission for children with acute respiratory viral infections based on 
demographic criteria and clinical symptoms.4,5,7-11 Although these clinical prediction 
rules show the potential to improve clinical judgement, validation in other cohorts is 
often lacking or implementation in daily practice is difficult due to subjective criteria.8,9 
Moreover, children under two months of age were either excluded or the studies were 
designed in such a way that all patients in this age group were automatically admitted 
to the hospital. A more objective, reproducible and sensitive prediction of disease 
severity for all age groups may be achieved by using biochemical and hematological 
markers.12-16 
Therefore, plasma proteins that were not yet extensively studied in the context of viral 
LRTI were identified from literature. Pentraxin 3 (PTX3) has been described as an early 
sensitive and specific marker for bacterial pneumonia in broncho-alveolar lavages of 
mechanically ventilated adults, and as a severity marker of meningococcal disease in 
children.17,18 In 2016 a study was published that showed that PTX3 levels are also a 
marker for LRTI in children and is more sensitive than CRP, which is frequently used in 
clinical care.19 No correlation between CRP levels and severity of viral disease has been 
described. When CRP levels are very high they indicate bacterial infection, however 
often CRP is moderately increased and then CRP is not able to differentiate between 
viral or bacterial aetiology of infection.20-23 Serum amyloid A (SAA) appears to be more 
sensitive than CRP for the detection of bacterial infections in neonates, although it is not 
used in daily practice.24 The SAA/CRP ratio can be used as a marker for severe disease 
in children with bacterial infections.25 Nakayama et al. have shown that SAA levels 
increase in children with different viral infections, including viral LRTI. However, an 
association with disease severity was not established.26 Serum amyloid P component 
(SAP) can activate the classical complement pathway and interacts with mannan-binding 
lectin (MBL). SAP is involved in inflammation and used as a marker for atherosclerosis 
and auto-immune disease.27 Skinner et al. have shown that SAP levels were not 
increased during bacterial pneumonia, suggesting a limited potential as biomarker in 
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infectious disease.28 No studies were found that assessed the role of SAP during viral 
infections. 
Properdin (CFP) is a positive regulator of the alternative pathway of the complement 
system and it is a pattern recognition molecule that can bind to apoptotic/necrotic cells 
or microbial pathogens (including viruses) to facilitate phagocytosis and clearance.29,30 
Familial deficiencies in CFP are known and are associated with susceptibility to 
meningococcal infections.31,32 However, an increased susceptibility to viral infections 
has never been published. 
In this study we tested the aforementioned plasma proteins for their correlation with 
severity of viral lower respiratory tract infections in children. 
Materials and Methods
Study design
Children younger than 3 years of age were eligible for inclusion if they attended one of 
the two hospitals in Nijmegen from September until May with symptoms of an acute 
viral lower respiratory tract infection (LRTI). Symptoms included signs of increased 
respiratory effort (e.g. tachypnea and/or use of accessory respiratory muscles or 
retractions) and/or expiratory wheezing and/or crackles and/or apnea. Patients with 
congenital or acquired immune deficiencies, immunosuppressive medication (including 
> 24 hours of corticosteroids) or severe psychomotor retardation were excluded. 
Eligible patients were identified by their physician, who notified the study team. When 
informed consent of both parents was obtained within 24 hours of admission patients 
were included in the study. Data on clinical parameters, course of disease, medical 
history and demographics were retrieved from medical records and questionnaires. 
Retrospectively, after discharge patients were allocated into three groups: mild, send 
home or only clinical observation; moderate, patients with need for supplemental 
oxygen and/or nasogastric feeding; and severe, patients with mechanical ventilation. 
Supplemental oxygen was started according to the protocols from the clinical wards in 
patients with an oxygen saturation of ≤ 92% for at least 10 minutes after use of 
decongestives. Results were evaluated in a training cohort (n=104, 2010-2012) and 
subsequently tested in a larger historical validation cohort with the same inclusion and 
exclusion criteria (n=141, 2006-2009). The study was approved by the Committee on 
Research involving Human Subjects.
Material collection
After informed consent, blood and a nasopharyngeal wash were collected within 24 
hours (acute), and after 4-6 weeks (recovery). A venous blood sample (3ml) was 
collected in sodium heparin tubes and immediately transported to the laboratory. 
Plasma (and cell fractions) were obtained after density centrifugation (Lymphoprep®, 
Axis Shield, Norway) and stored at -80°C. After instilling 0.5 ml of saline into one of the 
Processed on: 1-3-2017
508516-L-bw-Ahout
93
Assessing severity of disease in children with respiratory viral infections
6
nostrils, a catheter was introduced into the nasopharynx to aspirate nasopharyngeal 
fluid. Samples were instantly put on ice, transported to the laboratory and stored at 
-80°C. Multiplex RT-PCR was performed on the nasal wash to confirm viral aetiology of 
disease, as previously described.33 The assay was designed to detect fifteen viruses.
ELISA
Levels of SAA, SAP, PTX3, CFP and CRP were determined in two fold diluted plasma by 
ELISA following the manufacturer’s instructions (Hycult Biotech, Uden, The Netherlands, 
Catalog No’s HK333, HK331, HK347, HK334 and HK358, respectively)
Statistics
Data are expressed as percentages for categorical variables and as mean and standard 
error of the mean (SEM) or median and inter quartile range (IQR) for the non-parametric 
continuous variables. Kruskal-Wallis tests were performed on continuous variables, 
followed by Mann-Whitney U to further analyze differences. For categorical data, 
Chi-square testing was used. Paired data was tested with the Wilcoxon Signed-Rank 
Test. Correlations were calculated using Spearman’s rho. The optimal predictive 
combination of proteins was selected using the M5 method linear regression, which 
removes classifiers with the smallest standardized coefficient one-by-one until no 
decrease in error estimate is observed . The outcome of the obtained rule was analysed 
for its Receiver Operator Characteristics (ROC). Cut-off values were determined for 
both mild and severe disease. These cut offs were subsequently validated in a second 
cohort. A two-sided p value of < 0.05 was considered statistically significant. Statistical 
tests were performed by SPSS for Windows (Release 19, SPSS Inc., Chicago, IL) and 
Waikato Environment for Knowledge Analysis (WEKA) was used to perform linear 
regression. 34
Results 
Patient characteristics
The training cohort consisted of 104 children (overall inclusion percentage 60%) (Table 6.1). 
Children with severe disease were significantly younger and had more often siblings 
than patients in the mild and moderate groups. Duration of hospitalisation significantly 
increased towards more severe disease. 2% of the patients were not hospitalised 
(2/104), whereas 17% of the hospitalised patients had only mild disease. RSV was 
detected in the majority of patients (65%), in 43% viral co-infections were present. The 
highest proportion of RSV mono-infections was seen in children with a severe course of 
disease (p<0.001), as was previously published by our group.33
Processed on: 1-3-2017
508516-L-bw-Ahout
94
Chapter 6
Markers for infection and disease severity
Plasma levels of CRP, SAP, SAA and PTX3 increased significantly during disease 
compared to levels in recovery samples whereas CFP levels did not differ between 
these two time points (Figure 6.1A-B). When the acute disease group was subdivided 
into three severity classes, plasma levels of CRP during severe disease were significantly 
higher compared to patients with mild and moderate disease (Figure 6.2A). Although 
there was a stepwise incline in plasma levels of PTX3, there were no significant 
differences (Figure 6.2B). Plasma levels of SAP were also equal between the different 
disease severities (Figure 6.2C). SAA plasma levels however, were significantly higher 
during severe disease compared to mild disease (Figure 6.2D). CFP plasma levels did 
not differ between mild and moderate disease. In contrast to the other markers, the CFP 
plasma levels dropped significantly in patients with severe disease (Figure 6.2E).
Since disease severity can also be reflected by the duration of hospitalisation and the 
need for supplemental oxygen (as substitute for the need for hospitalisation) we tested 
whether they correlated with the plasma proteins. Both CRP and CFP correlated 
significantly with duration of hospitalisation (ρ=0.361, p≤0.001 and ρ=-0.22, p<0.05, 
respectively). However, PTX3, SAP and SAA levels did not. The need for supplemental 
oxygen was associated with higher levels of CRP and PTX3 (Figure 6.2A-B), whereas 
the other markers showed no significant difference.
The influence of age and viral aetiology on protein levels
Children with severe disease are significantly younger (Table 6.1), therefore we checked 
whether age is a confounder for our protein levels. After stratification of the cohort per 
severity and age group (under and above two months of age) protein levels were 
Table 6.1  Patient characteristics.
Total
N=104 (%)
Mild  
n= 20 (%)
Moderate 
n=52 (%)
Severe 
n=32 (%)
p-value
Gender (male) 54 (52%) 12 (60%) 24 (46%) 18 (56%) NS
Age (days) 92 
[38.2-289.8]
129 
[63.0-368.3]
165.0 
[66.0-422.0]
37.5 
[22.0-86.5]
<0.001*
Prematurity (< 35 wks) 5 (5%) 1 (5%) 3 (6%) 1 (3%) NS
Onset symptoms (days) 3.0 [2.0-4.8] 2.5 [1.3-3.8] 3.0 [2.0-5.0] 4.0 [2.0-4.8] NS
Duration admission (days) 6.5 [3.3-10.8] 2.0 [2.0-3.0] 6.0 [4.0-8.0] 11.0 [9.3-13.8] <0.001**
Supplemental oxygen 78 (75%) 0 46 (89%) 32 (100%) <0.001***
RSV infection 68 (65%) 8 (40%) 38 (73%) 23 (72%) <0.05 ****
% mono infection RSV 39 (57%) 3 (37,5%) 20 (53%) 16 (70%) <0.001
Values are given in numbers (percentages) or medians [25th – 75th percentiles]. * mild vs severe p=0.001, 
moderate vs severe p<0.0001 ** mild vs moderate/severe p<0.0001, moderate vs severe p<0,0001 *** mild 
vs moderate/severe (p<0,0001), moderate vs severe p<0,05 **** mild vs moderate/severe (p<0.05).
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compared. After Bonferroni correction no significant differences were found in the group 
under two months of age. Thus, age is no confounder for our markers in the prediction 
of severe disease. 
RSV mono-infections are more frequently seen in the severe disease group (Table 6.1). 
We tested whether patients with RSV mono-infections also had higher plasma levels 
compared to patients with the same disease severity without RSV mono-infections. We 
found that patients with RSV mono-infections had significantly higher SAA levels during 
severe disease (p<0.05). Levels of all other inflammatory markers were equal. 
Accuracy of the inflammatory markers to predict disease severity
After finding differences in plasma levels in patients with different disease severities the 
diagnostic performance of the proteins was tested. First, the performance of the 
markers to indicate the need for hospitalisation (supplemental oxygen) was assessed. 
Of 104 patients included for analysis 27 did not receive supplemental oxygen: 6 of 
these patients belonged to the moderate group (Table 6.1). The area under the curve 
(AUC) for the markers CRP and PTX3 was 0.63 and 0.64 respectively. The AUC for the 
other markers was 0.59 for SAA, 0.57 for SAP and 0.51 for CFP. 
Second, the performance of markers to indicate the need for mechanical ventilation 
(severe disease) was assessed. Of 104 patients included for analysis, 32 were 
mechanically ventilated (Table 6.1). The AUC of the markers that were associated with 
severe disease, CRP, SAA and CFP, was 0.73, 0.57 and 0.76 respectively. The AUC for 
the other markers was 0.56 for PTX3 and 0.53 for SAP. 
Figure 6.1  Comparison of plasma protein levels in children with acute respiratory viral infections 
(n=104) with their paired recovery sample (n=51) taken 4-6 weeks after acute infection are shown 
for CFP, SAA, SAP, CRP (A) and PTX3 (B) (Wilcoxon matched-pairs signed rank test).
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Figure 6.2  Comparison of protein levels between patients with mild (n=21), moderate (n=51) 
and severe (n=32) disease and for patients with (n=77) and without (n=27) the need for 
supplemental oxygen are shown for CRP (A), PTX3 (B), SAP (C), SAA (D) and CFP (E) (Mann 
Whitney U test).
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Combining inflammatory markers increases performance
As reflected by the AUC, none of the single markers was considered sufficient to identify 
mild disease and thus aid in the decision to discharge a patient. Whereas the AUC of 
some markers for severe disease were slightly higher, none of them exceeded 0.8. 
Therefore, linear regression modelling was used to analyse whether a combination of 
markers could increase the individual performance. The assumption was that distances 
between the three groups were equal. The linear regression resulted in the following 
model: (5.8 x PTX3) + (1.15 x CRP) – (4.1 x CFP) – (0.93 x SAA) + 106.25. The AUC for 
this rule is 0.65 for mild disease (no need for supplemental oxygen) and 0.89 for severe 
disease (mechanical ventilation). 
Based on the ROCs, a cut-off value for the identification of mild disease was set at 
93.50, which resulted in an AUC of 0.65 and sensitivity of 55%, a specificity of 70%, a 
positive predictive value (PPV) of 39% and a negative predictive value (NPV) of 82%). In 
< 2 months old children the AUC is 0.88 (sensitivity 87%, specificity 71%, PPV 93% and 
NPV 56%), whereas in > 2 months old patients the AUC is 0.50 (sensitivity 57%, 
specificity 47%, PPV 72% and NPV 31%).
The cut-off value for severe disease was set at 122 (sensitivity 69%, specificity 90% with 
a PPV of 76% and an NPV of 87%) with an AUC of 0.88. In children below two months 
of age the AUC for severe disease increased to 0.90 (sensitivity 72%, specificity 85%, 
PPV 82% and NPV 77%). In older children the AUC is 0.86 (sensitivity 55%, specificity 
93%, PPV 60% and NPV 91%).
Validation of prediction rules
A new cohort of 141 children was tested. Patient characteristics of the original and 
validation cohort were similar with respect to their distribution of age, gender and 
number of prematurely born infants (less than 35 weeks). In contrast to the training 
cohort, the presence of siblings was not significantly different between the severity 
groups in the validation cohort (Supplemental Table 6.1 and Supplemental Figure 6.1). 
Need for supplemental oxygen
Validation of the prediction rule for mild disease, need for hospitalization, resulted in 
51% sensitivity and 68% specificity (PPV 46% and NPV 72%). In children below two 
months of age the rule performed better the AUC increased from 0.67 to 0.79 (sensitivity 
55%, specificity 81%, PPV 46% and NPV 86%). In children > 2 months the AUC 
decreased to 0.58 (sensitivity 52%, specificity 60%, PPV 42% and NPV 69%).
Need for mechanical ventilation
When the prediction rule was applied to the validation set with a cut-off of 1.22, the 
sensitivity for severe disease was 71% with 87% specificity, PPV and NPV were 64% and 
90%, respectively. 
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In children below two months of age the AUC for severe disease is 0.87 (sensitivity 77%, 
specificity 57%, PPV 45%, NPV 84%). In older children the AUC remains 0.87 (sensitivity 
58%, specificity 90%, PPV 52%, NPV 92%). 
Discussion
In this study, we show that plasma levels of CRP, PTX3, SAA and CFP correlate with 
disease severity in children with acute viral LRTI. Furthermore, we demonstrate that a 
combination of these markers significantly increased the performance of the individual 
proteins to identify patients with severe disease. The designed prediction rule has been 
validated in a larger independent patient cohort with similar characteristics, which 
resulted in a comparable performance. Moreover, the performance of the rule was best 
in patients under two months of age (<60.5 days) in whom it is clinically difficult to 
predict the course of disease. 
Interestingly, most of the inflammatory markers investigated in this study have not been 
described in the context of viral LRTI or disease severity. The increase of CRP and SAA 
levels during viral infection was known and this was also the reason to include the 
proteins in our study. We were able to confirm the work of Huttunen et al. that the ratio 
SAA/CRP is significantly decreased in patients with severe disease compared to 
patients with mild and moderate disease (data not shown).25 Moreover, CRP and SAA 
levels both correlated with severity of viral LRTI’s and CRP was also correlated with 
length of hospitalisation. To the best of our knowledge, these findings have not been 
described before. The increase in PTX3 levels during more severe disease and a 
correlation with need for supplemental oxygen show the potential of PTX3 as biomarker 
for viral LRTI in children. This was already proposed by others, who saw a correlation 
with peak temperature, duration of fever and presence of pneumonia in mechanically 
ventilated patients.17,19 Although SAP levels significantly increase during infection, no 
correlation could be observed with disease severity in children with viral LRTI. Therefore, 
it appears that SAP could not be used as a biomarker for disease severity in viral or 
bacterial infections.28 This study is the first to describe the remarkable kinetics of CFP 
(Properdin) levels, which decrease during severe viral infection in children. We were 
unable to find an explanation in literature. However, since CFP levels restored in the 
available recovery samples, a deficiency is highly unlikely. Other possible explanations 
for the decrease might be consumption, as occurs with other complement factors, or 
an (unrecognised) bacterial co-infection. Although cultures were routinely taken at the 
intensive care unit before the start of SDD antibiotics, bacterial infections cannot be 
ruled out completely. A sub analysis of patients with (n=10) and without (n=15) positive 
bacterial cultures on the ICU showed no difference in protein levels (data not shown). 
During the study period selective digestive decontamination (SDD) was standard 
practice in the ICU and therefore all severe patients would have had at least one gift of 
prophylactic antibiotics before the study samples were taken. 
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The prediction rule for the identification of children with a mild course of disease 
appeared to be insufficient for clinical use (AUC 0.65). However, the performance in 
children under two months of age (AUC 0.88) is promising and might provide additive 
value in clinical decision making. Currently, there are no comparable laboratory based 
studies assessing the identification of mild disease. Clinical rules for safe discharge 
based on age and findings at physical examination have been developed. Unfortunately, 
in these studies children below 2 months of age were excluded or automatically 
admitted regardless of the necessity of treatment.5,31,35,36
The identification of patients with severe disease was accurate with the chosen 
inflammatory markers (AUC 0.89). The prediction performed better than age on itself 
(AUC 0.77). A prediction rule based on IL-8 and RANTES in plasma and CD4+ T cell 
counts accurately identifies severe disease, but needs to be validated in an independent 
cohort to establish clinical potential.16 A combination of biochemical, hematological and 
clinical data might further improve accuracy. A drawback of introducing clinical variables 
is that most of the published risk factors in clinical prediction are not objective or may 
change rapidly in time. Moreover, signs and symptoms of children can be ambiguous 
at the moment of presentation and only become clear after prolonged observation. 
Prediction rules using clinical data, often show a lower AUC and validation studies of 
these rules are lacking or have a smaller sample size.4,37
The advantage of measuring markers in plasma is the easy implementation, speed, 
reproducibility and standardisation. Moreover, with the use of linear regression tools it 
is easy to add new markers to optimize the rule. It is tempting to speculate that some of 
the biomarkers precede clinical symptoms and could therefore be used early in the 
course of disease to predict severe outcome. Currently, there is no targeted therapy for 
most respiratory viruses and therefore there are no consequences to the early 
identification of patients with a severe course of disease besides optimalisation of 
supportive care. The identification of children with a mild course of disease has more 
visible consequences, as can be measured in reduced hospitalisation rates or length 
of stay in the hospital. To truly estimate the value of the markers a prospective study is 
needed, moreover it would be interesting to measure the markers earlier in the course 
of disease. However, even before the markers are implemented in the clinic, biomarkers 
could be used to stratify patients in clinical studies and as secondary end-point in 
intervention studies. With the current development of point-of-care tests, plasma protein 
levels can be available within a relevant time frame. 
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Supplemental Table 6.1 Patient characteristics validation cohort. 
Total 
n=141 (%)
Mild  
n=43 (%)
Moderate 51 
n=63 (%) 
Severe 
n=35 (%)
p-value 
Gender (male) 84 (60) 24 (55) 36 (57) 24 (69) NS
Age (days) 84 [35-211] 174 [58-299] 99 [39-220] 45 [25-96] <0.001*
Prematurity (< 35 wks) 20 (14) 5 (12) 6 (10) 9 (26) NS
Onset symptoms (days) 4 [3-6] 4 [3-7] 4 [3-6] 5 [3-6] NS
Duration admission (days) 5 [2.25-8.75] 2 [0-4] 5 [3-7] 11 [8-13] <0.001**
Supplemental oxygen 92 (65%) 0 57 (91%) 35 (100%) <0.001***
RSV infection 94 (67) 28 (57) 40 (70) 26 (74) NS
RSV mono-infection 60 (62.5) 12 (24) 25 (44) 21 (60) <0.05****
Values are given in numbers (percentages) or medians [25th – 75th percentiles]. *mild vs severe p<0.001 and 
moderate vs severe p<0.01. ** mild vs severe p<0.05. ***mild vs moderate/severe and moderate vs severe 
p<0.001.
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Supplemental Figure 6.1 Comparison of protein levels between patients with mild (n=43), 
moderate (n=63) and severe (n=35) disease and for patients with (n=169) and without (n=76) the 
need for supplemental oxygen are shown for CRP (A), PTX3 (B), SAP (C), SAA (D) and CFP (E) 
(Mann Whitney U test).
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Abstract
Background: Respiratory syncytial virus (RSV) is a common cause of bronchiolitis in 
infants with a wide spectrum of disease severity. Besides environmental and genetic 
factors, it is thought that the innate immune system plays a pivotal role. The aim of this 
study was to investigate the expression of immune receptors on monocytes and the in 
vitro responsiveness from infants with severe RSV infections.
Methods: Peripheral blood mononuclear cells (PBMCs) from infants with RSV infections 
were isolated. Classical, intermediate and nonclassical monocytes were immuno-
phenotyped for the expression of CD14, CD16, human leukocyte antigen (HLA)-ABC 
and HLA-DR. PBMCs were stimulated with lipopolysaccharide to determine the secretion of 
tumor necrosis factor and interleukin (IL)-10 with enzyme-linked immunosorbent assay. 
Results: During RSV infection, intermediate monocytes are increased in the peripheral 
blood, whereas classical and nonclassical monocytes are reduced. The expression of 
CD14 and HLA-ABC is increased on monocytes, whereas the expression of HLA-DR 
is suppressed. Low HLA-DR expression is correlated with increased disease severity. 
PBMCs from infants with severe RSV infections show an impaired IL-10 response in 
vitro.
Conclusions: Phenotyping subpopulations of monocytes combined with in vitro 
responsiveness reveals significant differences between nonsevere and severe RSV 
infections. Reduced HLA-DR expression and impaired IL-10 production in vitro during 
severe RSV infections indicate that an imbalanced innate immune response may play 
an important role in disease severity.
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Introduction
Respiratory syncytial virus (RSV) is a common cause of bronchiolitis in children <2 
years of age.1 The clinical manifestations of RSV infection range from a common cold 
to severe lower respiratory tract infections that require oxygen treatment. Although known 
risk factors such as prematurity, cardiopulmonary disease and immune deficiencies are 
used in clinical prediction models, these factors only successfully predict approximately 
50% of severe RSV infections.2 Severe RSV infections that require oxygen treatment 
typically occur in infants <3 months of age and usually involve primary infections. 
The occurrence of severe RSV infections is associated with subsequent wheezing 
episodes and diagnosis of asthma.3 Tregoning and Schwarze describe several factors 
determining the pathogenesis of RSV disease, including physical, environmental and 
genetic factors.4 In addition to these factors, it is increasingly thought that the innate 
immune system plays an important role in determining the clinical course of infection. 
Innate immune cells like monocytes are recruited from the blood stream to the site of 
infection, where they can either directly contribute to the host antimicrobial defense 
or supply the inflamed tissue with differentiated macrophages and dendritic cells to 
target the pathogen.5 Circulating monocytes are part of the innate immune system and 
appear to be heterogenic. Different subpopulations of circulating monocytes reflect 
developmental stages, and each subset has a distinct role in inflammatory processes 
and infectious diseases.6 Based on the expression of CD14 and CD16, monocytes 
can be divided into 3 subpopulations: classical CD14++CD16−, intermediate 
CD14++CD16+ and nonclassical CD14+CD16++ monocytes.7,8 The regulation of the 
immune response and the role of monocytes and its receptors in disease severity have 
previously been shown for bacterial infections. The expression of human leukocyte 
antigen (HLA)-DR on monocytic cells is reduced during severe bacterial infections, 
and a possible mechanism for this correlation between low HLA-DR expression and 
increased disease severity is a phenomenon called immunoparalysis.9–11 HLA-DR 
molecules are membrane-bound molecules that play a role in antigen presentation 
and T cell activation. Immunoparalysis refers to the combination of reduced HLA-DR 
expression and reduced in vitro responsiveness to lipopolysaccharide (LPS) resulting 
in severe disease progression. Although extensive research is deciphering the disease- 
enhancing effect of immunoparalysis in the field of bacterial infections, the role of 
immuno paralysis is yet to be elucidated in the context of severe viral respiratory tract 
infections.
In the context of RSV, the role of antiviral monocytes has been appreciated for decades 
and, in vitro, interaction of RSV with monocytes leads to an upregulation of innate 
inflammatory mediators.12–15 These inflammatory cytokines shape the homeostatic 
balance for eliciting an adequate immune response. In vivo, an imbalance in cytokine 
production contributes to RSV pathogenesis and severe RSV infections.16 However, it is 
unknown whether monocytes can play a role in the regulation of the immune response 
against RSV and thereby either prevent or contribute to disease severity.
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In this study, we assessed immunological markers on monocytes in infants with nonsevere 
and severe RSV infections based on the need for oxygen treatment. For this purpose, 
circulating monocytes were phenotyped in a cohort of infants with RSV infections. The 
expression of CD14, HLA-ABC and HLA-DR was correlated with the presence of RSV 
infection and with disease severity. Finally, peripheral blood mononuclear cell (PBMC) 
stimulation was performed to assess the in vitro responsiveness of PBMCs during RSV 
infections in infants.
Materials and Methods
Study Design
Children <2 years of age hospitalized with RSV bronchiolitis were prospectively included 
from November 2010 to April 2013 after informed consent from both parents. Bronchiolitis 
was defined as an acute infection of the lower airways, characterized by increased 
respiratory effort and expiratory wheezing and/or crackles and/or apnea. Nasopharyngeal 
aspirates from all patients included were RSV positive. Clinical data were collected from 
questionnaires, including age, sex, gestational age, birth weight, breastfeeding, duration 
of symptoms, duration of oxygen therapy, the use of  corticosteroids and/or antibiotics, 
vaccination with palivizumab and duration of  hospitalization. Within 24 hours after 
presentation to the hospital, 3-mL sodium heparinized blood was collected. Retro-
spectively, patients were classified into 2 groups: no oxygen treatment versus oxygen 
treatment by nasal cannula or mechanical ventilation (when oxygen saturation was <93% for 
>10 minutes).17,18 Recovery samples were collected 4–6 weeks after presentation. Samples 
from healthy infants undergoing elective surgery for inguinal hernia served as age- and 
sex-matched controls. Nasopharyngeal aspirates from all healthy controls were RSV 
negative.
Virus Detection
Multiplex real-time reverse transcription polymerase chain reaction for 15 viruses was 
performed on nasopharyngeal aspirates as previously described.19
Cell Differentiation
A thin blood smear of sodium heparinized blood was made, and Giemsa staining was 
used to enable cell differentiation.
Isolation of PBMCs 
PBMCs were isolated using Lymphoprep (Axis-Shield, Oslo, Norway). Briefly, blood 
was anticoagulated with sodium heparin (BD Vacutainer, Becton Dickinson, Franklin 
Lakes, NJ) and diluted with an equal volume of phosphate-buffered saline. The diluted 
blood was carefully added on top of the Lymphoprep and centrifuged at 800g. PBMCs 
were harvested, washed twice in phosphate-buffered saline and counted by the use of 
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a hemocytometer. PBMCs from infants with RSV infection were stored in liquid nitrogen 
in 10% fetal calf serum and 10% dimethylsulfoxide.
Stimulation of PBMCs
Directly after collection, 5 × 105 PBMCs in a 100µL volume were added to an equal 
volume of Roswell Park Memorial Institute medium (negative control) or LPS (Escherichia 
coli 1 ng/mL) and incubated at 37°C and 5% CO . After 20 hours, the supernatant was 
stored at −20°C for cytokine measurement.
Immunophenotyping
PBMCs were thawed and leukocyte subsets were determined using fl w cytometry; 2 
× 105 PBMC were incubated with 50µL flurochrome-labeled monoclonal antibodies for 
30 minutes in the dark on ice in 96-well microtiter plates. CD14 V500, CD16 Alexa Fluor 
700, HLA-ABC V450 and HLA-DR Qdot605 were used (Becton Dickinson). Results were 
acquired on a BD LSR II flow cytometer, and data were analyzed using FlowJO (Tree Star, 
Inc, Ashland, OR). For gating, live cells were selected as 7-AAD-negative cells. Next, 
HLA- DR-positive, HLA-ABC-positive and SSC high cells were selected to include anti-
gen-presenting cells and exclude NK cells, T cells and B cells. CD14-positive cells were 
selected and divided into CD16- negative and CD16-positive cells to select classical 
CD14++CD16−, intermediate CD14++CD16+ and nonclassical CD14+CD16++ 
monocytes. CD14, HLA-ABC and HLA-DR expressions were measured by the 
geometric mean of fluerescense intensity.
Enzyme-linked Immunosorbent Assay
Tumor necrosis factor (TNF) and interleukin (IL)-10 concentrations were measured in 
supernatant of the stimulation assay with commercial enzyme-linked immuno sorbent 
assay kits (PeliKine Compact, Sanquin, the Netherlands) according to the manufacturer’s 
instructions. The detection limits were 78 and 9.4 pg/mL, respectively.
Statistical analysis
The distribution of categorical variables was presented as percentages per category. 
Expression levels of membrane-bound receptors were depicted as geometric mean 
fluorescence intensity and presented as medians with interquartile range. The 
Kruskal-Wallis test was performed followed by the Mann-Whitney U test for individual 
comparisons. Cytokine values were presented as mean with standard error of the mean, and 
Mann-Whitney U test was performed for statistical analysis. Pearson tests were performed 
to test for correlations. A value of P < 0.05 was considered statistically significant. All 
statistical tests were performed with GraphPad (GraphPad Inc, La Jolla, CA).
Study Approval
The study protocols were approved by the Regional Committee on Research involving 
Human Subjects Arnhem-Nijmegen (serving as the Institutional Review Board) and 
2
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were conducted in accordance with the principles of the Declaration of Helsinki. Written 
informed consent was obtained from the parents of all children.
Results
Characterization of Study Population
Forty-eight patients were included for flowcytometry analysis. Fifteen healthy controls 
were included for comparison. There was no significant difference in age and sex 
between groups (see Table 7.1). The gestational age and birth weight of the healthy 
controls were lower compared with those of RSV-infected infants. There was no 
difference in the presence of prematurity between the groups (see Table 7.1). There was 
no difference in gestational age between infants without oxygen treatment and infants 
with oxygen treatment (see Table7. 1). In a second cohort for in vitro responsiveness 
to LPS, 37 patients and 12 healthy controls were included. There was no significant 
difference in age, sex or prematurity between groups. The gestational age and birth 
weight of the healthy controls were lower compared with those of RSV-infected infants 
(see Table, Supplemental Digital Content 1, http://links.lww.com/INF/C336).
Total Monocyte Count Is Not Increased During Acute Infection and 
Does Not Discriminate Between Disease Severity
There is no significant difference in the absolute number of peripheral monocytes of 
infants during RSV infection compared with the recovery phase (Figure 7.1). There is no 
difference in monocyte count between disease severity groups (Figure 7.1).
The Percentage of Intermediate Monocytes Is Increased During  
RSV Infection
We first determined whether the subsets of monocytes in the peripheral blood are 
different during RSV infection compared with healthy controls or recovery samples. 
Monocytes were divided into 3 subpopulations based on the expression level of CD14 
and CD16: classical CD14++CD16−, intermediate CD14++CD16+ and nonclassical 
CD14+CD16++ monocytes. The main population of circulating monocytes consists of 
classical monocytes, and the percentage of these classical monocytes was significantly 
lower in the acute phase compared with the recovery phase (Figure 7. 2A). During RSV 
infection, a significantly higher percentage of intermediate monocytes compared with 
healthy controls and with the recovery phase was observed (Figure 7.2A). The percentage 
of nonclassical monocytes is significantly lower in the acute phase compared with 
healthy controls and the recovery phase (Figure 7.2A). Besides a reduced percentage 
of classical monocytes in RSV-infected infants with oxygen treatment, no differences 
were observed between disease severity groups (Figure 7.2B). These data suggest 
that the pool of peripheral blood monocytes is dynamic and changes in favour of 
intermediate monocytes during RSV infection.
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CD14 Expression on Monocytes Is Increased During RSV Infection
We next investigated whether monocytes during RSV infection are phenotypically 
different. The expression level of the surface marker CD14 was measured, and we 
observed an increased expression of CD14 on all 3 subpopulations of monocytes 
during the acute phase of infection (Figure 7.3A). This increased expression of CD14 
was present in all RSV-infected infants, and there was no difference in the expression of 
CD14 between the disease severity groups (Figure 7.3B). We observed no correlation 
between CD14 expression and age (data not shown).
HLA-ABC Expression on Monocytes Is Increased During  
RSV Infection
Antigen-presenting molecules on monocytes have been implicated in disease 
occurrence and progression. To determine whether monocytes contained increased 
amounts of antigen-presenting molecules during RSV infection, we first measured the 
expression level of HLA-ABC on all subsets of monocytes. We observed an increased 
expression of HLA-ABC on all 3 subpopulations of monocytes during RSV infection 
(Figure 7.4A). There was no difference in the expression of HLA-ABC between disease 
severity groups after RSV infection (Figure 7.4B). We observed no correlation between 
HLA-ABC expression and age (data not shown).
Table 7.1 Cohort Characteristics.
Healthy (n= 15) No Oxygen (n = 8) Oxygen (n =40) p Value
Age (d) 79.0 [68.0–94.0] 80.5 [60.0–181.5] 70.0 [37.0–181.8] NS
Male gender (%) 12 (80) 4 (50) 20 (50) NS
Gestational age (wk) 37.0 [33.0–39.0] 39.4 [38.3–40.0] 39.0 [37.0–41.0] <0.05*
Prematurity (%) 7 (47) 1 (13) 8 (20) NS
Birth weight (kg) 2.6 [2.1–3.1] 3.2 [2.8–4.1] 3.2 [2.8–4.0] <0.05†
Breast-feeding (%) 7 (47) 3 (37.5) 25 (62.5) NS
Symptomatic (d) 0 (0) 4.0 [3.0–5.0] 4.0 [3.0–5.0] NS
Duration O2 (d) 0 (0) 0 (0) 4.5 [2.0–8.8] <0.001‡
Duration MV (d) 0 (0) 0 (0) 0 [0–8.8] <0.05§
Corticosteroids (%) 0 (0) 0 (0) 0 (0) NS
Antibiotics (%) 0 (0) 4 (50) 22 (55) NS
Palivizumab (%) 0 (0) 0 (0) 0 (0) NS
Hospitalization (d) 0 (0) 4.0 [2.0–7.5] 8.0 [5.0–11.0] <0.001
*Healthy vs. no oxygen and oxygen P < 0.05. †Healthy vs. oxygen P < 0.01. ‡Oxygen vs. no oxygen P < 0.001. 
§Oxygen vs. no oxygen P < 0.001. ¶Healthy vs. no oxygen and oxygen P < 0.001, oxygen vs. no oxygen P < 0.05.
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Low HLA-DR Expression on Monocytes Is Correlated With Increased 
Disease Severity and Prolonged Hospitalization
Low HLA-DR expression on monocytes has been associated with increased disease 
severity of bacterial infections. We determined the level of HLA-DR expression on 
monocytes to correlate HLA-DR expression with disease severity in RSV infection. 
The HLA-DR expression on classical and intermediate monocytes was significantly 
lower during RSV infection (Figure 7.5A). The expression of HLA-DR on classical 
and intermediate monocytes correlates with diseases severity. Monocytes from 
RSV-infected infants with- out oxygen treatment have comparable expression levels of 
HLA- DR compared with healthy controls (Figure 7.5B). Severe RSV-infected infants 
requiring oxygen therapy have lower expression levels of HLA-DR compared with both 
RSV-infected infants without oxygen therapy and healthy controls (Figure 7.5B).
We observed no correlation between HLA-DR expression and age, suggesting that age 
is most likely not a potential confounder for the reduced HLA-DR expression in severe 
RSV infections (data not shown). As a second parameter, we determined whether 
HLA-DR expression was correlated with the duration of hospitalization. Reduced 
HLA-DR expression on classical monocytes significantly correlated with prolonged 
hospitalization (Figure 7.5C). These data indicate that low HLA-DR expression is 
Figure 7.1  Monocyte count in the peripheral blood determined by blood smear analysis. Monocyte 
counts during the acute phase of RSV infection and during the recovery phase. Values are 
depicted as medians ± interquartile range. Testing was performed with Kruskal-Wallis and if 
significant followed by the Mann-Whitney U test.
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Figure 7.2  The percentage of intermediate monocytes is increased during RSV infection. A, 
Percentages of monocyte populations in the acute phase of RSV infection compared with healthy 
controls and the recovery phase. B, Percentages of monocyte populations in infants categorized 
by disease severity. Values are depicted as medians ± interquartile range. Testing was performed 
with Kruskal-Wallis and if significant followed by the Mann-Whitney U test (*P < 0.05, **P < 0.01, 
***P < 0.001).
A
B
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Figure 7.3  CD14 expression on circulating monocytes is increased during RSV infection. A, CD14 
expression on monocytes during the acute phase of RSV infection compared with healthy controls 
and the recovery phase. B, CD14 expression on monocyte populations in infants categorized by 
disease severity. Values are depicted as medians ± interquartile range. Testing was performed 
with Kruskal-Wallis and if significant followed by the Mann-Whitney U test (*P < 0.05, **P < 0.01, 
***P < 0.001).
A
B
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Figure 7.4  HLA-ABC expression on circulating monocytes is increased during RSV infection. A, 
HLA-ABC expression on monocytes during the acute phase of RSV infection compared with 
healthy controls and the recovery phase. B, HLA-ABC expression on monocyte populations in 
infants categorized by disease severity. Values are depicted as medians ± interquartile range. 
Testing was performed with Kruskal-Wallis and if signify followed by the Mann-Whitney U test 
(*P < 0.05, **P < 0.01).
A
B
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Figure 7.5  Low HLA-DR expression is correlated with increased disease severity and prolonged 
hospitalization. A, HLA-DR expression on monocytes during the acute phase of RSV infection 
compared with healthy controls and the recovery phase. B, HLA-DR expression on monocyte 
populations in infants categorized by disease severity. Values are depicted as medians ± 
interquartile range. C, Correlation between duration of hospitalization and HLA-DR expression on 
classical monocytes. Testing was performed with Kruskal-Wallis and if significant followed by 
Mann-Whitney U test. Testing for correlation was performed with the Pearson test (*P < 0.05, 
**P < 0.01, ***P < 0.001).
A
B
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associated not only with the presence of RSV infection but also with increased disease 
severity, oxygen treatment and prolonged hospitalization.
Severe RSV Infections Are Associated With Impaired In Vitro IL-10 
Production Upon Stimulation With LPS
Besides low HLA-DR expression, impaired proinflammatory cytokine production has 
been associated with disease severity in bacterial infections. Cytokine production of 
PBMCs from healthy and RSV-infected infants upon in vitro stimulation with LPS was 
determined to investigate whether decreased LPS responsiveness was associated with 
severe RSV infections. No significant difference in TNF production upon LPS stimulation 
was observed between the severity groups and the healthy controls (Figure 7.6A). 
PBMCs from RSV-infected infants without oxygen therapy produced similar amounts of 
IL-10 compared with healthy controls (Figure 7.6B). However, PBMCs from RSV-infected 
infants that require oxygen therapy produced significantly lower amounts of IL-10 upon 
LPS stimulation compared with healthy controls (Figure 7.6B). There was no correlation 
between age and either TNF or IL-10 production (data not shown).
Discussion
This study shows an increased percentage of circulating intermediate monocytes during 
RSV infection. An increased expression of CD14 and HLA-ABC was present during RSV 
infections. Conversely, reduced HLA-DR expression on monocytes was present during 
RSV infection and low HLA-DR expression was correlated with increased disease 
severity and prolonged hospitalization. Finally, an impaired in vitro IL-10 production of 
PBMCs from infants with severe RSV infections compared with healthy controls was 
observed. Analysis of our data indicates that the immune profile of monocytes changes 
Figure 7.5   Continued.
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during RSV infection and that, in particular, low expression of HLA-DR correlates with 
the increased disease severity of RSV infection.
The observed increase of intermediate monocytes is in line with studies investigating 
pediatric bacterial and viral infections.20,21 This is the first report implicating an increase 
of intermediate monocytes as a consequence of RSV infection. These data suggest 
that the increase of intermediate monocytes is applicable to many infectious diseases, 
Figure 7.6  Severe RSV infections are associated with impaired in vitro IL-10 production upon 
stimulation with LPS. Cytokine production of PBMCs from healthy controls and RSV-infected 
infants, categorized by disease severity, after 20-hour stimulation with LPS for (A) TNF and (B) IL-10. 
Values are represented as means with SEM. Testing was performed with the Mann-Whitney U test 
(*P < 0.05).
A
B
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including viral respiratory tract infections. CD14++CD16+ monocytes are termed 
proinflammatory because of their ability to produce high amounts of cytokines. Next, 
they possess high levels of HLA-DR and are potent inducers of T cell proliferation.22,23 
Previous data suggest that these activated monocytes migrate to inflamed tissues to 
locally support the ongoing T cell activation.24 In the context of RSV, the increased 
percentage of intermediate monocytes might be a reflection of immune activation and 
these monocytes may be subsequently attracted to the inflamed lung tissue to exert 
local antiviral immunity.
Besides the increase of intermediate monocytes, all subsets of monocytes during 
RSV infection in our cohort expressed higher levels of CD14. Maus et al showed 
that monocytes are recruited from the blood stream to become alveolar monocytes 
during infection.25,26 These recruited monocytes have a high expression of CD14, exert 
enhanced cytokine production and are able to replace resident alveolar macrophages. 
Next, viral proteins are able to promote a Th1 response via CD14.27,28 Polarization 
toward aTh2-dominated response is present during RSV infections, and therefore, the 
increased expression of CD14 on monocytes might be a defense mechanism against 
RSV.16 Whether the high CD14-expressing monocytes in our cohort in the peripheral 
blood during RSV infection are indeed recruited to the inflamed lung tissue and polarize 
the local immune response against RSV cannot be determined in this study.
In our cohort, expression levels of HLA-ABC on monocytes are higher during infection, 
whereas expression levels of HLA-DR on monocytes are suppressed. HLA-ABC and 
HLA-DR expression on monocytes functions to bind peptide fragments from pathogens 
and present them for recognition by, respectively, CD8+ and CD4+ T cells. Increased 
expression of HLA-ABC suggests that during RSV infection, circulating monocytes 
are primed for antigen presentation. However, HLA-DR expression on monocytes is 
reduced, and this is most pronounced in patients with severe RSV infections. Low 
HLA-DR expression has been associated with immunoparalysis and disease severity 
in bacterial infections.11,29,30 Our data suggest that RSV exerts a more pronounced 
inhibitory effect on HLA-DR expression during severe RSV infections. Reduction of 
HLA-DR expression by RSV on monocytic cells has already been observed in vitro.31 
Connolly et al describe a direct effect of RSV infection on hampering of HLA-DR 
surface translocation.32 However, direct blocking of HLA- DR surface translocation 
as the underlying mechanism of reduced HLA-DR expression in vivo is unlikely as 
viremia has only sporadically been detected during RSV infection. Soluble inflammatory 
mediators present in the blood could be responsible for the observed reduced HLA-DR 
expression in infants with severe RSV infections. For instance, high cortisol levels have 
been associated both with severe RSV infections and reduced HLA-DR expression 
and might explain the reduced HLA-DR expression in severe RSV infections.33,34 The 
correlation between reduced HLA-DR expression and prolonged hospitalization 
confirms our conclusion regarding HLA-DR and disease severity. The decision whether 
to admit RSV-infected infants or send them home is mainly based on the need for 
oxygen treatment. For many patients presenting at the emergency room, it is difficult 
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to determine the course of disease and thereby the future need for oxygen treatment. 
Therefore, the difference in HLA-DR expression between infants without oxygen 
treatment and infants with oxygen treatment may have important clinical implications 
and could help the clinician to decide whether to admit a patient with RSV bronchiolitis. 
Transcriptional profiling of blood from RSV-infected infants showed a suppression of 
important T cell genes, in particular, in younger infants, and CD4+ T cells are lower 
in severe RSV infections compared with nonsevere RSV infections.19,35 Our observed 
immune profile with reduced HLA-DR expression on monocytes during severe RSV 
infections might explain the low CD4+ T cell responses seen in severe RSV infections.19 
Further research dissecting the mechanism of reduced HLA-DR expression will give 
more insight in the immunomodulatory effects of RSV.
A second hallmark of immunoparalysis is a reduced TNF production upon stimulation 
with LPS, which was not observed in our cohort of infants with RSV infections. We 
conclude that although HLA-DR expression is decreased during RSV infection, there 
is no apparent immunoparalysis as seen in bacterial infections. Mella et al observed 
a correlation between impaired LPS responsiveness and severe RSV infections by 
stimulation of whole blood.36 Although the stimulation of whole blood might include 
more cells involved in clinical disease, stimulation of PBMCs has proven to be useful to 
decipher the mechanisms between cytokine release and disease severity.37
We observed a significantly impaired IL-10 production upon LPS stimulation by PBMCs 
from infants with severe RSV infections compared with healthy controls. The role of 
IL-10 is contrary as it has been associated with either the development of asthma or the 
protective immunity in a murine model.38–40 IL-10 has been implicated as an important 
cytokine that influences immunopathology in RSV infection by limiting T-cell-mediat-
ed lung injury.41 Our observed impairment of anti-inflammatory cytokine production by 
PBMCs indicates a shift toward a less anti-inflammatory and a more proinflammatory 
profile in vivo.
In this study, we were able to include an age- and sex- matched control group with 
infants who required an inguinal hernia operation. Although age and sex were matched 
between the control group and the RSV-infected infants, the gestational age in the 
control group was significantly lower compared with the RSV- infected infants. We 
believe that this difference of 2 days would not significantly impact the matching 
between healthy controls and RSV-infected infants. Low gestational age, in particular 
<32 weeks of age, is a risk factor for severe RSV infection. When comparing prematurity, 
defined as gestational age <37 weeks, there are no significant differences between 
the groups. Therefore, the difference in gestational age is unlikely to interfere with the 
results observed in severe RSV-infected infants.
In summary, striking differences are found in monocytes of infants with RSV infections. 
The increase of intermediate monocytes, the high CD14 expression and the high 
HLA-ABC expression suggest that activation of monocytes occurs during RSV 
infection, which might result in recruitment of monocytes to the local site of infection. 
The reduced expression of HLA-DR combined with reduced in vitro responsiveness 
Processed on: 1-3-2017
508516-L-bw-Ahout
121
Monocytes and RSV infection
7
during RSV infection, however, might be an important indicator of immunosuppression 
of monocytes during severe RSV infections.
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Abstract
Matrix metalloproteinases (MMPs) play an important role in respiratory inflammatory 
diseases, such as asthma and chronic obstructive pulmonary disease. It was 
hypothesized that MMP-8 and MMP-9 may function as biological markers to assess 
disease severity in viral lower respiratory tract infections in children. MMP-8 and MMP-9 
mRNA expression levels in peripheral blood mononuclear cells (PBMCs) and 
granulocytes obtained in both the acute and recovery phase from 153 children with 
mild, moderate, and severe viral lower respiratory tract infections were determined 
using real-time PCR. In addition, MMP-8 and MMP-9 concentrations in blood and 
nasopharyngeal specimens were determined during acute mild, moderate, and severe 
infection, and after recovery using ELISA. Furthermore, PBMCs and neutrophils 
obtained from healthy volunteers were stimulated with RSV, LPS (TLR4 agonist), and 
Pam3Cys (TLR2 agonist) in vitro. Disease severity of viral lower respiratory tract 
infections in children is associated with increased expression levels of the MMP-8 and 
MMP-9 genes in both PBMCs and granulocytes. On the contrary, in vitro experiments 
showed that MMP-8 and MMP-9 mRNA and protein expression in PBMCs and 
granulocytes is not induced by stimulation with RSV, the most frequent detected virus 
in young children with viral lower respiratory tract infections. These data indicate that 
expression levels of the MMP-8 and MMP-9 genes in both PBMCs and neutrophils are 
associated with viral lower respiratory tract infections disease severity. These 
observations justify future validation in independent prospective study cohorts of the 
usefulness of MMP-8 and MMP-9 as potential markers for disease severity in viral 
respiratory infections. 
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Introduction
Respiratory viral infections are an important cause of hospitalization among children 
younger than 5 years of age with estimated population-based hospitalization rates of 
1–2%.1-3 Human respiratory syncytial virus (RSV) is the most commonly identified virus 
with detection rates up to 40–85% in infants hospitalized for respiratory infections during 
winter epidemics,4-6 The clinical manifestations range from a simple common cold to 
severe lower respiratory tract symptoms requiring mechanical ventilation. About 6– 11% 
of the children admitted to hospital with RSV infection require intensive care admission.7,8 
Up to 35% of the children hospitalized with bronchiolitis did not receive any supportive 
intervention.9 On the other hand, it is crucial to avoid discharge of those children 
who may experience clinical deterioration. Among children sent home with the diagnosis 
bronchiolitis, 4.6–6.8% required hospitalization later on during infection.10,11 Biomarkers 
to assess severity of viral lower respiratory tract infections, in particular RSV infection, 
may be helpful to clinicians in the decision whether a child needs to be hospitalized.
Lung injury during severe RSV infection is thought to be mediated by both direct 
cytotoxic effects of the virus and the result of the induced inflammation. Pathologic 
features of severe RSV infection include extensive bronchiolar epithelial destruction, 
peribronchial lymphocyte infiltration, necrosis of bronchial epithelium, and mucus plugs 
in the small bronchioles.12,13 Matrix metalloproteinases (MMPs) are family of zinc endo- 
peptidases capable of degrading components of the cellular matrix, and consequently, 
are suggested to be important in several diseases associated with tissue remodeling. 
Pronounced increase in their expression is thought to be associated with a variety of 
inflammatory disease, including respiratory diseases.14
MMPs play a role in cellular migration of neutrophils, lymphocytes, and other immune 
cells to the lungs by degrading extracellular matrix, but also have pro- and anti-inflam-
matory properties. The activity of MMPs is regulated through binding to tissue inhibitor 
of metalloproteinases (TIMPs) leading to in- activation. An imbalance in production and 
activation, or inactivation by TIMPs might augment airway inflammation through direct 
or indirect effects upon signalling pathways that influence migration of leukocytes 
through the tissues.14,15 Increased concentrations and activity of MMP-8 and MMP-9 
have been observed in respiratory samples obtained from adults and children with 
acute lung injury and pneumonia16-19 as well as in chronic lung diseases such as 
asthma.20,21 In addition, a relation between MMP-9 concentrations and disease severity 
of pneumonia 16,18 and asthma 22,23 has been described.
Yeo et al. have reported that MMP-9 protein expression is increased in human airway 
epithelial cell lines infected with RSV.24 In addition, MMP-9 gene expression is increased 
in the lungs of RSV-infected mice.25 Another study demonstrated that nasopharyngeal 
samples from infants infected with RSV and parainfluenza virus (PIV) contain increased 
MMP-9 and TIMP-1 concentrations.26
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In the current study, it was hypothesized that MMP-8 and MMP-9 gene expression 
levels, and consequently, MMP-8 and MMP-9 plasma concentrations may function as 
biomarkers for disease severity in viral lower respiratory tract infections.
Methods
Study Design
Children younger than 5 years of age with laboratory confirmed viral lower respiratory 
tract infections were prospectively included during three consecutive winter seasons 
(November–April in the years 2006–2009). Patients with congenital heart or lung 
disease, known immunodeficiency’s or glucocorticoid use were excluded. Viral lower 
respiratory tract infections was defined as an acute infection of the lower airways, 
characterized by increased respiratory effort (tachypnea and/or use of accessory 
respiratory muscles and/or expiratory wheezing and/or crackles and/or apnea) in 
combination with a confirmed viral etiology by multiplex real-time polymerase chain 
reaction (RT-PCR) on nasopharyngeal washes as described previously.27 The multiplex 
RT-PCR assay detect 15 different viral pathogens; influenza virus types A and B, 
coronavirus 229E and OC43, human bocavirus, enterovirus, adenovirus, parechovirus, 
PIV types 1–4, human metapneumovirus, rhinovirus (RV), and RSV.
Written informed consent was obtained from all parents and the study was approved by 
the Committee on Research involving Human Subjects of the University Nijmegen 
Medical Centre. Within 24 hr after admission a blood sample and nasopharyngeal 
aspirate was collected and parents from hospitalized children were asked permission 
to draw a second blood sample and nasopharyngeal aspirate 4–6 weeks after 
admission. Medical history, demographics, and clinical parameters were collected 
from questionnaires and medical records. Patients were classified into three different 
groups based on severity of disease. Children without hypoxia or severe feeding problems 
were allocated in the mild group, those requiring hospitalization for supplemental 
oxygen (oxygen saturations <93%) and/or nasogastric feeding in the moderate group 
and children requiring mechanical ventilation in the severe group.
Sample Collection
A nasopharyngeal aspirate was collected by introducing a catheter, connected to a 
collection tube and an aspiration system, into the nasopharyngeal cavity. Then, 1.5 ml 
of saline was instilled into the catheter and, while slowly retracting the catheter, the 
nasopharyngeal fluid was aspirated in a collection tube. Afterwards the catheter was 
flushed with 1 ml of saline and added to the collection fluid. The samples were kept cold 
and immediately transferred to the laboratory. The nasopharyngeal aspirate was 
centrifuged at 500g for 10 min at 48C to spin down the mucus and cells, after which the 
supernatant was frozen at -80C.
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Five millilitres of blood was collected into sodium heparin tubes and directly transferred 
to the laboratory. A thin blood smear was prepared and stained with (May-Grunwald-)
Giemsa to determine the percentages of granulocytes and PBMCs. PBMCs were 
obtained by density gradient centrifugation (Lymphoprep1; Axis Shield, Oslo, Norway) 
and stored in Trizol at -80C for RNA isolation. Plasma samples were stored at -80C for 
ELISAs
Quantitative mRNA Expression of MMP-8 and MMP-9 in PBMCs and 
Granulocytes
RNA from PBMC and granulocytes was extracted using Trizol (Invitrogen Life Technologies, 
Bleiswijk, The Netherlands) according to the manufacturers’ protocol. Subsequently, 
a clean-up was performed on total RNA with the RNeasy Minikit (Qiagen, Venlo, 
The Netherlands) according to the manufacturers’ instructions. Total RNA (2 mg, 
measured with spectrophotometry, Nanodrop, Wilmington) was reverse transcribed 
using a high-capacity cDNA reverse transcription kit according to the manufacturers’ 
instructions (Applied Biosystems, Foster City, CA) and cDNA was stored at -20C. 
The relative gene expression was measured with SYBR Green PCR Mastermix (Applied 
Biosystems; P/N 4367659) on the ABI 7500 Fast Real Time PCR system using standard 
program and software. After 40 repetitions a dissociation curve was performed as 
control for the specificity of the PCR reaction. The following primers were used: hActin 
F: CGTCACACTTCATGATGGAGTTG, hActin R: CTTCCTTCCTGGGCATGGA; hMMP-9 
F: GCCCCCCTTGCATAAGGA, hMMP-9 R: CAGGGCGAGGACCATAGAG; and hMMP-8 F: 
CCAGTTTGACATTTGATGCTATCAC, hMMP-8 R: CTGAGGATGCCTTCTCCAGAA. All 
reactions were performed in duplo. Actin was used as reference gene. After a quality 
check (melting temp, curve of reaction, and standard deviation Ct) the DCt of the 
MMP-8 and MMP-9 to actin was calculated and expressed as relative expression.
MMP-8, MMP-9, and TIMP-1 Concentrations in Plasma and 
Nasopharyngeal Washes
Concentrations of total MMP-8 and MMP-9 in plasma, nasopharyngeal aspirate, and 
supernatants of cell stimulation assay were measured by ELISA according to the 
manufacturers’ protocol (DuoSet, R&D systems, Abingdon, UK). In addition, TIMP-1 
concentrations in plasma were determined as described above.
In Vitro Stimulation of PBMCs and Neutrophils From  
Healthy Volunteers
After informed consent, blood was drawn from healthy volunteers and collected in 
EDTA tubes. Blood was diluted 1:1 with pyrogene-free PBS (Lonza, Basel, Switzerland). 
PBMCs and granulocytes were obtained by density gradient centrifugation (Lymphoprep1; 
Axis Shield). After washing, PBMCs were brought at a concentration of 5 x 106 cells/ml 
in serum-free RPMI (Gibco, Invitrogen, Paisley, UK) with 100 U/ml of penicilin/streptavidin 
(Gibco, Invitrogen). Granulocytes were purified by lysing the red blood cells (0.155 M 
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NH4Cl, 0.0001 M Na2EDTA and 0.01 M KHCO3), and, after washing, granulocytes were 
suspended at a concentration of 5 x 106 cells/ml in RPMI supplemented with 0.5% 
human serum albumin (Sanquin, Amsterdam, The Netherlands). Mononuclear cells 
(5 x 105 in 100 ul) were added to round-bottom 96-well plates and stimulated with either 
100 ul culture medium (negative control), 1 ng/ ml LPS (Escherichia coli serotype 
055:B5, Sigma– Aldrich, purified as described previously 28 or MOI 1 of RSV A2 (kindly 
provided by Dr. R. de Swart, Erasmus MC, Rotterdam, The Netherlands). RSV A2 was 
cultured in HeLa cells and purified by ultracentrifuge over a sucrose 30% gradient. 
After incubation for 24 hr at 378C and 5% CO2. supernatant was collected and stored 
at -80C.
Neutrophils (5 x 105 in 100 ul) were stimulated and incubated in the same way for 4 hr 
and supernatant was stored at -80C. Apoptosis was determined on the FACScalibur by 
Annexin V apoptosis detection kit (BD) according to the manufacturers’ instructions and 
no differences between stimuli were found after 4 hr.
Statistics
Values are expressed as percentages for categorical variables and as mean and 
standard error (SE) or median and interquartile range (IQR) for continuous variables. 
For variables that were not normally distributed, Kruskal–Wallis test was performed to 
compare continuous variables followed by Mann–Whitney U-tests for individual comparisons. 
Chi-squared tests were performed to compare categorical data. A two-sided value of 
P < 0.05 was considered statistically significant.
Results
Patient Characteristics
In total, 153 patients were included. In 109 patients (71%) RSV was detected. RSV positive 
children were significantly younger than RSV negative children. No other significant 
differences were observed between these groups (Table 8.1).
A total of 54, 60, and 39 children were classified as having mild, moderate, and severe 
disease, respectively. Patients with severe disease were significantly younger compared 
to those with mild disease (105 days vs. 278 days; P < 0.05). More prematurely born 
children were observed in the severe group compared to the mild and moderate group. 
No other significant differences in clinical parameters were found between the different 
severity groups (Table 8.2). In addition, total leukocytes and neutrophil counts were 
comparable between all groups.
Disease Severity Is Associated With Increased Gene Expression Levels 
of MMP-8 and MMP-9 in Both Granulocytes and PBMCs
During acute viral infection we observed increased expression of the MMP-8 and MMP-9 
genes in both
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PBMCs and granulocytes compared to recovery. No differences in gene expression of 
MMP-8 and MMP-9 in both PBMCs and granulocytes were found between RSV positive 
and RSV negative children during acute infection. In general, gene expression of the 
MMP-9 gene was higher in granulocytes than in PBMCs. For MMP-8, the same trend 
was noticed (Figure 8.1A,B and 2A,B).
Increased disease severity was associated with higher expression levels of the MMP-8 
and MMP-9 genes in both PBMCs and granulocytes. To determine whether this 
association was dependent on the type of virus, RSV positive and RSV negative children 
were analyzed separately. For RSV positive patients, the same association was found 
between disease severity and gene expression levels (Figure 8.1C,D and 2C,D). For 
RSV negative patients, MMP-8 and MMP-9 gene expression was higher in children with 
severe disease compared to those with mild. In addition, RSV negative children with 
severe disease had higher expression levels of the MMP-8 gene in both PBMCs and 
granulocytes compared to those with moderate disease (data not shown).
Disease Severity Is Associated With Increased MMP-8 Plasma Levels
The plasma concentration of MMP-8 was increased during acute RSV infection 
compared to recovery. In RSV negative patients this difference was not significant 
(Figure 8.3A). Higher MMP-8 plasma concentrations were found in children with severe 
and moderate disease compared to those with mild disease (Figure 8.4A). In 
nasopharyngeal washes, the concentration of MMP-8 was increased during acute RSV 
infection compared to recovery washes (Figure 8.3D). No significant differences of 
MMP-8 concentrations in the nasopharyngeal washes were observed between the 
different severity groups (Figure 8.4D). In both RSV positive as RSV negative patients 
MMP-9 concentrations in the nasopharyngeal washes were increased during infection 
(Figure 8.3E). Children with moderate disease had increased MMP-9 concentrations in 
nasopharyngeal washes compared to those with mild disease. However, no significant 
Table 8.1  Patient Characteristics.
Total (n= 153) RSV+ (n= 109) RSV– (n= 44) P-value
Age (days ± SE) 206 ± 26 149 ± 20 347 ± 72 <0.001
Male 95 (62%) 70 (64%) 25 (57%) NS
Prematurity 21 (14%) 16 (15%) 5 (11%) NS
Family history of atopy 82 (57%) 56 (54%) 26 (63%) NS
Symptomatic days before 
presentation (days ± SE)
5.5 ± 0.4 5.2 ± 0.4 6.3 ± 1.1 NS
Data are presented as number (%), unless otherwise specified. For variables that were not normally distributed, 
Kruskal–Wallis test was performed to compare continuous variables followed by Mann–Whitney U-tests for 
individual comparisons. Chi-squared tests were performed to compare categorical data. A two-sided value of 
P < 0.05 was considered statistically significant. NS, not significant, SE, standard error.
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differences in MMP-9 concentrations were observed in children with severe disease 
compared to those with mild and moderate disease (Figure 8. 4E). TIMP-1 concentrations 
in plasma or nasopharyngeal washes were not increased during acute infection and 
there was no correlation with disease severity (Figure 8.3C and 4C). The ratio between 
MMP-9 and TIMP-1 plasma concentrations, an indicator for enzyme activity, was not 
increased during acute RSV infection. This ratio was significant higher in the recovery plasma 
of RSV negative patients compared to the acute samples (Figure 8.3F). No relation between 
disease severity and the plasma MMP-9 and TIMP-1 ratio was found (Figure 8. 4F).
No differences in plasma or nasopharyngeal levels of MMP-8, MMP-9, and TIMP-1 
plasma concentrations were observed between RSV positive and RSV negative children 
during acute viral respiratory infection. In general, MMP-8 and MMP-9 concentrations 
were higher in nasopharyngeal samples compared to plasma.
MMP-9 Plasma Concentrations Are Correlated With the Number  
of Granulocytes
MMP-9 plasma concentrations correlated with the number of granulocytes measured 
during acute RSV infection (Pearson’s correlation coefficient 0.33; P ¼ 0.019). No 
correlation was found between the number of granulocytes and MMP-8 plasma and 
nasopharyngeal concentrations and MMP-9 nasopharyngeal concentrations (data not 
shown). Furthermore, there was no correlation between symptomatic days before 
presentation and levels of MMP-8 and MMP-9 gene expression or concentration of the 
protein in plasma and nasopharyngeal washes (data not shown).
Table 8.2  Patient Characteristics for Mild, Moderate, and Severe Infections
Total 
(n = 153)
Mild 
(n = 54)
Moderate 
(n = 60)
Severe 
(n = 9)
P-value
Age (days) 206 ± 26 278 ± 52 206 ± 38 105 ± 36 <0.01
Male (%) 95 (62%) 32 (59%) 36 (60%) 27 (69%) NS
Prematurity (%) 21 (14%) 5 (9%) 6 (10%) 10 (26%) <0.05
Family history of atopy (%) 82 (57%) 27 (52%) 36 (62%) 19 (55%) NS
Symptomatic days 
before presentation  
5.5 ± 0.4 7.0 ± 1.1 4.8 ± 0.3 4.6 ± 0.4 NS
RSV (%) 109 (71%) 35 (65%) 45 (75%) 29 (74%) NS
Leukocytes counts 8.7 ± 0.7 9.8 ± 1.1 8.6 ± 1.0 8.2 ± 1.4 NS
Neutrophil counts 3.5 ± 0.5 3.1 ± 0.7 2.9 ± 0.7 4.3 ± 1.1 NS
Data are presented as percentages or mean ± standard error (SE). Cell counts are given as *10E6 cells/ml ± 
SE. For variables that were not normally distributed, Kruskal–Wallis test was performed to compare continuous 
variables followed by Mann–Whitney U-tests for individual comparisons. Chi-squared tests were performed to 
compare categorical data. A two-sided value of P < 0.05 was considered statistically significant. NS, not 
significant.
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MMP-8 and MMP-9 mRNA and Protein Expression by PBMCs and 
Neutrophils Is Not Induced by RSV In Vitro
To investigate whether the source of plasma MMP- 8 and MMP-9 during RSV infection 
was the result of direct interaction of PBMCs or neutrophils with RSV, PBMCs and 
neutrophils were stimulated with RSV in vitro. Stimulation of PBMCs with LPS (TLR4 
agonist) induced MMP-9 secretion, whereas stimulation with RSV had no effect. None 
of the stimuli induced MMP- 8 secretion by PBMC (Fig. 5A). Stimulation of PBMCs with 
RSV did not result in increased gene expression of MMP-8 and only a moderate increase 
Figure 8.1  Gene expression levels of MMP-8 and MMP-9 in granulocytes from children with viral 
lower respiratory tract infections. Relative gene expression levels (mean ± standard error) of 
MMP-8 (A) and MMP-9 (B) in PBMCs from children during acute RSV positive and RSV negative 
viral lower respiratory tract infections and after recovery of infection. Relative gene expression 
levels of MMP-8 (C) and MMP-9 (D) for RSV positive children with mild, moderate, and severe 
disease. Mann–Whitney U-test was performed to compare children infected by RSV and other viruses. 
Paired analyses (Wilcoxon) were performed to compare acute and recovery samples. A two-sided 
value of P < 0.05 was considered statistically significant.
A
C
B
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of MMP-9 expression was observed (Figure 8.5B). Unstimulated neutrophils secreted 
high levels of MMP-8 and MMP-9. Stimulation with LPS and RSV had no effect on the 
release of MMP-8 and MMP-9 by neutrophils (Figure 8.5C).
Figure 8.2  Gene expression levels of MMP-8 and MMP-9 in granulocytes from children with 
viral lower respiratory tract infections. Relative gene expression levels (mean ± standard error) of 
MMP-8 (A) and MMP-9 (B) in PBMCs from children during acute RSV positive and RSV negative 
viral lower respiratory tract infections and after recovery of infection. Relative gene expression 
levels of MMP-8 (C) and MMP-9 (D) for RSV positive children with mild, moderate, and severe 
disease. Mann–Whitney U-test was performed to compare children infected by RSV and other 
viruses. Paired analyses (Wilcoxon) were performed to compare acute and recovery samples. 
A two-sided value of P < 0.05 was considered statistically significant.
A
C
B
D
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Figure 8.3  MMP-8 and MMP-9 concentrations in plasma and nasopharyngeal samples from 
children during acute lower respiratory tract infections and after recovery. Plasma concentration 
of MMP-8 (A), MMP-9 (B), TIMP-1 (C), and concentration in nasopharyngeal washes of MMP-8 (D) 
and MMP-9 (E) from children during acute RSV positive and RSV negative viral lower respiratory 
tract infections and after recovery of infection. Ratio’s between plasma MMP-9 and TIMP-1 (F). 
Concentrations (ng/ml) are given in mean ± standard error. Mann–Whitney U-test was performed to 
compare children infected by RSV and other viruses. Paired analyses (Wilcoxon) were performed 
to compare acute and recovery samples. A two-sided value of P < 0.05 was considered statistically 
significant.
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Discussion
This study demonstrates that disease severity of viral lower respiratory tract infections in 
children is associated with increased gene expression levels of the MMP-8 and MMP-9 
genes in both PBMCs and granulocytes. These associations were observed in children 
with lower respiratory tract infections caused by either RSV or other respiratory viruses. 
The in vitro experiments in this study show that MMP-8 and MMP-9 mRNA and protein 
expression in PBMCs and granulocytes is not induced by stimulation with RSV. 
Consequently, other factors than direct viral interaction induce gene expression in PBMCs 
and granulocytes.
This is the first study that describes an association between MMP-8 and MMP-9 gene 
expression and disease severity of viral lower respiratory infections in children. This 
association was significant for children with a RSV infection and there was a trend for 
children with a viral lower respiratory infection caused by other viruses, indicating to a 
more general marker for disease severity during respiratory viral infections.
Several studies have shown that transcriptional analysis of peripheral blood cells can 
be used to discriminate the etiology and disease outcome.29-32 Ramilo et al. compared 
the transcriptional profiles of PBMCs of children with infectious diseases, and identified 
a set of genes that could separate influenza A infections from bacterial infections 
(Staphylococcus aureus, Escherichia coli, and Streptococcus pneumoniae).31 Both 
MMP-8 and MMP-9 were not represented in the selected set of classifier genes. 
Retrospective analysis of the microarray data set was performed by us, and showed 
that mRNA expression of MMP-8 and MMP-9 were elevated in all groups compared to 
controls, indicating a more general marker for inflammatory disease (data not shown). 
No data were available on disease severity, so it is not possible to exclude an association 
with disease severity. In an experimental model of viral infection of the upper respiratory 
tract in adults with RSV, influenza, and RV, no up- regulation of MMP-8 and MMP-9 was 
detected in whole blood transcriptional profiles.33 However, these infections were all 
mild with consequently low levels of inflammatory markers.
This study shows that in MMP-8 plasma concentrations were increased during acute 
infection with RSV. Although MMP-8 plasma concentrations were higher in moderate 
and severe disease compared to mild disease, there was no step-wise relation with 
disease severity. This is in contrast with the gene expression data and indicates a 
different source of plasmaproteins than the circulating cell population. This is in line with 
the study of Hartog et al. in which they found elevated MMP-8 concentrations in plasma 
and lung fluid in adults with hospital-acquired bacterial pneumonia compared to healthy 
controls.16 They found an association between clinical severity scores and MMP-8 
concentrations in BAL fluid, but not in plasma.
Although MMP-9 plasma concentrations were increased during acute viral respiratory 
infections in children, no association between MMP-9 plasma concentrations and disease 
severity was found in this study. Previous studies have described such an association 
for several inflammatory diseases, such as pneumonia16, tuberculosis infections34, septic 
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Figure 8.4  MMP-8 and MMP-9 concentrations in plasma and nasopharyngeal samples from 
children with mild, moderate, and severe RSV infection. For RSV positive children plasma concentration 
of MMP-8 (A), MMP-9 (B), TIMP-1 (C), and concentration in nasopharyngeal washes of MMP-8 (D) 
and MMP-9 (E) in mild, moderate, and severe disease are given. Ratio’s between plasma MMP-9 
and TIMP-1 (F). Concentrations (ng/ml) are given in mean ± standard error. Mann–Whitney 
U-tests were performed to compare mild, moderate, and severe disease. A two-sided value of 
P < 0.05 was considered statistically significant.
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shock 35, and asthma22. This may be related to the fact that, in consistent with other 
studies 36-38, MMP-9 concentrations were correlated to neutrophil counts, although no 
significant differences in neutrophil counts between the different severity groups were 
observed in this study.
TIMP-1 is an inhibitor of the protease activity of all known MMPs.39 Previous studies have 
described an association between an imbalance between MMP-9 and TIMP-1 and tissue 
degradation and airflow obstruction in asthma and chronic bronchitis.37,40 In addition, 
elevated MMP-9/TIMP-1 ratios have been observed in plasma from patients with status 
asthmatics.22 Furthermore, it has been shown that increased TIMP-1 concentrations, but 
not MMP-9, in nasopharyngeal washes of RSV- infected children correlated with disease 
severity and this suggests that a disturbed MMP-9/TIMP-1 homeostasis contributes to 
disease severity.26 The ratio of MMP-9 and TIMP-1 concentration in plasma did not 
show a correlation with disease severity in this study and indicates that MMP-9 is 
differentially regulated at the mucosal level during infection.
Although both MMP-8 and MMP-9 concentrations in nasopharyngeal samples were 
increased during acute infection compared to recovery samples no association with 
disease severity was observed. The wide range of nasopharyngeal concentrations 
between individuals is partly due to the variation induced by aspiration volumes from 
the nasopharyngeal cavity. Currently, more standardized methods have been 
developed, such as flocked swabs, which can be used for viral diagnostics as well as 
protein analysis.41,42 Normalization of protein levels to stable metabolites present in the 
mucus might further improve the use of nasopharyngeal samples for diagnostics, 
although these methods are not available yet. Further it should be taken in account that 
upper respiratory samples do not necessarily represent the situation in the lower 
airways and the systemic inflammatory response.
The in vitro experiments in this study show that MMP-8 and MMP-9 mRNA and protein 
expression in PBMCs and granulocytes were not induced by stimulation with RSV. Other 
factors than direct interaction between RSV and host cells could explain the increased gene 
expression levels of MMP-8 and MMP-9 in children with viral lower respiratory tract infections. 
Influx of bone marrow-derived neutrophil precursors in blood from children with severe RSV 
infections can result in higher MMP-9 expression due to granule protein production, such as 
MMP-8 and MMP-9, during immature stages of neutrophil development.43 Also inflammatory 
mediators, such as growth factors, pro-inflammatory cytokines, oxidative stress upon viral 
infection can induce elevated gene expression levels of MMPs.14 It has also been shown that 
the lung injury caused by mechanical ventilation has resulted in increased MMP-8 and 
MMP-9 expression.44 However, in this study, the last mentioned cannot completely explain 
the differences in gene expression since also differences in gene expression between 
patients with mild and moderate disease were observed, all non-ventilated patients.
The results of this study indicate that neutrophils are the major source of MMP-9 
production. The higher MMP-8 and MMP-9 concentrations in nasopharyngeal samples 
compared to plasma may therefore reflect the influx and degranulation of neutrophils in 
the airways during infection.
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This is in contrast to observations made by others that suggest that airway epithelial 
cells are the primary source of MMPs. It has been shown that MMP-9 gene expression 
is increased in human airway epithelial cell lines infected with RSV.24 However, another 
study indicated that infected human airway epithelial cells are not the primary source of 
MMPs and TIMP-1 and that infiltrating leukocytes are responsible for MMP-9 in airway 
samples.26 Also in a RSV infection model in mice, of which it is known that the epithelial 
cells are not infected, it was demonstrated that gene expression of MMP-9 is elevated 
in the lungs most likely by infiltrating cells.25 For MMP-8, no correlation with neutrophil 
counts was observed and gene expression levels in granulocytes and PBMCs were 
comparable indicating that MMP-8 transcription and secretion was different regulated 
than MMP-9. This is supported by differences in the degranulation of subcellular 
neutrophilic granules, in which MMP-8 and MMP-9 are stored and differences in 
 transcriptional events that induce MMP-8 and MMP-9 mRNA expression.45 For example, 
it has been shown that pro-inflammatory cytokines, particularly IL-1b, play a central role 
Figure 8.5  Stimulation of PBMCs and neutrophils by LPS and RSV in vitro. Human PBMC of 
healthy volunteers (n = 4) were stimulated with LPS (1 ng/ml) or RSV A2 (MOI 1) and MMP-8 and 
MMP-9 concentrations in supernatant were measured after 24 by ELISA (A) or at transcriptional 
level by q-PCR (B). Neutrophils were stimulated for 4 hr and MMP levels were determined in the 
supernatant (C).
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in the modulation of MMP-8 expression.46,47 Future studies may reveal the role for MMP-8 
plasmaconcentrations as a potential biomarker to assess disease severity in viral lower 
respiratory tract infections in children.
The relation of MMP-8 and MMP-9 with viral load in the nasopharyngeal cavity have not 
been investigated in this study. In experimental respiratory viral infection models, 
inflammatory markers such as cytokines correlated with viral load and the symptom 
scores, indicating that the amount of virus is the driving force for inflammation.48 Also in 
children, disease severity has been associated with high viral titers.49,50 Further research 
might reveal the role of inflammatory mediators in the pathogeneses of severe 
respiratory viral infections.51 In this light, it is interesting to consider inflammatory 
mediators, such as MMPs, as potential targets for therapy.
Some limitations of this study need to be considered. First, the younger age of the 
children with the most severe lower respiratory tract infections may have caused a bias 
in the results. However, age was not correlated with MMP-8 and MMP-9 plasma 
concentrations, which suggests that age alone cannot explain the observed differences. 
According to these results, did not found significant differences in MMP-8 and MMP-9 
serum concentrations in children, 2–18 years of age.52 Second, multiple viruses were 
detected in 40% children with lower respiratory tract infections and it cannot be entirely 
exclude that the presence of multiple viruses have induced a different inflammatory 
response.
The results of this study suggest that the expression of MMP-8 and MMP-9 genes are 
potential marker candidates for diagnostic use to assess disease severity in children 
with viral lower respiratory tract infections. Markers for disease severity do not have 
clinical implication at present, because currently antiviral treatment is not available. 
However, new antiviral treatment of patients will be based most likely on diagnostics 
predicting disease severity and susceptibility.53,54 Furthermore, markers for disease 
severity are also important for research purposes to study effects of interventions, such 
as treatment. Although currently no biomarkers at transcription level are available in the 
clinic, because the processing is time consuming, innovative techniques may enable 
rapid analysis of the expression of multiple genes at transcriptional level in the near 
future.55
In conclusion, increased expression of the MMP-8 and MMP-9 genes was observed in 
PBMCs and granulocytes obtained from children with severe viral lower respiratory tract 
infections. MMP-8 and MMP-9 gene expression levels in circulating cells may be useful 
markers to support clinical evaluation of disease severity in viral respiratory infections. 
These results justify future follow-up, that is, the validation in independent prospective 
study cohorts of the usefulness of MMP-8 and MMP-9 as a potential markers for disease 
severity in viral respiratory infections.
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Abstract
Background: Respiratory viral infections follow an unpredictable clinical course in 
young children ranging from a common cold to respiratory failure. The transition from 
mild to severe disease occurs rapidly and is difficult to predict. The pathophysiology 
underlying disease severity has remained elusive. There is an urgent need to better 
understand the immune response in this disease to come up with biomarkers that may 
aid clinical decision making.
Methods: In a prospective study, flow cytometric and genome-wide gene expression 
analyses were performed on blood samples of 26 children with a diagnosis of severe, 
moderate or mild Respiratory Syncytial Virus (RSV) infection. Differentially expressed 
genes were validated using Q-PCR in a second cohort of 80 children during three 
consecutive winter seasons. FACS analyses were also performed in the second cohort 
and on recovery samples of severe cases in the first cohort.
Results: Severe RSV infection was associated with a transient but marked decrease in 
CD4+ T, CD8+ T, and NK cells in peripheral blood. Gene expression analyses in both 
cohorts identified Olfactomedin4 (OLFM4) as a fully discriminative marker between 
children with mild and severe RSV infection, giving a PAM cross-validation error of 0%. 
Patients with an OLFM4 gene expression level above -7.5 were 6 times more likely to 
develop severe disease, after correction for age at hospitalization and gestational age.
Conclusion: By combining genome-wide expression profiling of blood cell subsets 
with clinically well- annotated samples, OLFM4 was identified as a biomarker for 
severity of pediatric RSV infection.
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Introduction
Respiratory viral infections are an important cause of hospitalization among children 
younger than 5 years of age. Human Respiratory Syncytial Virus (RSV) is the most 
common (40–85%) identified virus in infants hospitalized for respiratory infections 
during winter epidemics, with hospitalization rates between 1 and 2%.1-6 Clinical 
manifestations range from common colds to severe lower respiratory tract infections 
requiring mechanical ventilation. Risk factors for a severe course are known, but the 
majority of patients admitted to an Intensive Care Unit were previously healthy. 7-9 Since 
transition from mild to severe disease can occur within hours, one of the key challenges 
for clinicians is to differentiate children who need hospitalization for supportive care 
from those who can safely be discharged. Currently, young infants with mild bronchiolitis, 
especially those younger than 12 weeks of age, are often admitted to a hospital since 
they have an increased risk of severe disease. However, up to 35% of children 
hospitalized with bronchiolitis do not receive any supportive intervention.10 Conversely, 
it is crucial to avoid early discharge of those children who may experience clinical 
deterioration. Among children sent home with the diagnosis bronchiolitis, 4.6–6.8% 
require hospitalization later on.11,12
Much research has been done on the immune response against RSV in humans. 
Several reports suggested an important role for the innate immune system, while others 
found an inadequate adaptive immune response especially in young children and in 
individuals who present with a severe clinical picture.13 The uncertainty in the nature of 
the immune response against RSV is reflected in the unpredictable clinical course of 
the infection as well as in the difficulty of developing an adequate vaccine. We as well 
as others previously reported that T lymphocytes can be markedly decreased in the 
more severe cases of the disease. We reported that in severe cases both CD4 and CD8 
T cell numbers, as well as NK cells were reduced in peripheral blood.14 However, it 
remains unclear whether this indicates an inadequate immune response against RSV, 
for instance by massive apoptosis or decreased production of T cells, or that peripheral 
blood poorly reflects an ongoing immune response that might be very active.
The detection and application of biomarkers to assess severity of viral lower respiratory 
tract infections, in particular RSV infection, may assist clinicians in the prediction of 
severe disease in children with bronchiolitis and may help to reduce the number of 
unnecessary hospitalizations or clinical deterioration after discharge. Furthermore, 
markers for disease severity are important research tools to study effects of interventions 
by new therapies or to stratify patients by disease severity.15,16 Several studies have 
shown that transcriptional analysis of peripheral blood cells may be used to define 
different etiologies of disease and disease outcomes.17-20 In a seminal proof-of-concept 
study, Ramilo et al. (2007) compared the transcriptional profiles of PBMCs of children 
with infectious diseases and identified a set of genes that can separate influenza A 
infections from bacterial infections (Staphylococcus aureus, Escherichia coli and 
Streptococcus pneumoniae).20 Recently this group also reported that these transcriptome 
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profiles also contained information regarding viral etiology (influenza, rhino virus and 
RSV) and the course of disease.21
This study was initiated to obtain insight into the changes occurring in adaptive and 
innate immune cells during RSV infection and to identify possible biomarkers of disease 
severity. To identify transcriptional biomarkers to separate mild from severe disease, 
genome-wide gene expression analyses were performed on blood samples of 26 children 
with a diagnosis of severe, moderate or mild RSV infection in two winter seasons. 
A validation cohort of 80 children spanning three other consecutive winter seasons by 
flow cytometry and Q-PCR was used to validate various candidate biomarkers.
Material and Methods
Study design
In this prospective cohort study, 3 ml of Sodiumheperanized blood and naso pharyngeal 
samples were obtained from two cohorts of patients with RSV bronchiolitis within 
24 hours after first contact with the hospital. Medical history, demographic data, 
and clinical assessments were collected from questionnaires and medical records. 
Exclusion criteria were corticosteroid use in past 48 hours, congenital significant heart 
or lung disease and immunodeficiency, Presence of 15 different viral pathogens was 
tested by multiplex RT-PCR on nasopharyngeal samples as previously described.22 
Patients were classified retrospectively into three groups based on severity of disease. 
The mild group included children without hypoxia or severe feeding problems. The 
moderate group included children requiring hospitalization for supplemental oxygen 
(oxygen saturations <93%) and/or nasogastric feeding. Children requiring mechanical 
ventilation were included in the severe group. Recovery samples were obtained 4–6 
weeks after acute infection from children with moderate and severe disease. The first 
cohort consisted of 26 patients with RSV infections, divided into mild (n = 9), moderate 
(n = 9) and severe (n = 8) disease. From all moderate and severe diseased patients 
recovery samples were obtained. This cohort was used for micro-array analysis and 
initial qPCR validation of genes of interest. The second cohort comprised 80 children 
with viral lower respiratory tract infections both RSV positive and negative, and was also 
divided into three groups: mild (n = 14), moderate (n = 42) and severe (n = 24). This 
cohort was meant for validation purposes. All subjects were recruited at two hospitals 
in Nijmegen, the Canisius Wilhelmina Hospital and the Radboud university medical 
center, the Netherlands. The study protocols were approved by the institutional review 
board (Commissie Mensgebonden Onderzoek: Regional Committee on Research 
involving Human Subjects Arnhem-Nijmegen, The Netherlands) and were conducted in 
accordance with the principles of the Declaration of Helsinki. Written informed consent 
was obtained from the parents of all children.
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RNA isolation and microarray gene expression analyses
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation 
(Lymphoprep, Axis Shield, Norway), counted and subsequently stored in Trizol reagent 
(Invitrogen, The Netherlands) at -80°C in the same laboratory by the same team for both 
cohorts. RNA from PBMC was extracted using Trizol (Invitrogen Life Technologies) according 
to the manufacturer’s protocol. Total RNA was isolated using the RNeasy Minikit (Qiagen). 
RNA integrity and quality was assessed using capillary electrophoresis [RNA 6000 Nano 
LabChip (Agilent)] on an Agilent Bioanalyzer 2100 system. RNA processing, target labeling 
and hybridization to gene expression arrays was performed by standard methods as 
described.23 Biotin labeled cRNA was obtained using the One-Cycle Eukaryotic Target 
Labeling Assay Affymetrix), after which 15 µg of fragmented, biotin labeled cRNA was 
hybridized to Affymetrix GeneChip Human Genome U133 plus 2.0 arrays according to 
standard Affymetrix protocol (Affymetrix Inc, Santa Clara, CA).
Flow Cytometry
Immunophenotyping of cryopreserved PBMCs were performed after thawing. The 
following combinations of markers and fluorescent antibodies were used: CD14–FITC, 
CD16.56–phyco- erythrin, CD3–peridinin chlorophyll protein, CD19–allophycocyanin, CD4–
phycoerythrin– Cy7, and CD8–allophycocyanin–Cy7 (all Beckman Coulter, Miami, FL). 
Samples were acquired immediately after staining on a BD FACSCanto (Becton 
Dickinson, Heidelberg, Germany) and analyzed using flow cytometry analysis software 
(FlowJo analyses 7.6, Three Star, Ashland, OR). The following subsets were defined: 
CD4+ T cells (CD4+CD3+CD8-), CD8 T cells (CD8+CD4-CD3+), NK cells (CD3-CD56+), 
B cells (CD45+CD19+) and monocytes (CD14+).
Data analysis
Quality control analyses were performed as previously described.23,24 Scanned images 
were inspected for artifacts, percentage of calls present (<25%) and controls of RNA 
degradation. This led to some arrays being discarded. On each remaining array, probes 
labelled outliers by the Affymetrix scanning software and overexposed probes (with 
maximum PM intensity level >63.000) were removed. Subsequently, probesets with 
less than 8 probes remaining were discarded. For each comparison, robust multichip 
analysis (RMA) was used for background removal, quantile normalization of probe 
intensity levels and probe set summarization. The resulting values were log2-trans-
formed for further analysis, giving probeset expression levels between 0 and 16. We 
then selected only those probesets that showed at least a two-fold difference (up or 
down) on a minimum of two arrays with respect to the median expression over all arrays 
in that particular comparison.24,25 Finally, Significance Analysis of Microarrays (SAM)26 
was applied to find differentially expressed probesets with a significance level of 
q <0.05. To select only biologically relevant changes, we demanded additionally that 
the absolute expression level was larger than log2(200) and that the absolute difference 
between groups was larger than 2 fold.
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In a subsequent supervised analysis, we trained a PAM classifier (“Prediction Analysis of 
Microarrays”27, attempting to find a minimum number of discriminative genes that yielded an 
optimal cross-validation error (i.e. the predicted test error). For visualization purposes, 
samples were clustered based on selected probesets by complete linkage hierarchical 
clustering with 1-correlation as a distance measure, using the Matlab Bioinformatics toolbox 
(Mathworks, Natick, MA). The original and processed data were deposited in the NCBI Gene 
Expression Omnibus (GEO; http:/ /www.ncbi.nlm.nih.gov/ge o ; GSE69606). All microarray 
experiments were performed according to the MIAME guidelines.
RT-PCRReal-time quantitative PCR was used to measure the expression of genes of 
interest. Initial validation of gene expression of OLFM4 detected in the first cohort was 
performed with SYBR Green PCR Mastermix (Applied Biosystems; P/N 4367659) with 
forward 5 -` atcaaaacacccctgtcgtc- 3 a`nd reverse 5 -` gctgatgttcaccacaccac-3`primers 
for OLFM4. Actin was used as a reference gene with forward primer 5 -` cgtcacacttcat-
gatggagttg-3 a`nd reverse primer 5 -` cttccttcctgggcatgga-3 .` After validation of the 
microarray, the second cohort was analyzed with commercially available Taqman 
primers (OLFM4 Hs00360669_m1 and GAPDH Hs99999905_m1). All samples were 
run for 40 cycles in duplicate on an Applied Biosystems 7500 Fast Real-Time PCR 
System. Ct values of OLFM4 were normalized against the reference gene GAPDH.
OLFM4 plasma measurement
OLFM4 concentrations were measured in randomly selected plasma samples of 49 
patients from the validation cohort by a commercial ELISA kit (E90162Hu, Uscn Live 
Science Inc., China) according to the instructions of the manufacturer.
Published microarray data mining
A data mining search was performed in NCBI GEO and in EBI Arrayexpress, online 
databases with datasets and profiles of previously performed microarray studies to 
validate our results.28,29 Terms for searching were: OLFM4, Affymetrix, whole blood 
children, RSV and/or homo sapiens. More than 90 microarray studies were found. Based 
on the population (children/infants), sample size, disease type and available information 
per sample, 18 studies were selected. From the series matrix files, the results were log 
transformed and OLFM4 gene expression was selected and analyzed to gain insight in 
its behavior in different disease states and ages.
Statistics
The distributions of categorical variables are presented as percentages per category. 
Numerical variables are reported as means with standard deviation (SD) or medians 
with interquartile ranges (IQR) depending on whether or not the variables were normally 
distributed (Kolmogorov-Smirnov’s test, p>0.05). To determine whether OLMF4 was 
independently associated with receiving mechanical ventilation, multivariable log-binomial 
regression analyses were per- formed in the validation cohort resulting in adjusted 
Relative Risks (RR).30 Analysis were performed with SPSS v21 and graphpad v5.
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Results
We previously reported that RSV infection, especially in severe cases, was associated 
with lymphopenia. This was not only visible in NK and CD8+ T cells, known to be 
directly involved in anti-viral immunity, but surprisingly also in CD4+ T cells, whereas B 
cells were unaffected.14 In the current study, we analyzed recovery samples of 6 severe 
patients after clearance of the infection (on average 4 weeks after discharge) and found 
that the numbers of NK cells as well as CD4+ and CD8+ T cells had returned to normal, 
indicating that the lymphopenia was transient (S1 Fig).
Microarray analyses point to OLFM4 as a marker gene to  
classify disease severity
Patients used for microarray analysis with a clinical diagnosis of mild disease were 
older at time of admission to hospital than those with severe disease. The length of stay 
in hospital increased with increasing disease severity. No statistically significant 
differences were seen in gender, number of premature infants and duration of symptoms 
(Table 9.1). The microarray analysis of PBMC of children with mild versus severe 
disease showed that 564 probesets were expressed differentially (428 upregulated and 
136 downregulated genes) under conditions as described in material and methods 
(q <0.05; >2 fold difference; absolute expression value > log2(200). As biomarkers should 
discriminate between non-disease and disease, the genes expressed differentially in 
children with mild versus severe disease as well as during acute severe RSV infection 
versus recovery were selected.
The analysis of paired acute and recovery samples of children with severe RSV infection 
resulted in 808 differentially expressed probesets (647 upregulated and 161 
downregulated). Of these 808 probesets, 448 showed over- lap with the 564 probesets 
in the comparison of mild versus severe disease, 365 genes being upregulated and 
83 genes being downregulated (Figure 9.1 and Figure S2). Table 9.2 shows the top 25 
Table 9.1  Patient characteristics. 
Mild 
(N = 9)
Moderate 
(N = 9)
Severe 
(N = 8)
p-value
Age (months) 8.7 [3.6–9.3] 1.9 [1.5–8.3] 2.4 [1.1–4.9] NS
Gender (male) 6 (67%) 8 (89%) 6 (75%) NS
Gestational age (wks) 40 [36.9–41.0] 38.6 [37.2–40.0] 35.1 [33.1–39.8] NS
Length of stay (days) 0 [0–3] 5 [2–9] 13 [6.3–19.8] p<0.001*
Values are given in numbers (percentages) and median with inter quartile range (IQR). P-values are based on 
Kruskall Wallis tests, followed by Mann Whitney U tests for individual comparisons.
*mild vs moderate p<0.01, moderate vs severe p<0.05, mild vs severe p<0.001
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of up- and downregulated genes, of which Olfactomedin 4 (OLFM4) was the most 
upregulated gene with a factor of over 40 fold. Since children in the severe group were 
younger compared to those with mild disease, a paired age-matched subanalysis was 
performed among 7 severe patients versus 7 patients with mild or moderate disease. 
This analysis resulted in 287 differentially expressed probesets, all upregulated. The gene list 
of upregulated probesets did not differ substantially from the main analysis. A supervised 
analysis (PAM) also identified OLFM4 as a fully discriminative marker between children 
with mild and severe RSV infection, giving a cross-validation error of 0%. As both SAM 
and PAM analyses revealed OLFM4 as a potentially important marker for disease 
severity in children with RSV infection and OLFM4 has-to the best of our knowledge- not 
been associated with respiratory tract infections before, this gene was chosen for 
further analysis. Interestingly, there was no marked upregulation of apoptosis genes in 
the severe group, indicating that the observed lymphopenia was not caused by 
increased apoptosis.
Validation of microarray findings by qPCR
To confirm our findings in the microarray analyses, qPCR was performed for OLFM4 in 
PBMCs of the same patients. One patient in the moderate group was excluded since 
insufficient material was left. OLFM4 expression was statistically significantly higher in 
patients with severe disease compared to those with mild and moderate disease 
(Figure 9.2A).
Figure 9.1  Venn diagram with differentially expressed genes between groups. Differentially 
expressed genes (q <0.05; >2 fold difference; absolute expression value >200) in patients with 
RSV infections comparing patients with mild vs severe disease and during acute infection vs 
recovery in patients with moderate and severe disease.
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OLFM4 gene expression in PBMCs is increased during acute viral 
respiratory infection and correlates with disease severity in a validation 
cohort
The validation cohort consisted of 80 children with viral lower respiratory tract infections, 
among which 47 had a confirmed RSV infection. This cohort reflects the patients presenting 
in a paediatric ward during respiratory season prior to viral diagnostics, therefore both 
Table 9.2   Top 25 up- and downregulated genes differentially expressed in PBMCs 
during severe RSV infection. 
Upregulated 
genes
Fold difference  
mild 
vs severe
Fold change 
severe 
vs recovery
Downregulated 
genes
Fold difference 
mild 
vs severe
Fold change 
severe 
vs recovery
OLFM4 49.7 43.2 GNLY -4.8 -4.0
MMP8 24.2 37.2 GZMH -4.5 -3.2
MMP8 24.1 33.6 GNLY -4.5 -3.7
CAECAM8 18.4 19.3 FGFBR2 -4.5 -5.1
ARG1 16.9 24.2 TRAC -3.9 -2.9
ANXA3 16.6 16.2 KLRF1 -3.8 -3.3
DEFA4 15.1 16.1 LGALS2 -3.7 -2.0
CA1 14.9 17.5 KLRC1 -3.7 -3.2
CHI3L1 13.9 11.0 KLRD1 -3.7 -3.0
LTF 13.0 12.6 TRAC -3.4 -2.8
SELENBP1 12.8 15.8 THOC4 -3.4 -3.1
CRISP3 12.3 12.3 GZMB -3.4 -2.3
ELANE 11.2 10.6 KLRD1 -3.4 -2.7
HP 11.0 11.9 IGHM -3.3 -2.0
CEACAM6 11.0 10.1 GZMK -3.3 -2.4
HBM 10.5 26.0 PRF1 -3.2 -2.2
CHI3L1 10.3 9.2 TRAC -3.1 -2.3
MPO 10.2 9.9 ITPKB -3.0 -3.5
ALAS2 10.2 21.7 SH2D1B -3.0 -2.6
IL1R2 10.2 10.5 SPON2 -3.0 -2.8
EPB42 10.1 15.3 PRF1 -3.0 -2.4
CEACAM6 10.1 9.7 TGFBR3 -2.9 -2.4
LCN2 10.1 10.3 FCER1A -2.9 -3.9
MPO 9.8 9.9 KLRB1 -2.9 -3.9
MMP9 9.8 11.6 GPR56 -2.9 -2.9
Genes that showed overlap in both the comparison mild vs severe disease and severe vs recovery samples 
are shown.
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RSV positive and negative patients were analysed. The characteristics of these patients 
differed from those of the patients in the discovery cohort, especially for age, gender, 
preterm birth, duration of symptoms. (S1 Table). In total, 115 PBMC samples were 
available for qPCR analysis, subdivided in 80 acute and 35 recovery samples. OLFM4 
gene expression levels during acute infection were higher compared to those obtained 
after recovery (p<0.001). In agreement with our microarray analyses, expression of 
OLFM4 in PBMCs was higher in patients with severe disease compared to those with 
mild and moderate disease (Figure 9.2B). For the confirmed RSV positive patients only, 
OLFM4 expression also served as a discriminating marker, similar to the full validation 
cohort (S3 Fig). Length of stay (LOS) in hospital, another measure for severity, was also 
correlated positively with gene expression levels of OLFM4 (ρ = 0.402, p<0.001).
OLFM4 expression correlates with disease severity in PBMCs  
but not in plasma
Since biomarkers in plasma are more easily obtained and processing is less time-
consuming, we measured protein levels of OLFM4 in plasma of 49 randomly selected 
patients of the validation cohort. Although OLFM4 plasma concentrations during acute 
infection were statistically significantly higher compared to those in recovery samples, 
no association with disease severity was observed (Figure 9.3). No correlation between 
protein levels and relative gene expression was found either (ρ = 0.270, p = 0.088).
Figure 9.2  OLFM4 gene expression values of patients from the micro-array and validation 
cohort. OLFM4 gene expression levels were significantly higher in patients with severe disease 
compared to those with mild and moderate disease in the micro-array cohort (Panel A) and an 
independent validation cohort (Panel B). Expression levels are presented as ΔCt and median with 
inter quartile range (IQR). Statistics were performed by Kruskall Wallis tests, followed by Mann 
Whitney U tests for individual comparisons.
A B
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In a multivariable model OLFM4 gene expression is a statistically 
significant marker for severe disease
To determine the predictive value of OLFM4 in patient with acute viral bronchiolitis, both 
RSV positive and negative patients we performed a multivariable analysis. Relative 
OLMF4 gene expression, gender, gestational age, and age at time of hospital admission 
(in weeks) were included as determinant and potential confounders, respectively in a 
multivariable model for mechanical ventilation (Table 9.3).
For OLMF4, a cut-off value of > -7.5 was chosen, which corresponds with an OLFM4 
expression level greater than 0.5% that of GAPDH. The unadjusted RR of mechanical 
ventilation was 8.6 with a 95% confidence interval (CI) of 2.2–34.0. After adjustment for 
age and gestational age, the RR was 6.1 (95%CI: 1.5–24.4), which indicates that children 
with OLMF4 gene expression levels above -7.5 have a 6-fold increased risk of severe 
infection requiring mechanical ventilation (Table 9.4). Gender did not add substantially 
to the final model. Including OLMF4 gene expression in the model as a continuous 
variable resulted in an age and gestational age adjusted RR of 1.20 (95%CI: 1.04–1.38), 
meaning that the risk of receiving mechanical ventilation increased by 20% with every 
step increase in expression level (range -12.6 through -1.33).
Figure 9.3 Plasma levels of OLFM4 in patients with viral RTI. OLFM4 plasma levels are statistically 
significantly higher during acute (n = 41) infections compared to recovery samples (n = 25) 
(Panel A). However, there are no statistically significant differences among the three severity 
groups (Panel B). Plasma levels (ng/ml) are presented as median with inter quartile range (IQR). 
Statistics were performed by Mann Whitney U tests for comparison acute vs recovery (p<0.05), 
and Kruskall Wallis tests for comparison mild vs moderate vs severe (p = 0.29).
A B
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Discussion
In this study we demonstrated that OLFM4 gene expression in PBMC is a previously 
unidentified classifier for severe disease in children with viral lower respiratory infections. 
OLFM4 expression was significantly increased during acute viral respiratory infections 
compared to recovery samples. Moreover, an association was found between OLFM4 
gene expression in PBMCs and disease severity; in a multivariable model OLFM4 
showed its power as a significant marker for severe disease. Children with mechanical 
ventilation have almost 10 times more often an increased OLFM4 expression in PBMC 
(greater than 0.05% of the GAPDh levels).
Therefore, OLFM4 fulfills the criteria as a biomarker for disease severity, in particular to 
discriminate mild from severe cases in young infants. For OLFM4 to formally be used as 
prognostic marker, a more extensive, prospective study will be required.
Table 9.3   Multivariable analysis of the association between OLFM4 expression levels 
and the risk of getting mechanical ventilation. 
Characteristics Univariate 
analysis 
(n=80)
Multivariate 
analysis
MV 
(n=24)
No MV 
(n = 56)
p-value p-value p-value OR (95% CI)
Gender (male) 12 (50%) 30 (54%) NS NS - - -
Age (weeks) 1.22 
[0.63–2.84]
3.95 
[1.95–12.7]
<0.001 <0.01; 
OR 0.96
0.05 0.96 0.93–1.00
OLFM4 expression -4.89 ± 2.53 -7.68 ±2.86 <0.001 4,71*10E-4; 
OR 1.43
<0.01 1.48 1.14–1.91
Premature (<37wks) 4 (17%) 11 (20%) NS NS - - -
Duration symptoms 11.0 
[10.0–13.0]
5.0 
[2.0–4.0]
NS NS - - -
Values are given in numbers (percentages) and mean ± standard deviation. MV = mechanical ventilation, 
NS = not significant, OR = odds ratio, CI = confidence interval
Table 9.4   Relative risk of getting mechanical ventilation determent by OFFM4 gene 
expression. 
Multivariate 
analysis
p-value OR 95% (CI) Relative risk
OLFM4 expression> -7.5 <0.01 15.78 1.93–46.57 8.7
OR = odds ratio, CI = confidence interval
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To the best of our knowledge, the OLFM4 gene has not been described in the context of 
viral respiratory infections. Although changes in cell populations occur during the acute 
phase of infection could be reflected in the gene expression profiles, it is remarkable that 
predominantly upregulated genes indicate severe disease, whereas only decreased cell 
populations are observed.14 To validate the OLFM4 gene expression changes during 
infectious disease we data-mined other micro-array studies that described pediatric and 
adult patient cohorts. In a study by Ioannidis et al. (GSE 34205), we found that OLFM4 
gene expression was higher in PBMCs obtained from patients with RSV (n = 51) or 
influenza virus (n = 27) infections com- pared to the gene expression in healthy infants (n 
= 22), p<0.01 and p<0.0001, respectively.31 No differences were found in OLFM4 gene 
expression between children under or above three months of age with either infection by 
RSV or influenza. In contrast, two other studies did not observe upregulation of OLFM4 in 
PBMCs from children during infection by measles or rotavirus (GSE 5808 and 2729).32,33 
Zaas et al. performed microarrays on whole blood obtained from adult volunteers at 
baseline and at the peak of their symptoms after being experimentally infected with RSV, 
influenza or rhinovirus (GSE 17156) . 34Although their data showed an upregulation of 
OLFM4 in RSV infected adults (p = 0.01), there were no differences in OLFM4 gene 
expression between the baseline and during symptomatic influenza or rhinovirus 
infections.34 Data of Ramilo et al. (GSE 6269–1) showed a statistically significant 
upregulation of OLFM4 in children, aged 0–16 years, diagnosed with influenza virus or 
bacterial infections (E. coli, S. aureus or S. pneumoniae) compared to healthy controls .20 
In this cohort, children with S. aureus or S. pneumoniae infections had statistically 
significantly higher OLFM4 gene expression compared to influenza A infected patients.20 
Thus, other studies have also seen upregulation of OLFM4 expresion after bacterial or 
viral infection. However, none of the studies looked at disease severity. OLFM4, also 
known as hGC-1 and GW112, was first cloned from G-CSF–stimulated human myeloid 
precursor cells and is mainly expressed in bone marrow, gastro-intestinal tract, prostate 
and pancreas.35 Earlier studies have shown that OLFM4 is involved in multiple cellular 
functions e.g. cell growth, differentiation and apoptosis.27 OLFM4 expression has been 
reported as one of several (prognostic) markers in oncology.27 In addition, its involvement 
in the immune response to inflammation has been described. OLFM4 expression is 
upregulated in some inflammatory diseases, such as chronic inflammatory bowel 
diseases36 and in Helicobacter pylori-infected patients .37 Liu et al. showed an enhanced 
immune response and inflammation in OLFM4-/- mice upon Helicobacter pylori infection. 
Their results indicate that OLFM4 inhibits NOD1 and NOD2-mediated NF-κB activation, 
suggesting that OLFM4 plays an important role in regulating innate immune responses.38 
In another study, Liu et al. demonstrated that neutrophils from OLFM4 -/- mice have 
increased capability to kill S. aureus and E. coli and are more resistant to systemic sepsis 
.39 These data suggest that OLFM4 may be an important regulator of host innate immunity 
against a broad array of bacterial infections. Data mining of gene expression profiling 
datasets (www.immgen.org) indicates that OLFM4 is besides being expressed in 
neutrophils, also highly expressed in Th1 cells. 
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Therefore the increased OLFM4 expression seen in the severe subgroup may indicate 
an highly active ongoing Th1 response. In summary, OLFM4 was upregulated in several 
viral and bacterial infections in many (but not all) previously published studies 
investigated.
Although OLFM4 mRNA has been described to be selectively expressed in normal 
human myeloid lineage cells, OLFM4 protein concentrations have been measured in 
PBMCs, B-lymphocytes, neutrophils and monocytes.40 This is in agreement with our 
results and those from the reanalyzed microarray studies, in which high and significantly 
different OLFM4 mRNA expression was found in PBMCs obtained from children with 
different severity of viral lower respiratory infections.
Clemmensen et al. showed that OLFM4 was present at protein level in only 20–25% of 
peripheral blood neutrophils, whereas mRNA for OLFM4 was present in all myelocytes 
and metamyelocytes, indicating post-transcriptional regulation as a basis for the 
heterogeneous expression of OLFM4 protein.41 This could explain the observed 
differences in our study between the transcription levels and the plasma concentration 
of the protein.
The advantage of measuring markers in plasma is the ease of implementation, speed, 
reproducibility and standardization. However, innovative techniques enable rapid 
analysis of the expression of multiple genes at transcriptional level in the near future.42
The severe CD4, CD8 and NK cell lymphopenia that we and others described before, 
can now be better explained. Together with the up regulation of activation markers on 
PBMC in the severe group and lack of apoptosis, the observed lymphopenia likely 
results from recruitment of T cells to the site of infection, i.e the lungs with an parent 
lower cell count in peripheral blood. In this respect peripheral blood may not reflect the 
situation in all parts of the body.
OLFM4 is associated with Th1 responses, an active or even overaggressive Th1 
response may underlie the severe clinical manifestations in this group. This is 
reminiscent of interpretations in the early RSV vaccine trails. Nevertheless, more 
accurate measurements at the site of infection will be needed to determine whether in 
the severe cases an inadequate adaptive immune response or a hyper responsive 
reaction (for instance by excessive production of cytokines) is responsible for the severe 
manifestations of RSV infection.
Notwithstanding this uncertainty, in this study we are the first to show that OLFM4 
transcription is associated with severity of disease in children with viral lower respiratory 
tract infections, also after correcting for age. These results emphasize the role of OLFM4 
in innate and adaptive immunity and encourages further research into the presence of 
OLFM4 in PBMCs and the pathogenesis of RSV infections. Moreover, it could lead to 
the development of a new diagnostic tool to predict a severe course of viral respiratory 
disease and aid the physician in clinical decisions.
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Supplemental
S1 Fig  Transient lymphopenia during severe RSV infection. Immune phenotyping with flow -
cytometry of circulating leukocytes of infants with severe RSV infection (n = 6) in the acute phase 
and after clearance of the infection (on average 4 weeks after discharge). The numbers of NK cells 
as well as CD4+ and CD8+ T cells return to normal, indicating that the lymphopenia was transient. 
Statistics were performed by paired students-t test, significance was set at p<0.05.
A
D
B
E
C
F
Processed on: 1-3-2017
508516-L-bw-Ahout
162
Chapter 9
S2 Fig  Discriminating mild disease from severe disease in children with RSV infection. 448 differentially 
expressed probesets were selected based on overlap in the comparison mild vs severe disease 
in RSV infected children and acute samples vs recovery samples of children with severe RSV 
infection. Samples were clustered based on these selected probesets by complete linkage 
hierarchical clustering with 1-correlation as a distance measure.
S3 Fig  OLFM4 gene expression values in PBMCs from RSV+ infants during acute mild, moderate 
and severe viral lower RTI and after recovery. Expression levels are presented as ΔCt and median 
with inter quartile range (IQR). Statistics were performed by Kruskall Wallis tests (p<0.001), 
followed by Mann Whitney U tests for individual comparisons: mild vs moderate p = 0.36, 
moderate vs severe p<0.001, mild vs severe p = 0.51.
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S1 Table  Patient characteristics of validation cohort. 
Values are given in numbers (percent- ages) and median and inter quartile range IQR 
Mild
(N=14)
Moderate 
(N=42)
Severe
(N=24)
p-value
Age (months) 3.2 [1.1-10.3] 4.9 [2.0-14.5] 1.2 [0.6-2.8] p<0.01*
Gender (male) 8 (57%) 22 (52%) 12 (50%) NS
Gestational age (wks) 36.8 [39.1-40.0] 38.0 [37.0-40.0] 38.9 [37.0-40.5] NS
Length of stay (days) 3 [2-3] 6 [4-9] 11 [10-13] p<0.001**
Confirmed RSV infection 3 (21%) 29 (69%) 15 (63%) <0.01***
* mild versus severe p = 0.05, moderate versus severe p<0.001 
** mild versus moderate and severe p<0.001, moderate versus severe p<0.001
*** mild versus moderate p<0.01, mild versus severe p<0.05
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Abstract
Respiratory syncytial virus (RSV) causes infections that range from common cold to 
severe lower respiratory tract infection requiring high-level medical care. Prediction of 
the course of disease in individual patients remains challenging at the first visit to the 
pediatric wards and RSV infections may rapidly progress to severe disease.
In this study we investigate whether there exists a genomic signature that can accurately 
predict the course of RSV. We used early blood microarray transcriptome profiles from 
39 hospitalized infants that were followed until recovery and of which the level of disease 
severity was determined retrospectively. Applying support vector machine learning on 
age by sex standardized transcriptomic data, an 84 gene signature was identified that 
discriminated hospitalized infants with eventually less severe RSV infection from infants 
that suffered from most severe RSV disease.
This signature yielded an area under the receiver operating characteristic curve (AUC) 
of 0.966 using leave-one-out cross-validation on the experimental data and an AUC of 
0.858 on an independent validation cohort consisting of 53 infants. A combination of 
the gene signature with age and sex yielded an AUC of 0.971. Thus, the presented 
signature may serve as the basis to develop a prognostic test to support clinical 
management of RSV patients.
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Introduction
Respiratory syncytial virus (RSV) causes infections that range from common cold to 
severe lower respiratory tract infection that in some instances may have a fatal outcome. 
Especially infants, elderly and patients with underlying chronic disorders suffer from 
severe RSV infections1,2. In infants, RSV is the leading cause of lower respiratory tract 
infections (LRTI) and is responsible for 80% of acute bronchiolitis cases 3. RSV infections 
pose a huge burden on society in terms of disease, logistics and socio-economic 
sequelae. There is an unmet need for an RSV vaccine, despite considerable research 
efforts no licensed vaccine has been developed. In industrialized countries, 1-5% of infants 
with RSV infection are hospitalized4–7. Some of these infants yet suffer from severe 
disease upon admittance, while others are admitted without severe symptoms since 
the course of bronchiolitis is highly variable and the need for supportive care cannot be 
predicted 8,9. Several risk factors for developing severe RSV disease in infants have 
been identified, including preterm birth, young age, sex and environmental factors like 
in- house smoking 10. Notwithstanding these known risk factors, current medical 
practice does not allow accurate prediction of whether an infant will further progress to 
severe RSV disease or not and could even be sent home safely. Genomic technologies 
have contributed to study the virus- host interaction, including virus discovery, 
pathogenesis studies, the design of antiviral strategies and identification of biomarkers 
to support clinical management of infectious diseases 11–14. For RSV infections, this has 
supported the characterization of vaccine-induced skewed host responses upon infection 
15,16. Meijas et al. 17 recently used blood transcriptome profiles obtained within 3 days of 
hospitalization to characterize the host response to RSV infection in infants compared 
with rhinovirus or influenza infections and identified transcriptional profiles that associate 
with RSV disease severity. However, a prognostic model for RSV severity based on 
gene expression profiles collected at admittance to the hospital has not been developed.
In this study we aim to identify and validate a gene signature that discriminates severe 
from less severe RSV LRTI that do not require advanced support. Such a signature 
together with other clinical parameters may improve the prognosis of less severe 
patients that could be safely sent home.
Material and Methods
Study design
Study subjects were recruited at Canisius Wilhelmina Hospital, Radboud University 
Medical Center, Nijmegen, and Erasmus Medical Center, Rotterdam, The Netherlands. 
Nasopharyngeal wash and blood samples were prospectively obtained from patients 
less than 2 years of age with a viral bronchiolitis. Patient enrolment occurred 7 days a 
week and samples were taken within 24 hours after first contact with the hospital. 
Seventy-three percent of all eligible bronchiolitis patients agreed to participate in the 
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study. The major reasons for non-inclusion were parental availability to sign consent and 
the hesitancy for the venipuncture. Only patients with an RSV infection, as retrospectively 
determined by PCR were included in the study. Exclusion criteria were: immunodeficien-
cy, systemic steroid treatment in the previous 2 weeks, blood transfusion, congenital 
heart and chronic lung disease. A Tempus tube (TempusTM, Applied Biosystems, Austria) 
and sodium heparin tube were filled with 3ml of blood. Medical history, demographic and 
clinical data were collected from medical records and questionnaires. The (hospitalized) 
patients were followed until recovery and were retrospectively classified as: mild for 
children without hypoxia, moderate for patients requiring supplemental oxygen (oxygen 
saturations <90%, ≥10 minutes) and severe for children requiring mechanical ventilation 
due to apnea, exhaustion and/or respiratory failure. Recovery samples were obtained 
after 4-6 weeks, during home visits. Blood samples were obtained from healthy controls 
(HC) without underlying diseases or medication subjected to elective surgery.
Study approval
The study protocol was approved by the Regional Committees on Research involving 
Human Subjects of Arnhem-Nijmegen and Rotterdam and were conducted in accordance 
with the principles of the Declaration of Helsinki. Written informed consent was obtained 
from the parents of all children prior to inclusion in the study.
Sample processing and blood transcriptome profiling
Inclusion of patients and sample collection was performed by a single MD at the 
hospitals. Multiplex RT-PCR was performed to test the nasopharyngeal washes on 15 
different viral pathogens, as previously described 18. Blood was collected in Tempus 
tubes for immediate stabilization of RNA and subsequently stored at -80°C. Total RNA 
was isolated from each blood sample, processed, assessed, labelled and hybridized to 
a single Affymetrix Human Genome U133 plus 2 gene chips; and image analysis was 
performed in the same lab and by one technician as described in supplementary 
material. The raw data has been deposited in the ArrayExpress database under access 
number E-MTAB-5195.
Data preprocessing
Microarray data was preprocessed using R 3.1.2 19 and Bioconductor 20. Upon initial 
quality control and VSN normalization (to render samples comparable), probeset (a 
combination of multiple probes) summarization was performed by median polish 21,22. 
Unless otherwise stated, all probesets/genes present on the Affymetrix GeneChip were 
used for data analysis. Samples were labelled and hybridized in two batches which did 
not correspond to any biological variable as samples were randomly assigned to the 
batches. The normalized expression values were adjusted for a batch effect (see 
supplementary Fig. S1) using ComBat 23. Additionally, we assessed confounding effects 
of clinical parameters age and sex on gene expression–severity relationship using 
“biasograms” 24.
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Differential expression analysis
To obtain a global view of the blood transcriptome changes in response to RSV infection 
(i.e. to evaluate whether whole transcriptome changes associate with severity), a 
principal component analysis (PCA) as an exploratory analysis was performed on the 
age by sex standardized data. Next, a differential expression (DE) analysis was 
performed on normalized-batch-adjusted data controlling for an age by sex effect using 
empirical Bayes linear models 25 implemented in the R package limma 26. Details of the 
models are found in supplementary material. We controlled for multiple testing via false 
discovery rate (FDR) using a Benjamini and Hochberg procedure 27. Gene set 
enrichment analysis was performed using Ingenuity pathway analysis (IPA, www.
qiagen.com/ingenuity).
Identification and evaluation of prognostic biomarkers
Since we are interested in identifying RSV-infected infants that will progress to severe 
stage upon presentation to the hospital, we grouped mild and moderate samples and 
aimed to separate these samples from infants that were presented with or progressed 
to severe disease after hospitalization. We chose to utilized probabilistic predictors (to 
predict the chance of an RSV- infected infant to be severe) because in clinical 
applications, probabilities are more informative than absolute yes or no predictions 28. 
Several probabilistic predictors exist in the literature and their performance depends on 
the type of the data they are being applied on 29. Using results of 29,30 and observed 
correlations in the data, three probabilistic classification functions that could be optimal 
for this data were chosen as described in supplementary material. These functions 
were support vector machines (SVM) 31, shrunken centroids discriminant analysis 
(SCDA)32 and random forest (RF) 33.
For each classification function, the experimental data was split into a learning set and 
a test set using leave-one-out cross-validation (LOOCV). Cross-validation reduces 
optimistic bias by ensuring that our models are evaluated on an independent dataset 
that was not used to constructed these models. Most probabilistic classification 
functions require hyper-parameters to perform variable selection among the huge 
number of variables (probesets). Usually, the best values for these hyper-parameters 
are also determined by cross-validation. Thus, the parameter(s) of the function were 
optimized using an inner loop of five-fold cross-validation on the learning set. Next, a 
prognostic model was built with the optimal parameter(s) on the entire learning set and 
evaluated with the test set, as described in supplementary material. The following R 
packages; CMA 34, e1071 35, pamr 36 and randomForest 37 were utilized for class 
prediction. The best calibrated and refined function amongst the three functions was 
selected and its performance evaluated using the area under the receiver operating 
characteristic (ROC) curve (AUC). Finally, the transcripts that maximized the binomial 
log-likelihood function, with the leave-one-out cross-validated data were retained as a 
gene signature from the selected function as described in supplementary material.
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Comparison of biomarkers to clinical parameters
Age and sex are readily available clinical parameters that have been determined to be 
associated to RSV disease severity 38. To assess the gain attained with a genomic 
model over a model with these clinical parameters, and the effect of standardization, 
the leave-one-out cross-validated predicted probabilities of progressing to severe for 
all samples were transformed to genomic scores (a genomic score is single measure 
of the genome of a sample as predicted by a model) for models with unstandardized 
and standardized data. Logistic regression models (see supplementary material) were 
then fitted with the genomic scores and/or clinical parameters and their AUCs compared.
Validation of biomarkers
For an independent validation, a subset of the Illumina RSV data of Meijas et al. 17 was 
used. Since the experimental data and validation data were obtained using different platforms, 
we linked the data using gene symbols and applied cross-platform transformation 
(to render gene expression comparable across datasets) as described in supplementary 
material. The transformed data was supplied to our prognostic model for predictions of 
probabilities of severity. For a confirmatory analysis of how well our prognostic model 
performs, we built and evaluated a prediction model with the chosen function (same 
function used to build our prognostic model) on the entire Illumina data and compared 
our validation performance to the performance from this (unrestricted) data.
Results
Study subjects and sampling
Thirty-nine infants hospitalized with acute RSV bronchiolitis were included in the study. 
Nasopharyngeal wash and whole blood samples for mRNA profiling were collected 
within 24 hours upon hospital admittance. Table 10.1 presents the characteristics of the 
study subjects. As expected, patients with the most severe course of RSV bronchiolitis 
were significantly younger than those with a relative mild or moderate course of this 
disease. The variables related to disease severity; duration of oxygen, and length of 
stay in the hospital were highest in the severe group, with ventilation indicating the 
method by which oxygen was supplied. The proportion of co-infections was lower in 
severe patients as compared to the other severity categories. There were no differences 
in the occurrence of other known risk factors.
Age and sex as confounders of gene expression–severity relationship
Figure 10.1a and b respectively illustrate the confounding effects of sex and age on the 
gene expression-disease severity relationship. These figures show that whereas age is 
negatively correlated to severity, sex is uncorrelated to severity. Nevertheless, the high 
positive/negative correlations of a considerable number of transcripts to sex and age, 
as well as severity, indicate a confounding effect of these variables on the expression- 
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severity relationship of these transcripts, thus warrant adjustment. Figure 10.1d and e 
illustrate the “biasograms” after an age by sex standardization. These figures show that 
standardization has no effect on severity correlated transcripts but as expected, transcripts 
that were originally correlated to age and sex become uncorrelated. A positive correlation 
of age to sex which signifies an age by sex interaction as a potential confounder on the 
gene expression-severity relationship was also observed (Figure 10.1c) and eliminated 
after standardization (Figure 10.1f).
Global blood transcriptome profiles associate with RSV disease severity
Figure 10.2 illustrate a PCA on the whole transcriptome and the first principal component 
accounts for 25% of the variance in the transcriptomes and associates with disease 
severity. Transcriptome profiles of HC and recovery samples group together on the first 
principal component and are located opposite to profiles of severe infants. The distinct 
groups do not form discrete clusters in the PCA but gradually shift from mild through 
moderate to severe, with considerable overlap. This shows that the blood mRNA 
profiles substantially capture the severity of lower respiratory tract RSV infection.
Number of differential gene expression relates to RSV disease severity
Table 10.2 presents results of differential gene expression analysis and reveals that the 
number of DE transcripts increases with disease severity. No DE transcript was 
identified between mild versus HC samples when applying a FDR of 5% and absolute 
fold change (FC) threshold of 2. However, 17 and 221 transcripts were DE between 
moderate and severe versus HC respectively. Interestingly, all transcripts that are DE in 
moderate class are also DE in severe class with larger FC. About 90% of these DE 
transcripts are up-regulated. Comparison of HC with recovery samples revealed a 
Table 10.1  Patient characteristics (n represents the number of samples per group)
Parameters Mild (n=7) Moderate (n=14) Severe (n=18)
Age (days) 153 [84, 291] 185 [60, 333] 31 [17, 76]
Gestational age (weeks) 40 [29, 41] 40 [37, 41] 39 [37, 40]
Birth weight (kg) 3.5 [3.0, 4.2] 3.4 [3.1, 3.9] 3.3 [2.5, 4.0]
Symptomatic days 4 [2, 6] 4 [3, 6] 3 [2, 4]
Duration on O2 (days) Ventilation 0
None
3 [2, 5]
Supplemental
8 [7, 11]
Mechanical
Length of stay (days) 4 [2, 6] 5 [3, 8] 11 [9, 13]
Breastfeeding 4 (57) 11 (79) 12 (67)
Male gender 5 (71) 10 (71) 12 (67)
RSV + other virus(es) 4 (57) 8 (57) 3 (17)
Data are presented as median and interquartile range (IQR) in square brackets [ , ] or number and percentage 
in brackets ().The median age of the healthy controls was 536 days (IQR [472, 602]).
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single down-regulated transcript while moderate versus mild yielded no DE transcript, 
severe versus mild or moderate yielded 178 and 49 DE transcripts respectively. Lastly, 
95 transcripts were DE between severe versus combined mild/moderate samples.
RSV induced blood transcriptome profiles reveal an inflammatory 
response 
Figure 10.3 shows that multiple relevant categories of molecular and cellular functions 
are significantly enriched when comparing severe to HC samples. With “Cell-to-Cell 
Signaling and Interaction” top category, gene sets related to activation of several types 
of immune cells including lymphocytes, granulocytes and specifically neutrophils are 
most significantly enriched. In addition, gene sets that are involved in migration and 
tissue infiltration of these same activated cell types are most significantly enriched 
within the category “Cellular Movement” that ranks third on this figure. Finally, several 
Figure 10.1  Confounding effect of Sex, Age and Age by Sex on gene expression–severity relationship, 
before: (a), (b) & (c) and after: (d), (e) & (f), an age by sex standardization. The blue and green 
lines represent the clinical variables, the cosine of the angle between the lines represents its 
correlation to the blue line (Sex is not correlated to Severity, Age is negatively correlated to Severity 
i.e. younger kids become severe and Age is positively correlated to sex i.e. females are older). The cloud 
of points represent the transcripts and their correlations to both variables with most transcripts 
uncorrelated to the variables (yellow cloud) while a considerable number (black cloud) are 
correlated to Severity, Sex, Age and Age*Sex. The associations between the transcripts and Sex, 
Age or Age*Sex are significantly eliminated after standardization while retaining that of Severity.
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high ranking molecular and cellular function categories and their underlying gene sets 
indicate the immune cells involved are strongly proliferating. A list of genes involved in 
each of these pathways is presented in supplementary Table S1. Taken together, blood 
transcriptome changes in RSV disease reveal a typical inflammatory response to a viral 
infection.
Figure 10.2  Global blood transcriptome profiling with principal component analysis: the first 
principal component (PC1) accounts for 25% of the variance in the dataset and associates with 
disease severity. This can be observed as a shift from healthy controls and recovery cases (left) 
through mild and moderate to severe cases (right), with considerable overlap.
Table 10.2  Number of differentially expressed transcripts for each contrast at FDR 
of 5% and absolute fold change cutoff of 2.
Mil-HC Mod-HC Sev-HC Mod-Mil Sev-Mil Sev-Mod RC-HC Sev-
(Mil+Mod)/2
UP 0 15 194 0 164 42 0 82
Down 0 2 27 0 14 7 1 13
Total 0 17 221 0 178 49 1 95
Where Mil: Mild, Mod: Moderate, Sev: Severe, HC: Healthy controls (<2years) and RC: Recovery samples.
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Early blood transcriptome changes to predict a severe outcome  
of RSV infection
To construct a predictive model, we combined mild and moderate cases as a single 
group and three probabilistic classification functions were chosen based on supplementary 
Figure S2 and results of Jong et al. and Kim & Simon. 29,30. Using these functions, 
classifiers were built and evaluated using LOOCV on the experimental data. SVM was 
chosen as the best calibrated and refined as shown on supplementary Figure S3 and 
henceforth considered for all analyses. The LOOCV predicted probabilities from SVM 
were used to evaluate its performance and are plotted on Figure 10.4a against the true 
RSV status as retrospectively determined. This figure shows that 5 samples out of 39 
were misclassified at a 50% cutoff and when applying a proposed uncertainty band of 
30-70% just one false negative is witnessed. Evaluation of the clinical characteristics of 
the single false negative patient as well as those patients with uncertain predictions 
(plotted within the proposed uncertainty band) did not reveal any recognizable pattern. 
The false negative patient had uniquely RSV and only a single patient plotted within the 
Figure 10.3  Ingenuity pathway analysis (IPA) Molecular and Cellular functions gene set analysis 
for severe vs healthy control contrast.
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uncertainty band had RSV + other virus(es). Figure 10.4b presents the corresponding 
ROC curve from the LOOCV predicted probabilities and AUC of 0.966 demonstrates 
the high discriminative power of our prognostic model.
Genomic biomarkers outperform clinical parameters age and sex
Figure 10.4c presents the ROC curves from logistic models of clinical parameters and/
or genomic scores. The genomic score model from the standardized data (AUC=0.966) 
outperforms that from the unstandardized data (AUC=0.915). In addition, there is a 
significant difference between a model with age and sex only (AUC=0.833) and that 
with a standardized (AUC=0.966) or unstandardized genomic score (AUC=0.915). 
Whereas there is a slight improvement from clinical parameters and standardized 
genomic score model (AUC=0.971), there is no improvement from the clinical 
parameters and unstandardized genomic score (AUC=0.911), indicating that indeed 
standardization completely removed an age-by-sex effect on the gene expression data.
Figure 10.4  Internal validation of gene signature: (a) samples’ predicted probabilities of being 
severe. (b) shows the ROC curve and the AUC for predicted probabilities. The AUC value of 
approximately 1 indicates how accurate our signature performs on this internal validation set. 
(c) shows that a genomic model from the age by sex standardized data out performs that from 
the unstandardized data. In addition, there is a significant difference between a model with clinical 
parameters and that with a genomic score and just a slight improvement when both parameters 
are included in a model.
a
c
b
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An 84 gene expression signature predicts absence of disease 
progression
To extract the prognostic signature, we selected top transcripts maximizing the binomial 
log- likelihood function using LOOCV predicted probabilities as illustrated on supplementary 
Figure S4. This figure depicts a 1-SE maximum of 95 transcripts corresponding to 
84 unique genes, which are displayed on Table 10.3. Of the 95 transcripts constituting 
the prognostic signature, 81 (85.26%) were found to be significantly DE between severe 
and non-severe patients (FDR cutoff of 5%, supplementary Table S2). The inclusion of 
non-DE transcripts in the classification model is expected, since not only DE genes are 
instrumental in class discrimination as illustrated by the two-dimensional scenario in 
supplementary Figure S5.
Performance of the genomic signature retained on an independent 
dataset
For an independent validation, a subset of the Illumina RSV data of Meijas et al. 17 was used. 
Since the experimental data and validation data were obtained using different platforms, 
we linked the data using gene symbols and applied cross-platform transformation 
(to render gene expression comparable across datasets) as shown on supplementary 
Figure S6 and extensive described in the supplementary material. Figure 10.5a presents 
Figure 10.5  Predicted probabilities of being severe from the validation data against true RSV 
status using; our diagnostic signature (a) and LOOCV on unrestricted data (b). (c) illustrates the 
agreement of the predictions from both models, green regions are perfect agreement, blue are 
disagreements at a 50% cutoff and red are disagreements at a 30% -70% uncertainty band. 
Finally, (d) presents the ROC curves and AUC from both models illustrating similar AUC values.
a
c d
b
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predicted probabilities of severe on the validation data using 75 of our 84 prognostic 
gene signature that were common in both experimental and validation datasets, while 
Figure 10.5b presents the LOOCV predicted probabilities from SVM on the entire 
Illumina data. Both figures show that using the unrestricted data leads to more certain 
probabilities and slightly improves specificity compared to our signature. Nonetheless, 
Figure 10.5c illustrates a large agreement between the predicted probabilities of the 
two models, while Figure 5d clearly reveals that both models are alike as demonstrated 
by the AUCs of 0.858 and 0.856 for our signature and the unrestricted model respectively. 
To assess the concordance of the expression patterns of our signature on both datasets 
(Affymetrix and Illumina), we plotted the log2 fold changes of the common 75 genes 
as shown on Figure 10.6. From this figure, one clearly sees that there is a huge 
concordance in the direction of expressions across datasets. Where there are slight 
Figure 10.6  Log2 Fold change between Severe vs Non-Severe infants for 75 common genes in 
Affymetrix and Illumina datasets. Red represent up-regulation while green represents a down- 
regulation and the significant FDR adjusted p-values are placed in the cells. As one can clearly 
see, there is a huge overlap in the direction expressions across datasets. Where there are slight 
differences, these differences are not significant as shown by a non-significant p-value in at least 
one of the datasets.
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differences, these differences are not significant as shown by a non-significant p-value 
in at least one of the datasets.
Discussion
RSV infection in infants may cause life-threatening disease. No vaccine is yet available 
and triage of patients is challenging since RSV infections may rapidly progress to 
severe disease. No reliable prognostic model to predict which RSV patient will not 
progress to severe disease and could be safely send home is available either. Thus, 
clinical care is symptom-based and a significant proportion of RSV infected infants 
is hospitalized for observation purposes. We have provided an 84 gene signature 
that discriminates hospitalized infants with less severe RSV infection from those infants 
with severe RSV disease. The identified signature yielded a LOOCV AUC of 0.966 
on the experimental data and was independently validated with an AUC of 0.858 and 
might serve as a basis to develop a prognostic test for clinical management of RSV 
disease.
In line with epidemiological observations 38 and observations of Mejias et al 17, we 
showed the confounding effects of age and sex on gene expression-severity relationship 
for RSV disease. Studies in any RSV patient cohort with a naturally occurring “skewed” 
distribution of age and sex can be standardized for these parameters. By adjusting for 
an age-by-sex effect in our analyses, we obtained age-by-sex independent results 
which can be effectively applied to any patient(s). The high performance of our signature 
on the age and sex matched validation data signifies age-by-sex independence and 
robustness of this signature. Fewer co-infections were observed in severe patients 
(Table 10.1). A similar trend has been described previously 39. In our cohort study we 
did not take into account co-infections since no consistent association between the 
occurrence or absence of co-infections with RSV disease severity have been reported 
39–43. Furthermore, we aimed at the identification of a gene signature in a natural 
“real-life” cohort of patients not stratified according to age or occurrence of co-infections.
We hypothesized that changes in blood cell type distribution and/or mRNA expression 
changes of the circulating cells collected from peripheral blood reflect local lung host 
response characteristics that associate with disease severity. PCA and DE analysis 
indeed revealed significant changes in the transcriptome profile of whole blood. Gene 
set analysis further shows that relevant processes are monitored including the 
activation, migration and tissue infiltration of lymphocytes, granulocytes and neutrophils. 
Individual DE genes in severe RSV disease revealed overexpression of the neutrophil 
associated genes MMP8 and MMP9, which have previously been related to severe RSV 
disease 44. ARG1 and CHI3L1 that have been linked to alternatively activated 
macrophages in a mouse model for vaccine enhanced RSV disease 16 were also found 
to be strongly up-regulated. This suggests that the collected blood transcriptome 
profiles indeed reflect local lung host response.
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In our class prediction analysis, three functions were evaluated and the best was 
chosen. While it has been pointed by 45–48 that selecting a minimal-error classifier leads 
to selection bias that should be corrected, the literature does not stipulate a selection 
bias when using calibration and refinement scores as evaluation measures. 
Nevertheless, we employed the nested cross-validation correction of selection bias 46 in 
our model building procedure by splitting our experimental data into learning and test 
sets with an inner loop split on the learning set for parameter(s) optimization. Though 
found to contain high variance, we utilized leave-one-out cross-validation for the test 
set because it yields approximately an unbiased estimate of the true (expected) 
prediction error 49 and because we were interested in the individual sample predicted 
probability of severe and not entirely on the expected predicted error. Nevertheless, 
where we were interested in the expected predicted error, as in the optimization of 
parameters, we utilized five- fold cross-validation as recommended by Breiman and 
Spector 50. To validate the identified signature, an independent dataset generated on a 
different platform was used. Despite (i) the several sources of variability between our 
experimental data and the validation data that stem from - but not limited to - array 
platforms and different clinical cutoffs of RSV severity statuses, (ii) different time of 
profiling, 1-3days after hospitalization and (iii) loss of information due to a reduction in 
signature because of no corresponding transcripts on Illumina platform and the 
aggregation of multiple transcripts to genes, our signature yielded an AUC of 0.858 that 
was comparable to accuracy (AUC of 0.856) when using the Illumina data (validation 
set) as experimental set. Cross-platform validation is rare due to lack of guidance on 
how this can be done reliably. We presented a cross-platform validation procedure.
The RSV patients enrolled in the study displayed varying disease severities but were all 
hospitalized thus representing a severe disease enriched subset of RSV infected 
infants. The patients enrolled however also represent a natural cohort of patients 
including a significant number of patients that eventually did not require extensive 
medical care and could have been discharged home. Since the blood samples were 
collected soon after hospital admission, the generated blood transcriptomes and the 
derived gene signature may serve as a basis for the development of a novel genomic 
tool to support clinical management of RSV disease including triage of patients 
presenting at the hospital provided that a rapid (real time) gene test can be developed. 
Larger transcriptome data sets are however required to construct predictive models 
that may also allow for discriminating mild from moderate and moderate from severe 
cases. Ultimately, one would like to extend the RSV biomarker program to earlier time 
point samples (e.g. obtained when visiting a general practitioner) and to samples 
collected from patients infected by other (respiratory) infectious agents or pathological 
conditions (comorbidities) in order to identify specific respiratory viral prognostic 
biomarkers. To this end a novel gene signature have to be developed using a much 
larger early blood sample cohort. The current results support the development of 
diagnostic tests for personalized medicine that not only provide information on the 
causative infectious agent, but also about the disease severity that may be expected.
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Abstract
Objectives: The pathophysiology of severe respiratory syncytial virus infections in 
infants remains to be elucidated. Gene expression analysis of peripheral blood was 
used to identify differences in the immune response of infants with severe RSV infection. 
Methods: Affymetrix microarray analysis was performed on whole blood of 51 patients 
<2 years of age with viral lower respiratory tract infection and on 12 age-matched healthy 
controls. Transcriptional modular framework analysis was applied and gene expression- 
based distance to health was calculated. Subsequently, micro-arrays on neutrophils 
and PBMC were performed and blood smears were analyzed.
Results: Gene expression-based distance to health correlated significantly with 
disease severity, duration of supplemental oxygen and length of hospitalization. The 
neutrophil associated module was most discriminative for patients with a severe RSV 
infection. This signature was partly caused by cell shift as shown by cell counts and 
neutrophil specific micro-arrays. In addition, neutrophil specific signatures in the PBMC 
enriched fraction of peripheral blood from severely ill patients was found.
Conclusion: Neutrophil transcriptome signatures correlate with severe RSV disease. 
Low density granulocytes co-purified during density gradient PBMC isolation are only 
present during acute RSV infection in children and may have an unexpected role during 
severe respiratory viral infections in children.
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Introduction 
In 2004 the WHO estimated that 78% of all worldwide mortality for children under the 
age of five years was caused by only six diseases. Acute respiratory tract infections 
(ARIs) and diarrheal diseases are number one in this ranking, each responsible for 17% 
of deaths. Millions of children are affected by ARIs each year accounting for nearly 2 
million deaths per year.1 Respiratory Syncytical virus (RSV) is the third most common 
pathogen in cases of childhood death due to ARI, after Streptococcus pneumoniae and 
Haemophilus Influenzae type b.2 Whilst treatment and protective vaccines are available 
for the bacterial causes of ARI, no vaccine or treatment exists for the majority of viral 
respiratory pathogens, including RSV. Disease severity of respiratory viral infections 
can range from a common cold to severe bronchiolitis with respiratory insufficiency, 
resulting in the need for mechanical ventilation. Especially infants, the elderly and 
patients with underlying chronic disorders are vulnerable for a severe course of viral 
respiratory infections. Although risk factors for severe disease in infants are known, the 
majority of infants on the ICU have no underlying co-morbidities. A combination of 
physical factors, the developing immune system, genetic background and immune 
modulatory capacities of the virus are thought to be important. 3 Nonetheless, although 
all infants have an immature immune system, only 1-10% of RSV infected infants need 
hospitalization.4,5 Hence, it is important to further elucidate the mechanisms behind the 
development of severe RSV disease. The use of microarray studies in adults and 
children has proven to be useful in gaining insights in the immune responses against 
pathogens. Studies comparing the gene expression profiles of patients suffering from 
different diseases have shown that the host response is very specific, enabling the 
identification of different etiologic viruses or bacteria.6-10 In addition, this host response 
gives information about underlying pathophysiology and mechanisms involved in the 
immune response against the pathogens.6-8,11 It has been shown that disease severity 
can be determined based on the host response.7,12 Chaussabel et al. described an 
alternative method to analyze gene expression data, based on modules of co-expression 
of genes.13 This results in lower error rates and more comprehensive results, providing 
a better insight in the pathophysiology of disease.13 Studies using this module showed 
a distinctive response of infants to RSV infections compared to other viruses.7 In this 
study, we further explore the immune response of infants with severe respiratory 
syncytial viral infections. By comparing gene expression from patients with different 
disease severities we intend to improve the understanding of the pathophysiology of 
severe disease.
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Methods
Study design
Nasopharyngeal wash and blood samples were prospectively obtained from patients < 
2 years of age with a viral bronchiolitis. Subjects were recruited at Canisius Wilhelmina 
Hospital and Radboud university medical center, Nijmegen, the Netherlands. Patient 
enrolment occurred 7 days a week and samples were taken within 24 hours after first 
contact with the hospital. The inclusion rate was 73%. The major reasons for exclusion or 
refusal were parental availability to sign consent and the hesitancy for the venipuncture. 
Exclusion criteria were: immunodeficiency, systemic steroid treatment in the previous 2 
weeks, blood transfusion, congenital heart and chronic lung disease. A Tempus tube 
(TempusTM, Applied Biosystems, Austria) and sodium heparin tube were filled with 3 ml 
of blood. Medical history, demographic and clinical data were collected from medical 
records and questionnaires. Patients were followed until recovery. At that point the patients 
were classified into three severity groups: mild for children without hypoxia, a moderate 
group for patients requiring supplemental oxygen (oxygen saturations <93%, ≥10 
minutes) and a severe group with children requiring mechanical ventilation. Recovery 
samples were obtained after 4-6 weeks, often during home visits. 
A healthy control group for the microarray was obtained from patients without underlying 
diseases or medication, who needed a venipuncture for screening purposes. A total 
cohort of 51 acute, 31 recovery and 12 healthy control samples were available for 
analysis. Only patients with an RSV infection were included in this study.
Material processing
Multiplex RT-PCR was used to test the nasopharyngeal washes on 15 different viral 
pathogens, as previously described 14. From the blood in the sodium heparin tubes a 
thin peripheral blood smear stained with Giemsa was made to determine the 
percentages of PBMC and granulocytes. The remainder was diluted 1:1 and added to 
5 ml lymphoprep (Lymphoprep®, Axis Shield, Norway) in a 15 ml Falcon tube for 
density gradient centrifugation. Plasma was obtained and PBMC and granulocytes 
were harvested. The neutrophils were subsequently lysed in isotonic ice-cold NH4Cl 
solution (8.3 g/L NH4Cl, 1 g/L KHCO3 and 37 mg/L EDTA) and washed. Both cell 
subsets were stored in Trizol® reagent (Invitrogen, The Netherlands) at -80°C. The 
Tempus tube was directly stored at -80°C.
RNA isolation and microarray gene expression analyses
RNA from Tempus tubes was isolated following the manufacturers protocol. RNA from 
granulocytes and PBMC was isolated with Trizol following the manufacturers protocol 
and subsequently cleaned with Qiagen RNA Clean up kit. RNA integrity and quality was 
assessed using capillary electrophoresis [RNA 6000 Nano LabChip (Agilent)] on an 
Agilent Bioanalyzer 2100 system. RNA processing, target labelling and hybridization to 
gene expression arrays was performed by standard methods as described 15. Biotin 
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labeled cRNA was obtained using the One-Cycle Eukaryotic Target Labelling Assay 
(Affymetrix). 15 µg of fragmented, biotin labelled cRNA was hybridized to Affymetrix® 
GeneChip® Human Genome U133 plus 2.0 arrays according to standard Affymetrix 
protocol (Affymetrix Inc, Santa Clara, CA).
Quality control analyses were performed as previously described. 15,16 Scanned images 
were inspected for artifacts, percentage of calls present (<25%) and controls of RNA 
degradation. Upon initial quality control and VSN normalization, probeset summarization 
was performed by median polish. 17,18 Samples were labelled and hybridized in two 
batches. The normalized expression values were adjusted for a batch effect using 
ComBat. 19 Differentially expressed genes were identified based on log2 fold changes 
and false discovery rates (FDR). FDR adjusted p-values were calculated using LIMMA. 
Corrections for false discovery rates (FDR) were performed via the Benjamini Hochberg 
method 20 Microarray data have been deposited in ArrayExpress database under 
access number xxx. All microarray experiments were performed according to the 
MIAME guidelines.
Modular frameworks and distance to health
First a normal range of gene expressions per gene was defined based on whole blood 
gene expression data from healthy controls. This resulted in a bandwidth of health. 
Subsequently, gene expressions of every individual patient and healthy control were 
compared to this bandwidth of health. Genes with a significant p-value (p<0.05) and at 
least 1 log2 fold difference were used for subsequent calculations. The fold changes 
were transformed into absolute numbers and summed to create a distance to health 
score. Furthermore, genes where assigned to modules as defined by Chaussabel et al. 
Translations from the Illumina probe assigned modules to Affymetrix probes was 
performed using DAVID 21 based on gene symbols. Fold changes of significantly 
changed genes were summed per module and divided by the total amount of genes in 
that specific module to correct for the module size. Clustering of samples was performed 
on the module data using Euclidian distance correlations. Visualization was performed 
using iTOL. 22
Cytometric bead array
The concentration of IL-6, G-CSF, IP-10, IL-8, IFN-γ, IL-1β, IL-10, TNF, MCP-1 and RANTES 
(category number 558276, 558326, 558280, 558277, 560111, 558279, 558274, 560112, 
558587, 558324, respectively) in two fold diluted plasma was measured with Cytometric 
Bead Array (CBA BDTM Flex sets, BD biosciences) according to the protocol provided 
by the manufacturer. Cytokine concentrations could be measured from zero up to 
10000 pg/ml.
Microarray data from neutrophil subsets
Affymerix CEL-files from a published study by de Kleijn et al. was downloaded from the 
Gene Expression Omnibus using their study coded GSE42358.23 In this study 
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micro-arrays were performed on three subsets of neutrophils based on CD16/CD61L 
expression, derived from healthy volunteers four hours after LPS infusion. A list from 
genes that were at least one fold differentially expressed between the young versus the 
normal and activated neutrophils. This list was used to cluster the neutrophil micro-arrays 
from the RSV infected infants. 
Statistics
The distribution of categorical variables is presented as percentages. Numerical 
variables are presented as mean with standard deviation (SD) or medians with inter 
quartile range (IQR) depending on the distribution of the data (Kolmogorov-Smirnov’s 
test, p>0.05). Kruskal-Wallis test was used to compare 3 or more groups and Mann- 
Whiney U for comparisons between two groups. The Kendall’s Tau test was used to 
study trends in non-parametrically distributed data. Corrections for false discovery 
rates (FDR) were performed via the Benjamini Hochberg method. 20
Study approval
The study protocols were approved by the Regional Committee on Research involving 
Human Subjects Arnhem-Nijmegen (serving as the IRB) and were conducted in 
accordance with the principles of the Declaration of Helsinki. Written informed consent 
was obtained from the parents of all children.
Results
Of the 51 included infants, 40 had an acute lower respiratory tract infections due to RSV 
infections and 12 healthy controls were included in this study. Recovery samples were 
available for 20 patients. Patients with a severe course of disease were significantly 
younger than those with a mild or moderate course of disease(Kendall’s tau correlation 
coefficient for trend -0.41, p=0.001, Table 1). There were no differences in the presence 
of other known risk factors. As expected the variables related to disease severity, 
duration of supplemental oxygen and duration of supplemental oxygen were highest in 
the most severe group (Kendall’s tau correlation coefficient 0.80 and 0.59, p <0.0001). 
The median age of the healthy controls was 300 days [180-562 days] and half of them 
were male. 
Distance to health correlates with different severity measures and enables clustering 
on disease severity. Calculation of a distance to health (DTH) per patient was performed 
by summing the fold changes of all significantly changed genes compared to the 
healthy controls. Euclidian distance correlations where determined of the samples 
based on the distances to health, the majority of infants clustered with other patients 
that experienced the same severity of disease (Supplemental figure 1 and Figure 1A), 
while the majority of recovery samples clustered with the healthy controls (Figure 1A). 
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The distance to health score increased from healthy towards a severe course of disease 
(Kendall’s tau for trend 0.461, p<0.0001) (Figure 1B). This measure also correlated with 
age, duration of supplemental oxygen and duration of hospitalization, Kendall’s tau of 
-0.296, 0.322, 0.314, all p<0.001 (Figure 1C and D). To assess whether patients fully 
recovered after 4-6 weeks, the DTH was calculated from the recovery group as well. Not 
all patients were fully recovered after this period in time based on the DTH (median 
4905.2, 5111.5, 5787.7, 6068.1 and 7666.5 for healthy, recovery, mild, moderate and 
severe samples, respectively). 
Six modules are differentially expressed among the different disease severities. 
To determine which modules were responsible for an increased DTH and thus severity 
of disease, we compared the modular scores across the severity groups. Out of 253 
modules, 73 were differently expressed among healthy controls and RSV infected 
infants, after correcting for multiple testing 40 modules remained significantly changed 
(p<0.05). In addition, 47 modules were significantly changed among the three severity 
groups in acute disease. Six modules remained significant after correction for multiple 
testing, of which the most differentially expressed module is the neutrophil module 
(M5.15). In this module upregulation correlates with increasing disease severity (Figure 2A). 
The other significant modules were the cytotoxic T cell / NK cell modules (M3.6 and 
M8.46) which show increased downregulation (Figure 2B,C), while the inflammation 
(M4.2) (Figure 2D), platelets (M1.1) (Figure 2E) and erythrocyte module (M2.3) (Figure 2F) 
are all upregulated with increased disease severity. When the 253 modules are 
combined in 22 groups with distinct cellular functions 24, the same significant differences 
were observed within the following groups: neutrophils, Cytotoxic/NK cells, inflammation, 
Table 11.1  Patient characteristics.
Mild (n=7) Moderate (n=15) Severe (n=18) p-value
Age (days) 153 [84-291] 185 [60-333] 31 [17-76] <0.01*
Male gender 5 (71) 10 (67) 12 (67) NS
Gestational age (wk) 40 [39-41] 40 [37-41] 39 [37-40] NS
Birth weight (kg) 3.5 [3.0 – 4.2] 3.4 [3.1-3.9] 3.3 [2.5-4.0] NS
Breastfeeding 4 (57) 11 (73) 12 (67) NS
Symptomatic (days) 4 [2-6] 4 [3-6] 3 [2- 4] NS
Duration O2 (days) 0 3 [2-5] 8 [7- 11] <0.0001**
Length of stay (days) 4 [2-6] 5 [3-8] 11 [9-13] <0.0001***
Data are presented as median and interquartile range (IQR) or number with percentage, a Kruskal-Wallis test 
was performed for groups and a Mann-Whiney U test for individual comparisons. * mild vs moderate and 
severe p< 0.001, trend test correlation coefficient - 0.412 p<0.01. ** All comparisons p<0.0001, test for trend 
correlation efficient 0.807, p<0.0001. *** All comparisons p<0.0001, test for trend correlation efficient 0.585, 
p<0.0001.
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platelets and erythrocytes. This method also revealed significant differences in the 
modules apoptosis/survival, plasma cells, mitochondrial stress, cell death and B cells 
(Supplemental figure 2). 
The changes in the specific modules during acute, and especially severe disease led 
us to further explore the immunological processes that underlie this difference in gene 
expression. Downregulation of the cytotoxic T cell/ NK cell, and T cell module may be 
explained by a decreased cell count of these specific cell types, as has been published 
Figure 11.1  Patients with viral lower respiratory tract infections cluster together on disease severity. 
A. The distance to health score of individual patients was used to create this graph. The outer green 
circle depicts the DTH scores of individual patients. With Euclidian clustering analysis the 
patients clustered based on disease severity, as reflected by the inner part of the figure. Further, 
duration of hospitalization and supplemental oxygen are shown in the middle circles of the graph. 
B. The DTH scores are shown per severity group, C. Correlation of DTH with duration of supplemental 
oxygen and D. length of stay in the hospital (spearman correlation).
A B
C
D
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11Figure 11.2 A-F  Individual scores per severity group on modules that are differently expressed 
during acute disease. Additional information on the modules A. Neutrophil modules: healthy and 
recovery values are similar, all scores are higher during acute disease (healthy vs mild p<0.05, 
healthy vs moderate / severe p<0.01 and healthy vs severe p<0.001). B. Cytotoxic T cell / NK cell 
module: the scores of the healthy, recovery, mild and moderate group are similar. The severe 
group has a lower score compared to the healthy and recovery group (p<0.0001). C. Cytotoxic T 
cell / NK cell module: the scores of the healthy, recovery and mild group are similar. Healthy vs 
moderate p<0.05, severe vs healthy and recovery group p<0.0001. D. Inflammation module: 
Healthy and recovery and mild scores are similar, healthy vs moderate p<0.001 and severe 
p<0.0001. E. Platelets modules, healthy and recovery, mild and moderate patients have similar 
scores, healthy infants have significantly lower scores compared to severe diseased patients 
(p<0.01). F. Erythrocyte module, scores between healthy and recovery, mild and moderate are 
similar. Healthy vs severe p<0.01.
A
C
E
B
D
F
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before by our group and others 25,26. Therefore, in this study these specific cell 
populations were not further explored. Also erythrocytes and platelets were not studied, 
since the required materials were not collected during the original study. We therefore 
choose to focus on the inflammatory response and neutrophils in this study. 
Cytokine and chemokines measurements as validation of  
the inflammation module 
Plasma was stored from the majority of patients and the levels of ten different proteins 
related to inflammation were measured. Interleukin-6, Interleukin-8, Interleukin-1β, IL-10, 
gCSF, RANTES and MCP-1 levels were statistically significantly lower in the healthy 
controls than in the RSV infected groups (Supplemental figure 3). For 27 patients both 
CBA and microarray data were available and a significant differences in IL-6, and RANTES 
concentrations among the three severity groups was found. RANTES correlated with 
DTH and the duration of supplemental oxygen (Pearson rho -0.45, p <0.001 and -0.43, 
p<0.05, respectively).
Neutrophil specific microarray
To see whether the upregulation of the neutrophil module is due to the influx of a new 
population of young and banded neutrophils or activation of normal neutrophils we 
used a dataset published by de Kleijn et al. 23. In this study gene expression studies 
were performed on subsets of neutrophils, e.g. normal, activated and young neutrophils, 
derived from volunteers 4 hours after LPS infusion. Two sets of genes were generated, 
the first comprised of differentially expressed genes when normal neutrophils are 
compared to activated neutrophils (figure 3A), and the second comprised of genes 
derived from the comparison of normal versus young neutrophils (Figure 3B). Genes 
from these lists were subsequently used on gene expression data from neutrophils of 
RSV infected infants. Clustering revealed no differences between the samples based 
on the activated neutrophils gene set (Figure 3C). However, the set based on young 
neutrophils enabled clustering of patients (Figure 3D).
Differences in neutrophil subsets as explanation for differences  
in gene expression in the neutrophil module
The highly differentially expressed neutrophil modules in patients with a severe course 
of disease may be caused by differences in absolute cell counts, as is the case for the 
downregulation of the cytotoxic T cell and NK module or, as indicated by the neutrophil 
micro-array, an influx of young neutrophils recruited from the bone marrow. Therefore, 
blood smears of the patients were analyzed. No differences were seen in absolute 
lymphocyte and leukocyte counts between the severity groups (Figure 4A and B). 
Neutrophil counts were increased in the severe group compared to the mildly diseased 
patients. The median of the moderate group was even higher than that of the severe 
group, but due to the large range of values no significance was reached (median of 
0.51, 2.62 and 2.15 *106 neutrophils/ml during mild, moderate and severe disease, 
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respectively) (Figure 4C). The number of banded neutrophils was significantly higher in 
patients with a severe course of disease (Figure 4D). The number of banded neutrophils 
correlated with the score on the neutrophil module, ρ=0.57, p<0.001. 
Gene expression differences based on subset of neutrophils
Thus far, we showed that the neutrophil module is highly differentially expressed in 
patients with a severe course of disease. This can be explained by the influx of young, 
banded neutrophils, as reflected by the differences in cell counts and results of the 
neutrophil gene expression. However, these small differences can therefore only partly 
explain this observation. From some patients also gene expression data of the PBMC 
fraction was obtained and it was checked whether the activation and young neutrophil 
gene lists from the LPS study could enable clustering within these PBMC. No clustering 
was seen in the expression of genes associated with activated neutrophils (Figure 5A). 
In contrast, the expression of genes associated with young neutrophils showed 
Figure 11.3  Gene list of most differentially expressed genes in activated (A) and young (B) 
neutrophils derived from LPS infused volunteers, are applied to neutrophils of RSV infected 
infants. C. No clustering of severe patients with the gene list of activated neutrophils. D Genelist 
of young neutrophils, two severely ill patients cluster together with 2 moderate patients. Purple 
represents upregulation and green downregulation.
A
C
B
D
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increased expression of all genes in severe disease, whilst the mild and moderately ill 
patients had no or low expression of these genes (Figure 5B). 
PBMC obtained during acute RSV infection reveals the presence  
of neutrophils
To explore the phenomenon of a neutrophil signature in PBMC, FACS analysis was 
performed on stored PBMC of infants with acute RSV infection to determine the 
presence of neutrophils. Based on the forward and sideward scatter and expression of 
CD15, the presence of 2,0 - 7,1 % CD15+ cells which are most likely neutrophils with a 
lower density in the PBMC fraction could be confirmed. 
Figure 11.4  Cell differentiation of the blood of the same patients as used for the micro-array. 
Cell differentiations of circulating blood cells in patients with RSV infections with different disease 
severities. Data are represented as amount per milliliter blood, with median and interquartile 
range, Mann Whitney U was used to test for differences between two groups.
A
C
B
D
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Discussion
In this study we analyzed gene expression profiles of infants with difference in levels of 
disease severity due to RSV infections to gain insight in the pathophysiological 
processes. We show that especially expression of genes related to the neutrophil 
module are strongly upregulated during severe RSV infection. Severe disease was also 
associated with downregulation of modules related to cytotoxic T, NK and B cells and 
upregulation of modules related to inflammation, platelets and erythrocytes. Upregulation 
of genes in the neutrophil module was further explored and we show that the response 
seems to be correlated with an influx of young neutrophils into the peripheral blood, and 
the appearance of a neutrophil signature in the lower density PBMC fraction. 
Clinically, the correlation of RSV infections with neutrophil responses has been demonstrated 
before, although this is not fully understood yet. A strong influx of neutrophils into the 
blood occurs at the peak of the clinical symptoms in infants with an RSV infection. 27-29 
A study by Lukens et al. on sequentially sampled patients with RSV infections showed 
a systemic neutrophil response with an increase of bone marrow-derived neutrophil 
progenitor cells during symptomatic disease.27 Also at the site of infection neutrophils 
counts increase, reflected by the presence of neutrophils up to 80% in bronchoalveolar 
lavages of patients with severe RSV infections requiring mechanical ventilation.29-32 
In non-ventilated children with severe RSV infections this neutrophil influx has been 
described as well, diminishing the likelihood of a ventilator induced phenomenon.26 
Neutrophils in the lungs of RSV infected patients are activated, as they show delayed 
apoptosis and release cytokines.33,34 To date, it has not been shown that neutrophils 
Figure 11.5  Gene list of neutrophils from LPS study based on activated (A) or young (B) 
neutrophils used in PBMC of RSV infected infants. A No clustering of patients when the gene list 
of activated neutrophils is applied to gene expression data of PBMC of RSV infected infants. B. 
The severely ill patients cluster together with 2 moderately ill patients based on the gene list of 
young neutrophils. Purple represents upregulation and green downregulation.
A B
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have a direct role in the anti-viral host response.35 However, RSV seems to have adapted 
to the neutrophils since it can bind to and transcribe itself in neutrophils in the peripheral 
blood resulting in neutrophils that express RSV proteins on their surface. 36
A specific population of neutrophils, that was found to co-purify with the PBMC fraction 
after density gradient centrifugation has been described in the context of auto-immunity. 
In 1986, Hacbarth et al. described these cells in patients with systemic lupus 
erythematosus (SLE) and named them low density granulocytes (LDG).37 The first 
publications on different densities of neutrophils appeared already in the seventies, 
where the granulocyte fraction after density gradient centrifugation was further subtyped 
using Percoll density gradient.38 The percentage of lower density neutrophils in this 
fraction increased during sepsis or bacterial infections.39 These ‘low-buoyant’ density 
granulocytes appeared to have emptied their granulae as was shown with electron 
microscopy and have diminished chemotactic capacities. 39 This neutrophil 
subpopulation was found to be pro-inflammatory. Moreover, these cells are easily 
triggered to form neutrophil extracellular traps.40 Further characterization of the LDG 
appear to be contradictory. Based on gene expression an immature granulocyte is 
expected, whilst a flow cytometry study showed that the LDG population resembles 
mature granulocytes which express low CD14 and high CD15.41 Microscopy studies on 
the nuclear morphology of these cells describe a mixed population of young and 
mature granulocytes. The origin of this neutrophil subset is still unknown.40 Besides 
literature on low density granulocytes, studies on granulocytic myeloid derived 
suppressor cells (G-MDSC’s) are also emerging. The G-MDSC is a heterogeneous 
subset of cells that expands during inflammation, infections and cancer and suppress 
T cell responses.42 This cell type is a likely candidate for our neutrophil signature in the 
PBMC fraction, since it also resides in the PBMC fraction after density gradient 
centrifugation and it is described in a wider range of immunological processes. 
Moreover, they closely resemble neutrophils, differences and similarities between 
G-MDSC and neutrophils are reviewed extensively by Pillay et al. 43. As was seen in 
LDG’s, the phenotype of G-MDSC’s ranges from immature to mature and all types 
share distinct features of the neutrophil e.g. nucleus morphology and surface markers. 
In this study, we used gene expression data from subsets of neutrophils based on 
surface markers to increase our insight in the composition of the neutrophil fraction in 
the PBMC. In a follow up study on the neutrophil subsets described by de Kleijn et al, 
P2 neutrophils (activated neutrophils or CD62Ldim/CD16bright) were found to be immune 
suppressive. It is tempting to speculate that G-MDSC’s are not the cell type that is 
responsible for the upregulation of the neutrophil module, since there was no clustering 
of severe patients in the PBMC micro-array when the P2 list was used. However gene 
expression data might not be the most optimal tool to pinpoint this specific cell 
population since gene expression, microscopic and flow cytometry data have proven 
to be contradictory in both LDG and G-MDSC’s. We have shown that our population 
has an immature gene expression profile and is CD15+ representing a form of innate 
immunity.23
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The neutrophil module upregulation may be related to several other factors. Bacterial 
co-infection or mechanical ventilation should also be considered as trigger for the 
immune response. The group of Ramilo et al. recently published a large study on infants 
with different viral respiratory infections, including RSV. 44 They also used a modular 
approach and showed similar results concerning disease severity in different cohorts 
of infants. We were able to validate their findings concerning the upregulation of specific 
modules during severe RSV infections in infants, on a different microarray platform. 
Although both groups exclude patients with (suspected) bacterial co-infections many of 
them received antibiotics, limiting the value of negative blood cultures. We reviewed the 
clinical charts of patients with a high score on the neutrophil module and made two 
important observations. First of all, not all patients with high neutrophil scores received 
mechanical ventilation or received antibiotics during their treatment. Second, patients 
with a high neutrophil score without the need for mechanical ventilation, did experience 
multiple apneas during their hospitalization. This finding indicate that the activation of 
the neutrophil module is not explained by a reaction towards a bacterial co-infection or 
mechanical ventilation only. It would be interesting to investigate whether there is a 
relation between neutrophil activation and the incidence of apnea in infants with RSV, 
because it has been shown that the occurrence of OSAS (obstructive sleep apnea) is 
correlated with neutrophilic inflammation of the lower airways. 45  
The increased expression of genes of the inflammation module as observed in this 
study is in-line with other studies which showed increased cytokine and chemokine 
levels during viral infections. 25,28 IL-6 and RANTES levels were significantly different 
among the severity groups and IL-8 correlated with disease severity measures as 
described before. 28 The downregulation of the NK and cytotoxic T cell module in 
patients with severe RSV infections is in line with other studies that show lower cell 
counts of T cells and NK cells during severe RSV infections. 25,26 The platelet and 
erythrocyte modules are upregulated during viral infections. Both cell types have im-
mune-modulatory capacities that are only now being recognized as important players 
in the immune system and immunological studies on these cell types start to emerge. 
Activated platelets can influence the cytokine response of monocytes upon stimulation 
with LPS, resulting in a decreased TNF response and increased IL-10 production. 46 The 
immune-modulatory effects of erythrocytes has been revealed by Elahi et al. who 
showed that neonatal erythroids are rendering the neonatal immune system hypo 
responsive and thereby contribute to neonatal susceptibility to infections. 47
Bont et al. conclude in their study that mechanical ventilation and hyperoxia results in 
an increased inflammatory response in the lungs of RSV infected patients. 48 However, 
an increase in the neutrophil and inflammation modules was also observe and 
mechanical ventilation and course of disease. Therefore, we think that mechanical 
ventilator or hyperoxia induced damage is not likely to be a major confounder.49
Although our study has a limited sample size, our findings are in accordance with a 
completely independent and recent study from Mejias et al.44 For future studies 
sequential data on the immune response of infants during RSV infection would increase 
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insight in the pathophysiology of the host response of severe disease. Increasing 
numbers of healthy controls and mildly ill patients would further increase the 
discriminative power of the used analysis methods. In summary, this study provides 
new insights into severe RSV infections by the use of micro-array analysis and indicate 
that neutrophils, cytotoxic T-cells, NK-cells, platelets and erythrocytes play a role in the 
pathophysiology of severe disease. A population of neutrophils, most likely LDG’s or 
G-MDSC’s, appeared in the PBMC fraction of patients with a severe course of their RSV 
infection. These findings open new avenues for further research on the pathophysiolo-
gy of RSV induced disease and could enable the development of a prognostic tool to 
predict the course of infection.
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Supplemental Figure 1 Heat map of significantly changed genes between the individual 
patients and the control group.
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Supplemental Figure 2 Median scores on functional modules per severity group. Twelve out 
of 27 functional modules changed in any of the three severity groups (Kruskal Wallis).
Supplemental Figure 3 Plasma levels of cytokines and chemokines in healthy infants, 
recovery samples and infants with different severities of an RSV infection. Plasma levels of 11 
healthy, 27 recovery, 7 mild, 39 moderate and 22 severe patients are depicted with median and 
interquartile ranges, samples below the detection limit were set to 1 to enable visualization. 
Significance is calculated among the mild, moderate and severe group.
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Abstract
Respiratory syncytial virus (RSV) causes mild infections in the vast majority of children. 
However, in some cases, it causes severe disease, such as bronchiolitis and pneumonia. 
Development of severe RSV infection is determined by the host response. Therefore, 
the main aim of this study was to identify biomarkers associated with severe RSV 
infection.
To identify biomarkers, nasopharyngeal gene expression was profiled by microarray 
studies, resulting in the selection of five genes: ubiquitin D, tetraspanin 8, mucin 13, 
β-microseminoprotein and chemokine ligand 7. These genes were validated by real-time 
quantitative PCR in an independent validation cohort, which confirmed significant 
differences in gene expression between mildly and severely infected and between 
recovery and acute patients.
Nasopharyngeal aspirate samples are regularly taken when a viral respiratory tract 
infection is suspected. In this article, we describe a method to discriminate between mild and 
severe RSV infection based on differential host gene expression. The combination of 
pathogen detection and host gene expression analysis in nasopharyngeal aspirates will 
significantly improve the diagnosis and prognosis of respiratory tract infections.
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Introduction
Respiratory syncytial virus (RSV) is the most common cause of viral respiratory tract 
infections among hospitalised children. Symptoms range from a common cold to 
severely compromised respiratory function, causing 6-15% of the admitted children to 
require intensive care1,2. It is difficult to predict the course of disease in infants, especially 
in children under the age of 3 months. Current clinical prediction rules are based on 
demographic criteria and clinical symptoms3-10 and although they may improve clinical 
judgement7,8, they are not routinely used in daily practice. More objective and 
reproducible predictions may be achieved by using biomarkers11-15.
Recent publications showed that gene expression profiles in peripheral blood mono - 
nuclear cells represent the subject’s health. Ramilo et al.16 were able to discriminate 
influenza A, Escherichia coli and Streptococcus pneumoniae infection with 95% accuracy, 
and distinguished E. coli from Staphylococcus aureus infection with 85% accuracy by 
analysing mRNA expression level in young patients. In the case of RSV infections, 
Mejias et al.17 showed, based on blood RNA profiles of infants, a classification of infants 
with RSV lower respiratory tract infection (LRTI) versus rhinovirus or influenza LRTI with 
95% accuracy. Additional studies confirmed these observations and described the 
discovery of several biomarkers in blood by which different states of disease could be 
distinguished18.
These findings may be of great value for clinical decision making. However, the studies, 
as described, were performed using blood samples, of which only limited volumes can 
be obtained from paediatric patients. Thus, it would be worthwhile to study whether 
other clinical materials could be used that reflect the host response and may harbour 
prognostic value. The nasopharynx is the point of entry of all respiratory viruses; 
moreover, a sample from this site is already taken to diagnose viral infections using 
real-time quantitative PCR (RT-qPCR)19. The use of nasopharyngeal aspirates (NPAs) 
for the measurement of host biomarker expression for prognostic purposes would be 
worthwhile to assess, especially as clinical laboratories would only need minimal 
adjustment to integrate this test into current practice. Knowledge in regards gene 
expression in the nasopharynx during RSV infections is limited and has been gained 
solely from animal models20.
In this study, we assessed the possibility of measuring host gene expression in NPA 
taken from children with laboratory-confirmed RSV infections and aimed to identify 
markers with potential prognostic value for the course of disease.
Materials and methods
Ethics. The study was approved by the Committee on Research Involving Human 
Subjects of the Radboud University Medical Center (Nijmegen, the Netherlands). All 
clinical samples collected from patients in our cohorts were enrolled following informed 
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consent from parents or guardians. The clinical information available to subjects being 
recruited for the study included a clear description of the risks and benefits of participation, 
indicating the required insurance and procedures, safe handling and protection of all 
data. All subjects were informed that there was no obligation to participate and that 
declining to participate or leaving the study had no adverse consequences.
Study design. Children <5 years of age with symptoms of viral LRTI were included. 
These symptoms included increased respiratory effort (e.g. tachypnoea and/or use of 
accessory respiratory muscles) and/or expiratory wheezing and/or crackles and/or 
apnoea. Retrospectively, the LRTI was confirmed by RT-qPCR on nasopharyngeal 
washes as described previously19. Patients with congenital or acquired immune deficiency, 
immunosuppressive medication (including >24 hours of glucocorticosteroids) or severe 
psychomotor retardation were excluded.
All subjects were recruited at two hospitals in Nijmegen. Subjects admitted were screened 
for symptoms typical for viral respiratory tract infection, as described previously. When 
RSV infection was suspected, a NPA was collected within 24 hours of admission (acute) 
and parents of hospitalised children were asked permission to draw a second NPA 
sample 4–6 weeks after admission (recovery). Medical history, demographics and 
clinical parameters were collected from questionnaires and medical records. Patients 
were classified into three different groups based on the degree of supportive care they 
needed during the course of disease: no supportive care; supplemental oxygen (when 
oxygen saturation was <93% for >10 minutes); or mechanical ventilation.
Microarrays were performed on samples from the cohort published by Brand et al.18 
(n=30, 2006–2009) and subsequently selected markers were validated in the cohort of 
I.M.L. Ahout and co-workers (personal communication; manuscript in preparation) 
(n=44, 2010–2012).
Sample collection. After informed consent, a NPA sample was collected by introducing a 
catheter, connected to a collection tube and an aspiration system, into the nasopharyngeal 
cavity. Then, saline (0.5-1.5 mL) was instilled into the catheter and, while slowly retracting 
the catheter, the nasopharyngeal fluid was aspirated in a collection tube. Afterwards, 
the catheter was flushed with saline and added to the collection fluid.
The samples were kept on ice and immediately transferred to the laboratory, where they 
were centrifuged (500×g) for 10 minutes at 4°C to spin down the mucus and cells, after 
which the pellet was mixed with Trizol (Life Technologies, Carlsbad, CA, USA) and 
stored at -80°C. RT-qPCR was performed using the supernatant to confirm viral 
aetiology of the disease19.
Microarray. RNA was extracted from NPA in Trizol according to the manufacturer’s protocol. 
The final RNA pellet was washed twice with 1 mL of 75% ethanol, air dried and 
resuspended in 100 µL of RNAse/DNase free water. Subsequently, a clean-up of the 
total RNA was performed with the RNeasy Minikit (Qiagen, Hilden, Germany) according 
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to the manufacturer’s instructions. RNA integrity and quality for the microarray was 
assessed using a RNA 6000 Nano LabChip on an Bioanalyzer 2100 system (Agilent, 
Santa Clara, CA, USA).
RNA processing, target labelling and hybridisation to gene expression arrays was 
performed. Biotin-labelled cRNA was obtained using the One-Cycle Eukaryotic Target 
Labeling Assay (Affymetrix Inc., Santa Clara, CA). 15 µg of fragmented, biotin-labelled 
cRNA was hybridised to Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays 
according to standard Affymetrix protocol.
Microarray data analysis. Quality control analyses were performed as previously 
described21. Scanned images were inspected for artefacts, percentage of present calls 
(<25%) and controls of RNA degradation. Background signal was removed using robust 
multichip analysis and probe intensity levels were quantile-normalised across arrays. 
Microarray analysis was performed using ArrayStar4 (DNAStar, Madison, WI, USA).
After the microarray data were obtained, comparisons were made based on supportive 
care: the need for supportive care (comparison 1) and mechanical ventilation 
(comparison 2). p-values were corrected for false discovery rate and, subsequently, the 
significant genes with a four-fold change were selected, while probes directed at 
noncoding sequences were excluded22.
The selected genes were not normally distributed according to the d’Agostino and Pearson 
omnibus normality test (α=0.05) (Prism 5; Graphpad Software, La Jolla, CA, USA). 
Therefore, a permutation test using MultiExperiment Viewer (tm4group; Dana-Farber Cancer 
Institute, Boston, MA, USA) with random group samples (105) was performed and the 
median fold change cut-off was set at 2.50 log. The overlapping genes between the two 
comparisons and the only upregulated gene were selected for validation by RT-qPCR.
Gene validation by RT-qPCR. Samples were defrosted on ice and RNA was extracted 
from NPA in Trizol according to the manufacturer’s protocol. The RNA pellet was washed 
twice with 1 mL of 75% ethanol, air dried, re-suspended in 100 µL of diethylpyrocarbonate- 
treated water. Subsequently, a clean-up was performed with the RNeasy Minikit according 
to the manufacturer’s instructions. The elutate was treated with TURBO DNA-free (Life 
Technologies); subsequently, cDNA synthesised by iScript (Biorad, Hercules, CA, USA) 
and stored at -20°C.
The RT-qPCR was conducted on a CFX96 (Biorad) using Taqman gene expression 
assays (Hs.00197374_m1, Hs.00610327_m1, Hs.00217239_m1, Hs.00738231_m1, 
Hs.00171147 _m1 and Hs.02758991_g1; Life Technologies) and IQ Powermix (Biorad). 
The PCR programme consisted of an initial 5 minutes at 96°C, followed by 40 cycles of 
15 seconds at 96°C and 45 seconds at 60°C. The data generated were analysed using 
CFX Manager 3.0 (Biorad) and the cut-off value was set by using the single threshold 
mode for quantification cycle (Cq) determination. The data were normalised by 
subtracting the Cq-value of the housekeeping gene, i.e. glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (Hs.02758991_g1; Life Technologies).
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Statistical analysis. Significance of the microarray analysis was calculated by a 
permutation test, with 105 random group samples using TMEV (tm4group). Significance 
of the RT-qPCR-measured gene expression was calculated by Mann–Whitney U-tests 
using Prism 5, where a two-sided value of p<0.05 was considered statistically significant.
Correlation was assessed by Spearman analysis using SPSS (IBM, Armonk, NY, USA), 
where a two-sided value of p<0.05 was considered statistically significant. For the 
patient characteristics, the Kruskal–Wallis analysis was performed; in the case of 
significance (p<0.05), we subsequently performed Mann-Whitney U-tests for individual 
comparisons using SPSS.
Results
Microarray data analysis. In this study, the clinical value of nasopharyngeal gene 
expression was assessed by conducting microarrays on NPAs of 30 infants with a 
confirmed RSV infection, both mono- (RSV) and co-infections. The patient characteristics 
are displayed in table 1. No significant differences were found, except for the parameters 
on which the clinical categorisation was based and gestational age.
To select potential biomarkers, comparisons were made using microarray analysis with 
regards to the need for supportive care: supplemental oxygen (comparison 1) and the 
need for mechanical ventilation (comparison 2). The permutation test led to an initial 
selection of 53 targets (table S1) for comparison 1 and 93 targets for comparison 2 
(table S2). By the subsequent introduction of a median fold change cut-off of 2.5 log, 16 
genes were selected that were significantly differentially expressed in comparison 1 
(table S3) and 28 genes were selected in comparison 2 (table S4). 
The two selections were compared and four overlapping genes were found (ubiquitin D 
(UBD), tetraspanin 8 (TSPAN8), mucin 13 (MUC13) and β-microseminoprotein (MSP)), 
which all showed downregulation. In addition to these genes, chemokine ligand 7 
(CCL7) was selected as the only upregulated differentially expressed gene in the whole 
microarray analysis (table 2).
Gene expression validation. In order to confirm differential expression of the genes 
selected by microarray analysis, RT-qPCR was used to validate these genes in an 
independent cohort. This cohort consisted of patients with RSV mono-infections to 
focus on the RSV specificity of the discovered genes. The final cohort consisted of 42 
RSV-infected infants, of whom the patient characteristics are displayed in table 3. No 
significant differences were found between the groups, except for the parameters on 
which the clinical categorisation was based, age and RSV serotype.
To assess the overall sample quality, the expression of GAPDH in all samples was 
plotted (figure 1). Generally, the amounts of RNA in the NPA samples were low; in a few 
samples, the amounts were too low to be able to measure gene expression, so these 
samples were excluded from further analysis.
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These results clearly show a low but consistent expression in all samples, irrespective 
of the patient’s health status. RT-qPCR analysis of our selected genes using nasopharyngeal 
samples from the validation cohort confirmed that the expression of all selected genes 
was significantly different, when comparing the recovery with acute samples. In this 
analysis, the acute group consisted of pooled expression data from all three groups: no 
supportive care, supplemental oxygen and mechanical ventilation. In case of TSPAN8, 
MUC13, MSP and CCL7, the expression differed significantly in comparison 2 (the need 
for mechanical ventilation) (figure 2). Subsequently, the correlation between the level of 
gene expression and known risk factors was assessed. Smoking at home, smoking during 
pregnancy, eczema, asthma and atopic family history did not show any correlation. 
For UBD only, a correlation with gestational age was found; however, gestational age is 
a well-known confounder, which does not exclude the value of UBD as severity marker23.
Figure 12.1  Nasopharyngeal expression of glyceraldehyde 3-phosphate dehydrogenase. Data 
are presented as median and interquartile range. Data were Mann-Whitney U-tested, two-sided 
(recovery, n=23; acute, n=42). No significant differences were found. Cq: quantification cycle.
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Figure 12.2  Nasopharyngeal expression of a–c) ubiquitin D (UBD), d–f) tetraspanin 8 (TSPAN8), 
g–i) mucin 13 (MUC13), j–l) β-microseminoprotein (MSP) and m–o) chemokine ligand 7 (CCL7) in 
recovery versus acute (a, d, g, j and m), need for supportive care (b, e, h, k and n) and need for 
mechanical ventilation (c, f, i, l and o). Data are presented as median and interquartile range. 
Data were Mann-Whitney U-tested, two-sided (recovery, n=23; acute, n=42). ΔCq: glyceraldehyde 
3-phosphate dehydrogenase-normalised quantification cycle. *: p<0.05; **: p<0.01; ***: 
p<0.001.
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Discussion
This study shows that nasopharyngeal aspirates taken to diagnose the viral cause of 
infection can also be used to identify biomarkers by microarray analysis that are 
associated with severe RSV infections. The value of these markers was confirmed in 
an independent patient cohort. To our knowledge, this is the first study in which 
nasopharyngeal host gene expression was studied in the context of infection.
Gene expression analysis was unforeseen at the time of collection and a large part of 
the material was used for other studies; therefore, the quantity of the total material and 
the quality of the RNA isolated from the NPAs was suboptimal. The results of the GAPDH 
expression assay show that the absolute Cq-values are high, but consistent.
The microarray analysis resulted in the discovery of five significantly differentially 
expressed genes in the nasopharynx of infants with different degrees of severities of 
RSV infection. Remarkably, most genes are down-regulated in severely ill patients; this 
was confirmed with RT-qPCR. In addition, previously published microarray studies 
performed on gene expression profiles in peripheral blood of infants also showed a 
significant downregulation of genes16,17.
The method, as described in this study, with the aim to identify genes with potential 
prognostic value, has proven successful by the validation of TSPAN8, MUC13, MSP and 
CCL7. Although UBD did not discriminate between any acute group, it differed 
significantly between the recovered and acutely ill patients. This clearly underlines the 
value of our approach, in which microarray analysis was used to select differentially 
expressed genes in a discovery cohort, which were independently validated by qPCR 
and RT-qPCR in a separate cohort.
Besides CCL7, none of the genes identified in this study has previously been described 
to be associated with RSV. UBD participates in the ubiquitination process, labelling 
proteins for their degradation via the proteasome. Mielech et al.24 have shown that 
coronaviruses actively reduce ubiquitination of host cell proteins and observed their 
potential to modify the innate immune response. With regard to TSPAN8, Yue et al.25 
described its ability to override the adhesive features of CD151. On this note, CD151 is 
involved with the infectious entry of human papillomavirus26, suggesting a significant 
infectious advantage for RSV when TSPAN8 is downregulated. Reduced amounts of 
MUC13 lead to decreased chemokine secretion in response to tumour necrosis 
factor-α. This pro-inflammatory activity of MUC13 suggests that disrupted or 
inappropriate expression of MUC13 could predispose to infectious disease27. The 
downregulation of MSP was previously described in the context of rhinovirus infection28. 
Mygatt et al.29 reported virus-mediated silencing of MSP, which seems in accordance 
with our findings. Finally, significant upregulation of CCL7 has been observed in mice 
infected with rhinovirus20 and in children during infection by different respiratory viruses, 
including RSV30. In addition, CCL7 was shown to be specifically upregulated when no 
mechanical ventilation was applied during RSV infection in mice and not differentially 
expressed when uninfected mice received mechanical ventilation31, strongly suggesting 
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that CCL7 upregulation is caused by RSV infection and is not a consequence of 
mechanical ventilation.
In conclusion, based on differential expression of TSPAN8, MUC13, MSP and CCL7 in 
readily available NPA samples, we can discriminate between severity of disease in RSV 
infected infants. This proves the potential of additional host gene expression analyses 
using regularly taken NPA samples, which, when combined with pathogen detection, 
would improve diagnosis of respiratory tract infections. Therefore, our findings demand 
further studies that might lead to the implementation of nasopharyngeal gene 
expression in diagnostics to guide clinical decisions in the context of respiratory tract 
infections.
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High pneumococcal density correlates 
with more mucosal inflammation 
and reduced respiratory syncytial virus 
disease severity in infants
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Chapter 13
Abstract
Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract 
infections in infants. A small percentage of the infected infants develops a severe 
infection, while most of these severely ill patients were previously healthy. It remains 
unclear why these children develop severe RSV infections. In this study, we investigate 
whether pneumococcal nasopharyngeal carriage patterns correlate with mucosal 
inflammation and severity of disease.
In total, 105 infants hospitalized with RSV infection were included and recovery samples 
were taken from 42 patients. The presence and density of Streptococcus pneumoniae 
was determined by RT qPCR to study its relation to viral load, inflammation (MMP-9 and 
IL-6) and severity of RSV disease.
We show that pneumococcal presence or absence in the nasopharynx does not correlate 
with viral load, inflammation or severity of disease. However, when pneumococcus is 
present in patients, a higher nasopharyngeal pneumococcal density was correlated 
with a higher RSV load, higher MMP-9 levels and a less severe course of disease.
Our results show correlations between S. pneumoniae density and viral load, 
inflammation and disease severity, suggesting that pneumococcal density may be an 
indicator for severity in paediatric RSV disease.
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Background
Respiratory syncytial virus (RSV) is a major cause of severe respiratory infections in 
infants below 6 months of age and the most common cause for bronchiolitis. 
Approximately 60% of all infants are infected with RSV during their first winter season 
and at the age of 2 almost all children have encountered RSV1. The vast majority of 
children will develop relatively mild symptoms, comparable to a common cold. However, 
approximately 2-3% will develop bronchiolitis and will be hospitalized2. Known risk 
factors for severe disease are age (<6 months), prematurity, congenital heart or lung 
disease and presence of siblings2-5. A considerable part of the severely ill patients were 
previously healthy and, at this moment, we do not understand why these children become 
severely ill. 
Mucosal surfaces of the human body are inhabited by complex microbial ecosystems, 
together called the ‘microbiome’. A growing body of evidence shows that the microbiome is 
crucial for the shaping of our immune system6,7. Because an over-exuberant immune 
response plays a crucial role in severe RSV infections, the composition of the microbiome 
during the first months after birth should be considered as a potential determinant for 
severity of disease upon infection with RSV8. Interactions between RSV and Streptococcus 
pneumoniae are well-documented previously. Most of these studies focus on the influence 
of RSV infections on secondary pneumococcal infections, e.g. showing an enhanced 
adherence of S. pneumoniae to RSV-infected cells9-13. However, whether the presence of S. 
pneumoniae in the nasopharynx may influence a subsequent RSV infection has not been 
studied in infants. There are studies showing that S. pneumoniae may aggravate RSV 
infections14,15. Cells infected by pneumococci are more susceptible to RSV infection in vitro 
and in a mouse model14. In a study in South-Africa, it was shown that vaccination against S. 
pneumoniae reduces viral-caused pneumonias by 31%, suggesting a promoting role for 
S. pneumoniae in viral respiratory infections15. In this study, the presence and density of 
S. pneumoniae was determined in a 66 clinical cohort of infants hospitalized with RSV 
infections. Classically, severity of an infection is thought to be dependent on two factors: 
pathogen load and inflammatory response. Previous studies have shown that bacterial 
colonization is able to influence viral infection rate16-18, but may also influence the inflammatory 
response during an infection19-22. Therefore, we studied correlations between pneumococcal 
colonization patterns and RSV load, levels of the inflammatory mediators IL-6 and MMP-9, 
both associated with RSV infection23-25 as well as S. pneumoniae infection26-28, and severity 
of disease.
Methods
Study design
Children younger than 2 years of age with laboratory confirmed viral respiratory tract 
infections were prospectively included during three consecutive winter seasons 
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(November-April in 2010/2011, 2011/2012 and 2012/2013). Written informed consent 
was obtained from all parents. Patients with congenital heart or lung disease, immuno-
deficiency or glucocorticoid use were excluded. Medical history, demographics and 
clinical parameters were collected from questionnaires and medical records. Patients 
were divided into three groups. Children without hypoxia were classified as ‘mildly ill’. 
‘Moderately ill’ children received supplemental oxygen, while ‘severely ill’ children 
required mechanical ventilation. Within 24h after admission, a nasopharyngeal aspirate 
(NPA) was collected (acute) and parents from hospitalized children were asked for 
permission to draw a second NPA sample 4-6 weeks after admission (recovery). 
The study was approved by the Central Committee on Research Involving Human 
Subjects of the Radboud university medical center.
Sample collection
The nasopharyngeal aspirates were collected by introducing a catheter, connected to 
a collection tube and an aspiration system, into the nasopharyngeal cavity. Then, 0.5 ml 
of saline was instilled into the catheter and, while slowly retracting the catheter, the 
nasopharyngeal fluid was aspirated in a collection tube. Afterwards the catheter was 
flushed with 1 ml of saline and this was added to the collection fluid. Samples were kept 
cold and were immediately transferred to the laboratory. Samples were taken for viral 
and bacterial diagnostics. For viral diagnostics samples were analyzed by multiplex 
PCR, quantifying 15 different viral pathogens, as previously described29. The remaining 
NPA was centrifuged at 500*g for 10 min at 4°C to spin down the mucus and 100 cells, 
after which the supernatant was frozen at -80°C for ELISA.
Bacterial diagnostics
Nasopharyngeal aspirates (300 µl) were resuspended in 343 µl lysis buffer (AGOWA 
magMini DNA Isolation Kit, AGOWA) with 57 µl protease. Then, 25-50 mg sterile 
zirconium beads were added and 500 µl phenol. The samples were disrupted using the 
TissueLyser (Qiagen) for 2 min, twice. The samples were then centrifuged for 10 min at 
10,000 rpm and the supernatant containing the released DNA was then purified 
according to the protocol included in the AGOWA mag Mini DNA Isolation Kit, as 
described previously30. Samples were resuspended in 50 µl elution buffer and stored at 
-80°C until further use. RT qPCR was used to quantify total bacterial carriage density 
(16s), S. pneumoniae (Sp), and H. influenza (Hi) by amplifying the 16s rRNA gene, the 
lytA gene and the hpd gene, respectively, as previously described30. Primers and 
probes used can be found in supplemental table 1. All samples were run in duplicate. 
Samples were analyzed on a Bio-Rad CFX96 Real-Time System. Primer and probe 
concentrations were optimized for each target and the machine. Final primer/probe 
concentrations were 5 nM for 16s, 200 nM for lytA (Sp) and 300 nM for hpd (Hi). 0.8 µl 
of each primer and/or probe was added to a 20 µl reaction volume. Standard curves 
were created using purified genomic DNA extracted from laboratory reference strains 
and quantified using the NanoDrop ND-1000. For S. pneumoniae, DNA was extracted 
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from TIGR431. For H. influenzae, DNA was extracted from R286632. As a measure for 
bacterial density, we determined the number of bacterial genomes per ml of NPA. We 
used the following formula: Number of genome copies per µl of extracted DNA = (mass 
in ng * Avagadro’s number) / (genome length for each bacteria * 109 * 650). 650 
daltons is the average weight of a DNA basepair. We then multiplied this number by 167 
to account for the difference between the volume of nasal wash used 125 in the 
extraction (300 µl) and the volume of extracted DNA (50 µl) in order to determine 
genome copies per ml of NPA30. As a negative control, a water sample was included 
during the whole procedure from DNA isolation to RT qPCR. For the specific bacterial 
RT qPCR’s Ct values above 35 were regarded as negative, based on the negative 
controls. For the 16s RT qPCR, Ct values above 30 were regarded as negative.
Inflammatory markers
MMP-9 concentrations were measured in the nasopharyngeal aspirates using R&D 
ELISA kits (R&D systems) according to the instructions of the manufacturer. Samples 
were 10,000x diluted for the MMP-9 ELISA, which therefore had a lower detection limit 
of 156 ng/ml. IL-6 concentrations were measured using a Sanquin ELISA kit according 
to the instructions of the manufacturer. Samples were 100-fold diluted and therefore the 
IL-6 ELISA had a lower detection limit of 156 pg/ml.
Statistical analysis
Values are expressed as percentages for categorical variables and as median and 
interquartile range (IQR) for continuous variables. Chi-squared tests were performed to 
compare categorical data between multiple groups. When significant differences were 
identified, Fisher’s exact tests were performed to specify which groups differed. As 
tested by Shapiro-Wilk’s test, none of the continuous variables were normally distributed. 
Therefore, Kruskal-Wallis H tests were used to compare continuous data between 
multiple groups. When significant differences were found, Mann-Whitney U tests were 
performed to specify which groups differed. To determine whether correlations existed, 
a Spearman correlation test was performed. A value of p<0.05 was considered 
statistically significant. All statistical analyses were conducted in GraphPad Prism 5.03 
or IBM SPSS Statistics 20.
Results
Patient characteristics
In total, 105 RSV-infected infants were included. From these 105 RSV infected patients, 
25 patients were categorized as mildly ill meaning there was no need for oxygen 
support, 53 patients were moderately ill and required oxygen support, 27 patients were 
severely ill necessitating mechanical ventilation. Significant differences between the 
severity groups were found for known risk factors like age and presence of siblings, but 
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also for hospital duration, daycare attendance, vaccination status and viral co-infections 
(table 13.1).
Presence of S. pneumoniae does not correlate with viral load, 
inflammation or disease severity
In all collected samples, 16s rRNA could be detected by RT qPCR. Samples could 
therefore be used for additional analysis (data not shown). First, we studied whether 
pneumococcal colonization influenced RSV infection. There were no significant 
differences between the pneumococcal positive group compared to the pneumococcal 
negative group, regarding viral load (figure 13.1A). This was also the case for the 
inflammatory mediators, MMP-9 and IL-6 (figure 13.1B). When looking at severity 
Figure 13.1  Pneumococcal presence does not correlate with RSV load, inflammation or disease 
severity. Viral load (A) and MMP-9 and IL-6 (B) were compared between the group positive for S. 
pneumoniae and the group negative for S. pneumoniae. Data shown are median ± IQR. Data 
were tested for significant differences using a Mann-Whitney U test. Pneumococcal presence was 
compared between the three severity groups (C). Differences in bacterial colonization rates were 
compared using Chi-square tests. When significant differences were found, Fisher’s exact tests 
were performed to specify which groups differed significantly. The moderately ill infants had a 
significantly higher colonization rate compared to the mildly infected infants (***p < 0.001).
A
C
B
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scores, the moderately ill infants had a higher percentage of pneumococcal positive 
infants compared to the mildly ill infants (figure 13.1C). However, we did not see this 
trend for the severe group. 
In conclusion, we detected no correlation between the presence of S. pneumoniae and 
viral load, inflammation or severity of disease. As shown in table 13.1, age is an 
important potential confounder. Therefore, we checked whether pneumococcal 
colonization was correlated with age (supplemental figure 13.1A). Some significant 
differences were found between the different age groups but no clear trends were 
found. The same analyses were performed for another potentially pathogenic 
nasopharyngeal bacterium (Haemophilus influenzae) to see if the effects found were 
specific for S. pneumoniae. No significant differences regarding viral load, inflammation 
and severity were found for H. influenzae (supplemental figure 13.2). Colonization with 
H. influenzae was also not age-dependent (supplemental figure 13.1B).
Pneumoccocal density correlates with viral load, inflammation  
and severity
As we did not see any differences between patients with or without pneumococcus, we 
then focussed on the patients that were pneumococcal positive. We studied whether 
pneumococcal density influences RSV infection. When correlating pneumococcal 
density with RSV load, we found that a higher density of S. pneumoniae was correlated 
with higher titers of RSV (figure 13.2A). This also holds true for MMP-9, for which a 
higher S. pneumoniae density correlated with higher concentrations of MMP-9. In 
contrast, IL-6 did not correlate with pneumococcal density (figure 13.2B). Lastly, we 
also compared the different severity groups and found that more severely infected 
infants had lower pneumococcal densities (figure 13.2C). 
In addition, pneumococcal density was not significantly different between the different 
age groups (supplemental figure 13.3A) and therefore not age-dependent. 
H. influenzae was also included, but no significant differences were found (supplemental 
figure 13.4) and H. influenzae density was not age-dependent (supplemental figure 
13.3B). These results indicate that the effects found are specific for S. pneumoniae.
Pneumococcal colonization and density does not change after  
RSV infection 
Additionally, 42 of the patients were also sampled 4-6 weeks after hospital discharge. 
Because viral respiratory infections are known to increase the risk of bacterial infections, 
we investigated whether pneumococcal colonization rates and density change after an 
RSV infection. Percentages of colonization were identical when comparing the acute 
and recovery group (figure 13.3A). Therefore, RSV infection did not change colonization 
rates in infants. Also, pneumococcal density of the pneumococcal positive patients 
was not significantly different between patients having an infection and patients in the 
recovery phase (figure 13.3B). Lastly, when we looked at the shifts in colonization, we 
saw that 25% of the infants was not colonized during the acute infection and remained 
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so during the recovery phase (figure 13.3C). Also, approximately the same number of 
infants acquired S. pneumoniae after an RSV infection as the number losing S. 
pneumoniae.
Figure 13.2  Pneumococcal density correlates with RSV load, inflammation and severity. Pneumo- 
coccal density was correlated with viral load (A) and MMP-9 and IL-6 levels (B). Correlations were 
tested for significance using a Spearman correlation test. Pneumococcal density was compared 
between the three severity groups (C). Data shown are median ± IQR. Differences in bacterial 
carriage density are tested using a Kruskal-Wallis test. When significant differences were found, 
Mann-Whitney U tests were performed to specify which groups differed (*p < 0.05, **p < 0.01).
A
B
C
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Discussion
This study is the first to report that S. pneumoniae density in the nasopharynx is 
correlated with viral load, inflammatory conditions and severity during RSV infection of 
hospitalized infants. We here show that pneumococcal carriage density is lower during 
severe RSV infections and that a low density correlates with a low RSV load and low 
levels of MMP-9. This indicates that S. pneumoniae colonization during RSV infection is 
associated with viral infection and the inflammatory response and therefore could 
influence the development of disease.
We used RT qPCR to determine bacterial carriage density instead of culturing methods. 
RT qPCR is faster and more sensitive than culturing techniques, especially when 
samples have to be frozen33, 34. Good correlations have been reported for S. pneumoniae 
and H. influenzae when comparing RT qPCR with quantitative culturing35. One important 
drawback of RT qPCR is that viable and nonviable bacteria cannot be distinguished. 
However, for our study, this is an advantage as it more accurately detects the presence 
of bacterial pathogens without any disturbance due to recent antibiotic treatment. In the 
Netherlands, patients with severe infections, who require mechanical ventilation, receive 
selective decontamination of the digestive tract (SDD) by use of antibiotics. Our study 
subjects were sampled within 24h after admission to the hospital. Therefore, we do not 
expect that the SDD regimen will have exerted an effect on bacterial carriage density 
measured by RT qPCR. Moreover, if SDD antibiotics would have such rapid effects, one 
would also expect to see the same trends for H. influenzae, but this is not the case. 
Figure 13.3  Pneumococcal colonization and density does not change after RSV infection. 
Pneumococcal colonization rate, density and shifts were compared between the acute and the 
recovery group. Differences in bacterial colonization rates were compared using a Fisher’s exact 
test of all patients that had an acute and recovery sample taken (A). Differences in bacterial 
density between de pneumococcal positive samples were compared using a Mann-Whitney U 
test. Data shown are median ± IQR (B). Shifts in pneumococcal density between all acute and 
recovery samples are shown (C).
A B C
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A recent study has shown that antibiotics given in the week prior to sampling reduced 
colonization rates of potential pathogenic bacteria, e.g. S. pneumoniae, M. catarrhalis, 
H. influenzae, S. aureus and β-hemolytic Streptococcus but had no clear effect on 
paediatric RSV disease severity scores36. In our study, we determined whether infants 
received antibiotic treatment in the 4 weeks prior to hospitalization. No significant 
differences were found in pneumococcal colonization or severity status (data not 
shown). 
We included a control group of infants who were hospitalized for a hernia operation to 
check how the inflammatory mediators behave in different groups. We see different 
dynamics for MMP-9 and IL-6 (supplemental figure 5). IL-6 is only elevated during the 
acute phase of disease, whereas MMP-9 is elevated both during the acute phase of 
disease and the recovery phase.
To our knowledge, we are the first to show a negative correlation between RSV disease 
severity and pneumococcal carriage density. Clinical studies have shown that the 
pneumococcal conjugate vaccine also results in a reduction of 31% of the viral 
respiratory tract infections15,38. This suggests that colonization with S. pneumoniae 
increases the risk of viral infection or that its presence enhances symptoms. However, 
our study shows that severely ill patients have lower pneumococcal carriage density, 
thus suggesting that high S. pneumoniae density protects against severe infections. 
S. pneumoniae and RSV are known to influence each other37. In vitro studies have 
shown that RSV infection of respiratory epithelial cells enhances the adherence of S. 
pneumoniae, possibly because the RSV G protein can serve as a receptor for S. 
pneumoniae9, 12. This is in accordance with our observation that higher RSV loads 
coincide with higher pneumococcal carriage density. 
MMP-9 is a matrix metalloproteinase which is involved in breakdown of extracellular 
matrix and appears to be a regulatory factor in neutrophil migration across the basement 
membrane39. High MMP-9 concentrations have been associated with severe RSV 
infections24. Studies have shown that RSV is able to induce MMP-9 production40. 
However, in our study no correlation was found between MMP-9 levels and RSV load 
(data not shown). Previously, we have shown that S. pneumoniae is able to induce high 
MMP-9 levels under in vitro conditions26. This is supported by this study where we show 
a correlation between pneumococcal carriage density and MMP-9 levels, in which 
higher numbers of S. pneumoniae led to higher concentrations of MMP-9. 
All our data together suggest that severely ill infants have lower pneumococcal loads, 
these lower pneumococcal loads are correlated with lower RSV levels and lower MMP-9 
levels. However, this suggests indirectly that severely ill infants have lower RSV levels, 
which seems contradictory. Although the general consensus is that viral load is probably 
correlated with disease severity, there is still discussion to what extent41-44. Our data do 
not show a correlation between RSV load and disease severity (Table I). A possible 
explanation for this discrepancy in our results is that at the moment the infants are 
included, they are in an advanced stage of disease. It is therefore possible that in the 
severe cases the virus has already partly been cleared and that severe inflammation is 
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cause of the severity, not viral load. Another explanation is that the interactions between 
S. pneumoniae, RSV load, inflammation and disease severity are multidirectional and 
more complex than we can grasp in this study. Other factors, that we did not include in 
this study, could play a role. We did carefully evaluated the presence of potential 
confounders that may explain the results of our study. When comparing severity groups, 
the severe groups had a lower daycare attendance and lower vaccination rates. These 
are both due to the fact that the severely ill patients were often too young for vaccination 
and daycare attendance. The severely infected patients also had more siblings, which 
is a known risk factor for severe RSV infections4,46. Vaccination, daycare attendance and 
presence of siblings can all influence pneumococcal carriage patterns. However, the 
severely infected infants did not yet receive pneumococcal vaccination and had more 
siblings. This would all have resulted in a higher pneumococcal load instead of a lower 
load. We cannot exclude that less daycare attendance in the severely infected infants 
may have contributed to lower pneumococcal carriage. Patients with severe infections 
had more RSV mono-infections compared to the other severity groups. This was 
already shown by our group in a previous cohort3. Finally, age could be a confounder 
as the severely ill patients are significantly younger compared to the moderate or mildly 
ill patients. As we have shown in supplemental figure 1 and 3, S. pneumoniae and H. 
influenzae carriage densities were not dependent on age, whereas the densities of S. 
aureus and M. catarrhalis were age dependent (data not shown). 
There are some limitations to our study. Based on the study design we cannot state 
anything on causality. We do not know whether pneumococcal density changes as a 
result of RSV infection, or whether the pneumococcal density was already different and 
potentially influenced susceptibility to an RSV infection. A prospective study is needed 
to definitely determine whether S. pneumoniae influences RSV severity. Moreover, there 
is a difference between absolute density and relative abundance. We did not look at the 
influence of relative abundance of S. pneumoniae.
Conclusions
In summary, we here show that S. pneumoniae density correlates to disease severity, 
viral load and inflammatory mediators, which suggests that S. pneumoniae density 
influences both viral load as well as the mucosal inflammatory response during an RSV 
infection. Once we understand the role of different bacteria residing in the upper 
respiratory tract in severity of RSV infections, we might be able to predict severity or 
modify the composition of the microbiome to prevent severe infections.
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Supplemental Figure 13.1  No clear age dependent colonization patterns were found for S. 
pneumoniae (A) and H. influenza (B). Differences in bacterial colonization rates were compared 
using Chisquare tests. When significant differences were found, Fisher’s exact tests were 
performed to specify which groups differed. Significant differences were found but no clear trend 
was visible.
Supplemental Figure 13.2  H. influenzae presence does not influence RSV load, inflammation 
or severity. Viral load (A) and MMP-9 and IL-6 (B) were compared between the group positive for 
H. influenzae and the group negative for H. influenzae. Data shown are median ± IQR. Data were 
tested for significant differences using a Mann-Whitney U test. H. influenzae presence was 
compared between the three severity groups (C). Differences in bacterial colonization rates were 
compared using Chi- square tests. No significant differences were found.
A
A
C
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Supplemental Figure 13.3  S. pneumoniae (A) and H. influenza (B) density are not age dependent. 
Data shown are median ± IQR. Differences in bacterial densities are tested using the Kruskal-Wallis 
test. No significant differences were found.
A B
Supplemental Figure 13.4  H. influenzae density does not influence RSV load, inflammation 
and severity. H. influenzae density was correlated with viral load (A) and MMP-9 and IL-6 levels 
(B). Correlations were tested for significance using a Spearman correlation test. H. influenzae 
carriage density was compared between the three severity groups (C). Data shown are median ± IQR. 
Differences in bacterial carriage density are tested using the Kruskal-Wallis test. No significant 
differences were found.
A
C
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Supplemental Figure 13.5  IL-6 levels are elevated during acute phase of disease, whereas 
MMP-9 is elevated during acute and recovery phase of disease. MMP-9 levels (A) and IL-6 levels 
(B) were measured during the acute and recovery phase of disease and were compared to a 
control group of healthy patients. Data shown are median ± IQR. Differences in cytokine levels 
are tested using the Kruskal-Wallis test. When significant differences were found the different 
groups were compared using a Mann-Whitney U test (*p<0.05, ***p<0.001).
A B
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Abstract
Maternal vaccination is currently considered as a strategy against RSV infections. In RSV 
infected infants, high mucosal IgG levels correlated better with reduced RSV load and 
lower mucosal CXCL10 levels than plasma IgG levels. For future vaccination strategies 
against RSV, more focus should be on the mucosal humoral immune response.
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Introduction
The first description of respiratory syncytial virus (RSV) was 60 years ago1, 2. Despite the 
long awareness of the virus and the morbidity it causes, still no vaccines are available. 
This may partly be due to one of the first vaccination trials in the sixties, which had a 
devastating effect on RSV vaccine development. But there are more hurdles to be taken 
in RSV vaccine development. An important difficulty is the fact that the largest target 
group are very young infants (<6 months of age), who may respond inadequately to 
vaccination. Also, RSV is very efficient in evading the immune response as is shown by 
reinfections throughout live and lastly, there is no animal model that is fully permissive 
to human RSV infection. 
Most vaccines aim to induce pathogen-specific IgGs. Palivizumab, a passively 
administered neutralizing monoclonal antibody, is able to protect infants from severe 
RSV disease3-5. This shows antibodies are able to prevent severe RSV infections and 
induction of neutralizing antibodies by vaccination could potentially work. A vaccination 
route that is often considered for RSV and which resembles passive immunization, is 
maternal vaccination. High levels of maternally-derived RSV specific antibody, 
measured in the sera of infants, protects against RSV infection during the first months 
of life6-8. Maternal vaccination aims to enhance the maternally derived IgG antibody 
levels in the infant. 
However, it is unknown if plasma IgGs also reach the mucosal locations, if plasma and 
mucosal IgG levels are correlated with each other and if both are equally protective. 
To answer these questions, we studied maternally derived pre-existing RSV-specific 
plasma and mucosal antibody titers and their correlation with RSV load and RSV- 
associated inflammation, i.e. CXCL10, in a clinical paediatric cohort. 
23 hospitalized children less than 3 months of age with laboratory confirmed RSV 
infections were prospectively included during two consecutive winter seasons 
(November-April in 2010-2011 and 2011-2012). Patients with congenital heart or lung 
disease, immunodeficiency or glucocorticoid use were excluded. Written informed 
consent was obtained from all parents of patients. The study was approved by the 
Central Committee on Research involving Human Subjects of the Radboudumc. 
Demographics and clinical parameters were collected from questionnaires and medical 
records. Within 24h after admission, a blood sample and a nasopharyngeal aspirate 
(NPA) were collected as previously described9. 
The mean age of the patients was 53 days, the average gestational age 38 weeks and 
48% of the patients was male (table 14.1). Regarding their disease status, mean 
duration of hospitalization was almost 10 days and the average RSV load gave a Ct 
value of 25. The young age of the infants enhances the chance that this was their 
primary RSV infection and therefore only maternal antibodies are studied. Moreover, 
from literature it is known that infants do not mount significant neutralising antibody 
responses before the age of 4 months10. 
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Maternally derived RSV-specific IgGs were measured in both plasma and nasal 
aspirates of patients by ELISA. 96-wells plates (Nunc Maxisorp) were coated with 1:200 
diluted whole RSV-A2 (4x107 FITC-detected infectious particles/ml) in PBS (Lonza). 
RSV-A2 was cultured and quantified as described previously11. Plates were incubated 
for 5 hours at 4°C, washed (PBS with 0.05% Tween-20) and blocked for at least 2 hours 
with 100µl PBS with 1% BSA (Sigma-Aldrich). A standard for IgG determination was 
prepared using two healthy volunteers. Samples were 1:10 diluted in duplo and 
incubated for 2 hours at room temperature. After washing, AP-conjugated antibody 
against human IgG (1:10,000 in 1%BSA) (Southern Biotech) was added and incubated 
for 2 hours at room temperature. After washing, substrate buffer (10 mM diethanolamine 
with 0.5mM MgCl2) was added. Absorbance was measured at 450 nm and 690 nm 
after 30 minutes and 60 minutes. Background binding was substracted from each 
sample measurement and results were calculated to arbitrary units (AU). In our pediatric 
cohort, no correlation was found between the levels of mucosal and plasma IgGs 
(figure 14.1A), suggesting that, next to passive transudation, additional mechanisms 
are at play during infection. It has been shown that, due to an infection, IgG antibodies 
can be actively secreted to the lumen12. 
For viral diagnostics, samples were analyzed by multiplex PCR, quantifying 15 different 
viral pathogens, as previously described13. In contrast to plasma IgG levels (figure 
14.1B), mucosal IgG levels were correlated with RSV load in which higher mucosal IgG 
levels resulted in a lower RSV load (figure 14.1B). This shows that mucosal IgG levels 
are a better correlate for viral load. 
High CXCL10 plasma levels are indicative for RSV-associated inflammation14. Therefore, 
we tested whether mucosal and plasma CXCL10 levels correlated with RSV load. The 
concentration of CXCL10 was determined using a Cytometric Bead Array (CBA), 
according to the manufacturer’s protocol (BD Biosciences). Briefly, CXCL10 levels of 
individual plasma samples (50µl) were analyzed, in duplicate, using the CBA kit on an 
LSR II flow cytometer. We found that a higher viral load resulted in higher mucosal 
CXCL10 levels, but not in higher plasma CXCL10 levels (figure 14.1C). Therefore, 
mucosal CXCL10 is a better correlate for viral load than plasma CXCL10. 
Finally, mucosal CXCL10 levels were correlated with plasma and mucosal IgG levels. 
We found a significant correlation showing higher mucosal IgG levels resulted in lower 
Table 14.1   Patient characteristics
RSV infected patients (n=23)
Age [median age in days ± IQR] 53 [31-70]
Mae (%) 11 [48]
Gestational age [median age in weeks ± IQR] 38.4 [38.3 - 38.5]
RSV load [median load n Ct value ± IQR] 24.8 [24.6 – 25.0]
Duration of hospitalization [median duration in days ± IQR] 9.6   [9.4 – 9.7]
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Figure 14.1  Mucosal IgG levels correlate better with respiratory syncytial virus load than plasma 
IgG levels. Mucosal and plasma samples were taken from RSV-infected infants. Viral load, 
mucosal and plasma IgG levels and mucosal and plasma CXCL10 levels were determined. 
Correlation analyses were performed using a Pearson correlation test. Graph-Pad Prism 5.03 was 
used for statistics (GraphPad Software). Values of p < 0.05 were considered statistically 
significant. Mucosal and plasma IgG levels were not correlated (A). Viral load was negatively 
correlated with mucosal IgG levels, but not plasma IgG levels (B). Viral load is positively correlated 
with CXCL10 levels in the nose, but not in plasma (C). Finally, mucosal CXCL10 levels were 
negatively correlated with mucosal IgG levels but not plasma IgG levels (D).
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mucosal CXCL10 levels (figure 14.1D). No correlation was found between mucosal 
CXCL10 and plasma IgG levels. This suggests that mucosal antibodies also reduce 
RSV-associated inflammation. As a control for confounders, none of the measured 
parameters were correlated with age or gender of the infants (data not shown). 
IgA is the predominant immunoglobulin present in the mucosa, therefore not many 
studies have focused on the presence and function of IgG at this location. However, as 
maternal vaccination aims to enhance mainly the IgG levels of the infant, it is of 
importance to study whether maternally derived IgGs are present on the nasopharyngeal 
mucosa of the infant and whether that correlates with viral load and the immune 
response. Our data suggest that high levels of IgG on the nasal mucosa are able to 
protect against RSV infections.
Although plasma IgG levels are often used as a readout for vaccine development, for 
future vaccine development it should be taken into account that mucosal IgG levels are 
potentially of greater importance than plasma IgG levels. These results suggest that 
mucosal (intranasal) vaccination, which aims to evoke a strong mucosal immune 
response15, may be a more effective vaccination strategy. For future studies, a group 
with very mild RSV infection should be included to determine what level of mucosal 
IgGs may protect against severe infection. Moreover, correlating maternal plasma IgG 
levels with mucosal IgG levels of the infant would give insight into the potential of 
maternal vaccination. Also, more knowledge has to be generated as to how IgG 
molecules are transported to the nasopharynx and whether this can be enhanced. This 
could lead to novel immunization strategies to improve mucosal protection by long 
lasting higher IgG levels in the nasopharynx.
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Introduction
Acute lower respiratory tract infections (LRTI’s) are the leading cause of childhood 
morbidity and mortality of children between two months and five years of age. Mortality 
due to LRTI is rare in the western world, but still substantial in parts of Africa, Asia and 
South-America. Viruses were previously considered to be less important as compared 
to bacteria as causative agents of (severe) LRTI. However, nowadays viruses are 
increasingly recognised as major pathogens in LRT in adults and in children. More than 
90% of children with bronchiolitis, over 50% of children with pneumonia and more than 
50% of asthma exacerbations in children are caused by a viral infection.1-6 The burden 
of disease in adults is equally high: viruses are implicated in 30-50% of patients with 
community acquired pneumonia (CAP) and in more than 80% of asthma exacerbations.5 
Influenza virus
Influenza is the only respiratory virus for which effective antiviral therapy and vaccination 
are available. However, the continuously changing genetic composition of the virus, 
leading to ‘antigenic drift’, forces frequent renewal of vaccines and hinders the 
development of long-lasting protective immunity. During every replication minor 
changes in the RNA can occur. This antigenic drift is due to the fact that the 
RNA-dependent RNA polymerase of the virus has an average of one error per replication 
in the absence of RNA proofreading enzymes.7,8 Due to the segmented nature of the 
influenza A, genome reassortment of hemaggluttinin (H) and sometimes neuramidase(N) 
genes, can occur between co-infecting Influenza strains. This abrupt and major change 
is called an ‘antigenic shift’.8-10 Reassortment between H and N genes of 2 (or more) 
different influenza strains occur through mixture of these strains in a susceptible host 
(human, avian, swine). Every antigenic shift event has the potential to cause a 
pandemic.8,10,11 
In Chapter two the clinical role of emerging respiratory viruses in the past two decades 
is discussed. The introduction of PCR and sequencing techniques enabled rapid 
detection of novel viruses as compared to slower traditional techniques such as viral 
culture. However, not all viruses are completely characterized according to the 
(modified) Koch’s postulates.12,13 In some cases, such as Bocavirus, the pathogenicity 
of the virus is not fully elucidated since this virus is also often detected in asymptomatic 
children.12-15 Since our publication in Hot Topics in Infection and Immunity in children IX 
several novel respiratory viruses have emerged.16 Examples are the MERS coronavirus 
(Middle East respiratory syndrome) in 2012, the novel influenza A H7N9 virus in 2013 
and novel outbreaks of enterovirus (EV) D68 infections in 2014.16 MERS is caused by an 
RNA β-coronavirus that was first isolated from a patient in 2012.17-19 The virus is thought 
to spread through dromedary camels.20 Infection can be asymptomatic or mild, but is 
often severe and results in acute respiratory distress syndrome and multi-organ 
failure.21-24 The case fatality rate is 40% in the general population and up to 60% in 
(elderly) patients with co-morbidities such as diabetes or cardiovascular disease. The 
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median age of patients is 50 years [range 1 -94 years]. Approximately 2% of the reported 
infections are in children, often with a relatively mild course of disease.21-25 Human to 
human transmission has been described, especially during hospital outbreaks.23 The 
virus is not (yet) adapted to the human host, limiting its efficiency in transmission and 
therefore its pandemic potential.19 Prevention of infection is the most important 
intervention, since there is no treatment or vaccine against the disease.25 In 2013 a 
novel Influenza A H7N9 virus emerged in China.19 Infections with this virus were 
associated with typical influenza symptoms, such as fever, cough, chest pain and 
pneumonia. Severe cases experience respiratory failure, acute respiratory distress 
syndrome, multi organ failure and/or encephalopathy. Influenza A H7N9 has a mortality 
rate of 39%, mainly in patients older than 60 years of age. 19,26 In patients below 60 years 
infections appear to resolve sooner and are often less severe.27 The mode of 
transmission is poorly understood. Birds are a potential source of infection since 
reductions in the number of new cases coincided with closure of poultry markets.19 
Human to human transmission cannot be excluded.28 
Enterovirus D68 (EVD68), a member of the Picornaviridae family was first isolated in 
1962 in children with pneumonia and bronchiolitis.29 Since 1962 EVD68 was occasionally 
detected as a cause of severe respiratory illness.30,31 EVD68 spreads in humans by 
close contact with infected people. In 2014 clusters of (severe) respiratory disease and 
asthma exacerbations coincided with children with acute flaccid paralysis. It appeared 
that the respiratory and neurologic problems were both caused by EVD68. 32-34 Since 
then EVD68 is also more frequently detected in other countries.31,35 
Monitoring of zoonotic viruses (camel MERS-Cov, avian Influenza A H7N9, avian 
Influenza A H10N8, swine influenza A H3N2) is difficult since infections do not always 
cause significant health problems in these animals. The limited understanding of the 
pathogenesis and transmission of these novel pandemic and lethal viruses warrants 
global alertness and intensive surveillance to enable early detection.36 Surveillance 
networks have contributed to a rapid detection and identification of the pandemic 
Influenza A H1N1 virus in 2009 and the prevention of this infection by vaccination. 
In Chapter 3 we describe the clinical symptoms and course of disease in Dutch children 
who were hospitalized for infection by influenza A H1N1. We observed that the majority 
of patients was older than 5 years and suffered from an underlying medical condition. 
However, the most severe and acute presentations occurred in previously healthy 
children below the age of 3 years.  In Chapter 4 clinical signs and symptoms of 
hospitalized children with PCR proven H1N1 influenza A infections are described as 
part of a nationwide retrospective study in the Netherlands. Groups at risk for a severe 
course of disease were identified. There were strong similarities between these risk 
groups and those previously reported for seasonal influenza.37-39 Especially children 
with neurological conditions and psychomotor retardation were at high risk for a severe 
outcome. The H1N1 influenza A virus that emerged during the pandemic continues to 
circulate worldwide and remains a major reason for ICU admission in both adults and 
children with and without risk factors. 40,41 A sudden onset and a severe course of 
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disease in previously healthy children have been documented during both pandemic 
and seasonal influenza infections. This observation is striking, since severe disease is 
mainly expected in high risk groups that are eligible for vaccination. 
The European Centre for Disease Control (ECDC) has pointed out that additional 
studies on risk groups for severe influenza are necessary before routine vaccination of 
children can be recommended.42,43 In Chapter 5 the criteria of the Dutch Health Council 
for introduction of vaccines in the national immunization program (NIP) were used to 
analyze whether influenza vaccination should be introduced in the NIP.44 In this review 
from 2013 we concluded that not all criteria were met. Recently, Cromer et al. showed 
that risk groups remain at risk for severe disease even after they are vaccinated.45 
Moreover, 40% of physician consultations and hospital admissions occurs in children 
under 15 year old. This indicates that the current risk group-based vaccination strategy 
does not protect this age group of healthy children.45 Several arguments favor general 
vaccination of children. Children are key participants in the spread of influenza, which 
is due to close contacts between children at schools and to immunological factors, 
such as an immature adaptive immune system, leading to prolonged shedding. 46-49 
Vaccination of all children against influenza instead of only risk groups does also protect 
non-vaccinated individuals by means of herd immunity. 50-52 Mathematical modelling 
using data of 14 influenza seasons in England show that vaccination of all children 
between 5-16 years is beneficial and cost-effective.53 The outcome of this mathematical 
analysis indicates that the vaccination of primary or secondary school aged children is 
highly cost effective. A combined vaccination program for primary and secondary 
school aged children provides an optimal strategy.54 Currently, seasonal influenza 
vaccination with a quadrivalent nasal live attenuated influenza vaccine (LAIV) is part of 
the NIP in England. 42,43,55 Initial reports have shown encouraging results indicating that 
both direct and indirect protection occur, resulting in a decreased incidence of influenza 
like illness and of upper and lower respiratory tract infections.56-58 To date, influenza 
vaccination for children is gradually rolled out over more areas in the UK.
There is no influenza vaccine available for children below 6 months of age, although the 
burden of disease is highest in children in this age group.45,59,60 Maternal vaccination 
may reduce the burden of disease by influenza in infants <6 months of age. Maternal 
vaccination is safe and recommended by the WHO since 2012.61 A recently published 
study on maternal vaccination in the 2013/2014 season showed an effectiveness of 71% 
to prevent influenza in infants younger than 6 months and an effectiveness of 64% to 
prevent hospitalization.62 This is in agreement with a previously published randomised 
controlled trial that produced similar results: 63% vaccine effectiveness and 29% 
reduction in periods of respiratory illness with fever.63 
Conclusions and future perspectives on part I of this thesis
Children at risk for severe influenza A H1N1 infections are also at risk for infection with 
seasonal influenza. A large proportion of hospitalized children, including those with 
severe disease, were previously healthy. The evidence that vaccination of all children 
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would lead to protection in the whole population was in 2013 not strong enough to meet 
the criteria of the Dutch Health Council to advise seasonal influenza vaccination for all 
children. However, the data on the burden of influenza disease in infants, the cost- 
effectiveness of vaccination of healthy children and the preliminary results of influenza 
vaccination of children in the national immunization program in the United Kingdom 
suggest that the Netherlands should also consider to provide influenza vaccination to 
all children. Before doing this, It will be necessary to study the public perception 
regarding influenza vaccination in the Netherlands and to educate the public about the 
advantages and disadvantages of use of this vaccine in children. This may alleviate 
safety concerns regarding influenza vaccination, which otherwise may be a reason for 
refusal.64-66 The Netherlands have a high uptake rate of influenza vaccination in high risk 
groups (81%).67,68 However, after the introduction of the HPV vaccination in young girls 
there was much debate in social media, politics and the scientific community regarding 
the safety, duration of protection and the age at which the vaccine was given, which 
illustrates the importance of appropriate information and education before and during 
the introduction of new vaccines.69,70 Moreover, the logistics of an extended influenza 
vaccine program will be challenging due to a yearly need for a vaccine which is adapted 
to the circulating seasonal influenza strain. Studies from the UK and the US show that 
school-based vaccination is a successful model resulting in higher uptake as compared 
to vaccination by general practitioners and health care centers.56,57 In addition, maternal 
vaccination is an effective way to reduce the burden of disease in children younger than 
6 months. Maternal vaccination is already advised in several European countries.71,72 
Studies are needed to assess whether routine vaccination of healthy children also 
reduces the burden of influenza in children less than 6 months of age via herd immunity. 
If this is true, we suggest to give higher priority to the introduction in the NIP of maternal 
vaccines against Bordetella pertussis and RSV, as compared to maternal vaccination 
against influenza.
Respiratory Syncytial virus (RSV)
RSV was discovered over sixty years ago. Infections by RSV are considered as a major 
burden of disease in children worldwide.73,74 To date there is no antiviral treatment 
available and vaccines against RSV are still under development. Administration of 
palivizumab, a prophylactic monoclonal antibody, provides passive immunization to 
high risk groups, but is not available for all children due to high costs. Moreover, 
palivizumab has little effect once patients are infected by RSV and is not useful as 
treatment of severe RSV infections.75,76 Therefore treatment of infections by RSV is 
limited to supportive care consisting of respiratory support and adequate hydration. 
The pathophysiology of disease by RSV is complex. Direct cytopathic effects of the 
virus and enhanced inflammatory responses are important in the pathogenesis of 
disease.77 Hospitalization for RSV bronchiolitis is necessary in approximately 1-3% of 
infants and children.78 The severity of disease in young infants can vary from mild upper 
respiratory tract infections to respiratory failure. The underlying cause for differences in 
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severity of disease still needs to be elucidated.79-81 Risk factors for a severe course of 
disease, such as prematurity, immunodeficiencies and congenital heart and lung 
disease are well described.82 However, RSV infection leads to a remarkable variability in 
level of severity. More than half of the young children in the ICU are otherwise healthy.83 
Clinicians use clinical parameters and known risk factors to predict the level of severity 
and the course of disease to assess once a patient with bronchiolitis should be admitted 
to the hospital. However, this assessment has limitations, since approximately one third 
of hospitalised patients do in retrospect not require supportive treatment, whilst 
4.6-6.8% of children who were sent home needs to be admitted later in the course of 
disease.84-86 
Biomarker discovery
In Chapters 6-10 we describe several biomarkers that can differentiate between 
different levels of disease severity of children with viral RTIs. In Chapters 6-8 we studied 
whether the biomarkers that were described in the context of (chronic) lung disease and 
immune responses against bacterial LRTI can be used to determine viral LRTI disease 
severity. 
In Chapter 6 we demonstrated that a combination of inflammatory proteins PTX3, CRP, 
SAA and Properdin can discriminate patients with a severe course of disease from 
children with a moderate course of viral disease. The area under the curve (AUC) of this 
combination of protein levels was 0.89.87,88 In a validation cohort of children with viral 
LRTI the test had a sensitivity and specificity of 71% and 87%, respectively. This study 
shows that a strategy to combine known inflammatory markers may be an attractive 
approach to optimize the performance of individual laboratory tests as biomarkers for 
disease severity. Measurement of PTX3, CRP, SAA and Properdin at an earlier stage of 
disease is necessary to test their true predictive value. In addition, the performance of 
these markers should be investigated in other paediatric infectious diseases. 
In Chapter 7 we studied the expression of surface markers on circulating monocytes 
during RSV infection and correlated the outcomes with disease severity. Monocytes are 
important innate immune cells in antiviral immunity.89-91 Circulating monocytes can be 
divided in three groups (classical, intermediate and nonclassical), based on their 
expression of CD14 and CD16.92 We demonstrated that significant shifts in monocyte 
subpopulations occurred during acute RSV infections. Changes included the expression 
of surface proteins CD14 and CD16, and the increased expression of HLA-ABC and 
decreased expression of HLA-DR. Decreased expression of HLA-DR on monocytes 
was correlated with disease severity. This phenomenon has also previously been 
observed during bacterial infections.93-95 Whether this may be of prognostic value, as 
was shown for septic neonates, is not yet clear.93 PBMCs of infants were stimulated with 
LPS in vitro. Furthermore, cytokine responses were measured in healthy controls and 
RSV infected patients with a severe and non severe course of disease. Patients with a 
severe RSV infection had normal TNF responses, but showed a decreased IL-10 
production when supernatant levels were compared to the responses of healthy 
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controls. This contradicts with previously observed ‘immune paralysis’, a phenomenon 
that is characterised by low HLA-DR expression and decreased TNF responses.93-95 We 
therefore assume that RSV does not induce the classical immune paralysis during 
severe infection, although an imbalanced immune response may play an important role 
in severe disease. 
Increased serum concentrations of MMP8 and MMP9 are present during acute lung 
injury and pneumonia in adults and children.96-98 MMP8 and MMP9 proteins can 
degrade the extracellular matrix, aid cell migration of inflammatory cells and have im-
munomodulatory capacities.99,100 MMP 9 levels are correlated with severity of asthma 
and pneumonia. 96,97 In Chapter 8 MMP 8 and MMP 9 protein levels and gene expression 
were measured in plasma and nasopharyngeal aspirates to see whether they can serve 
as a biomarker for severity of RSV disease.100 We observed some differences in plasma 
levels of MMP8 and MMP9 between children with mild and severe disease. However, 
the clinical value of MMP8 and MMP9 measurements as protein biomarkers for RSV 
disease severity is limited due to a broad overlap between the groups. In contrast, 
measurement of gene expression levels of MMP 8 and MMP 9 in both PBMCs and 
granulocytes may have more potential to be used as a future biomarker. MMP8 levels 
were differently expressed in granulocytes from patients with moderate and severe 
disease and in PBMCs from patients with mild and moderate disease. MMP 9 gene 
expression levels were also differently expressed in granulocytes from mildly versus 
moderately infected patients and in PBMCs from patients with moderate and severe 
disease. Moreover, a subsequent study demonstrated the potential of MMP9 as 
biomarker for severity of RSV infections in infants.101 In vitro studies on human airway 
epithelial cells demonstrate that RSV is a potent stimulus for MMP9 gene expression 
and release and that MMP9 can prevent RSV infection of human airway epithelial cells 
in vitro and infection of mice lungs. 101-103 In MMP9 knock-out mice neutrophil recruitment 
and cytokine production is significantly enhanced upon RSV infection.103 Kong et al. 
demonstrated that MMP9 knock-out mice or mice treated with siRNA to silence MMP9 
gene expression had less lung inflammation and decreased neutrophil influx upon RSV 
infection and decreased viral replication.102 They propose that excess MMP9 activity 
may also serve as novel target for therapeutics.102
Micro-array studies
In Chapter 9 we performed microarray analysis on the PBMC’s of children during a 
primary RSV infection. By using on a Prediction Analysis of Microarrays (PAM), 
Olfactomedin 4 was found as the sole marker that identified patients with severe disease 
with 0% cross-validation error. This finding was validated in another cohort of infants 
with RTI (both RSV positive and negative). The relative risk for de development of severe 
disease in children with a high OLMF4 level was 6.1, after correction for age and preterm 
status. We also observed that plasma levels of Olfactomedin 4 were not as discriminative 
as gene expression levels, which is in agreement with the data presented in Chapter 8. 
This indicates that analysis of gene expression levels in peripheral blood may be more 
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sensitive and suitable to determine severity biomarkers than by measurement of protein 
levels. Furthermore, we concluded, on the basis of data from other micro-array studies 
in children with viral infections, that the Olfactomedin 4 response is not RSV-specific. 
Olfactomedin 4 may therefore also be a marker for disease severity in other types of 
infections. Thus far the biological function of OLFM4 is not yet completely understood. 
Studies have mainly focused on its role in cancer, but it appears that OLFM4 also plays 
a role in innate immunity. It has been shown that during infections with H. pylori OLFM4 
may down-regulate the NF-kB pathway.104,105 In addition, OLFM4 deficient mice exhibit 
enhanced immunity against sepsis and infection by Escherichia coli and Staphylococcus 
aureus.106 This indicates that OLFM4 is an important negative regulator of neutrophil 
bactericidal activity by influencing cathepsin C activity.106,107 OLFM4 is a protein which is 
stored in specific granules of a subset of circulating human neutrophils (20–25 %).108 
However, until now no difference in OLFM4-positive and OLFM4-negative neutrophil 
functionality could be demonstrated. Interestingly OLFM4 is released in Neutrophil 
extracellular traps (NETs), but whether this elicits a different function or effect is not 
known.108,109 
Gene expression studies on PBMCs require a cell isolation step, which is time 
consuming and hinders application in the clinical setting. Therefore, we adapted 
protocols to measure gene expression on whole blood. First we investigated whether a 
gene signature in whole blood could be identified that predicts the course of RSV 
infection in infants with high accuracy. 
In Chapter 10 whole blood gene expression data was corrected for age and gender 
(two confounders for disease severity) and analyzed with different bioinformatic 
approaches, including machine learning to optimize biomarker discovery. We identified 
an expression profile of 84 genes in whole blood which distinguished the patients with 
severe RSV disease with good performance. This set of 84-genes was validated in an 
independent cohort (that used the Illumina microarray platform instead of the Affymetrix 
platform) and showed an AUC of 0.856 to identify patients with a severe RSV disease. 
The exact clinical value should be assessed in future studies. Transcriptional profiling 
can be used to separate bacterial from viral disease. Ramilo et al. were among the first 
that showed differences in the host response between children with viral and bacterial 
infections, and also differences in gene expression between the different viruses and 
bacteria.110,111 Herberg et al. recently published a validated two gene signature which 
allows differentiation between bacterial and viral causes of disease in children with 
fever.112 This two transcript RNA signature (FAM89A and IFI44L) has a high sensitivity 
and specificity (≥90%).112 A similar study was published simultaneously about infants 
with fever below 60 days of age, for which a gene set that consisted of 10 genes 
(including MMP9) was used. It was shown in a validation cohort that infants with serious 
bacterial infections could be identified with a sensitivity and specificity of >90%.113
Another method to analyze transcriptome data is by measurement of the distance to 
health.111 Distance to health compares the total gene expression of a patient having a 
certain disease, i.e. viral RTI, with the total gene expression of healthy infants and 
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compiles these differences to one score. In Chapter 11 we show that distance to health 
in children with RSV LRTI correlates with disease severity, length of hospitalization and 
duration of supplemental oxygen. This method has also been used in other studies and 
appears to be a good marker to ‘quantify’ disease severity during infectious diseases, 
such as tuberculosis and in children with RSV or Staphylococcus aureus infections.111,114,115 
The analysis of distance to health seems to offer a promising conceptual approach to 
study disease severity in infectious diseases. It is interesting to investigate whether this 
is also true for other non-infectious diseases. 
Chaussabel et al. developed a modular analysis method for micro-array studies that 
enabled the study of co-expressed genes instead of single genes. This provides a 
novel way to study the behavior of cell types and processes during infections.116  In 
Chapter 11 this method was adapted to the Affymatrix micro-array platform and applied 
to whole blood transcriptome profiles in order to improve the understanding of the 
pathophysiology of severe RSV disease. Six modules were identified that had significant 
differences in expression across the disease severities. The neutrophil module showed 
the most apparent difference between the severity groups, with significantly higher 
values in infants with severe disease compared to those with a mild and moderate 
course of disease. Cytotoxic T-cells and NK cells modules were downregulated during 
severe RSV infections. This was probably a result of lower cell counts as previously 
shown by our group.117 The modules on inflammation, platelets and erythrocytes were 
upregulated. Similar results were seen in another, more extensive study that compared 
the immune response against different viruses, but also between RSV disease 
severities.111 
The role of neutrophils during viral infections is intriguing and not well understood. In 
infants with severe disease a strong influx of neutrophils is observed in bronchoalveolar 
lavages and an accumulation of neutrophils is seen in lung tissue and mucus plugs of 
the airways in autopsies of infants who deceased during severe RSV infections.118,119 It 
appears that neutrophils play an important role in airway obstruction, a hallmark of 
severe RSV infection.76 Recently, several studies have elucidated that neutrophils have 
antiviral capacities.120,121 Neutrophil extracellular traps (NET) are induced by RSV and 
can prevent RSV from infecting new cells. However, an exaggerated formation during 
severe disease also contributes to disease severity.121 Iversen et al. demonstrated that 
an innate antiviral pathway can be activated by epithelium, which attracts neutrophils 
prior to the interferon response.120 NETs have been investigated in the context of other 
viral infections, such as influenza virus and appear to play a role in the containment and 
prevention of viral infection.122 123 It is intriguing that MMP8, MMP9 and OLFM4-markers 
that correlate with RSV disease severity-are stored in the granulae of neutrophils. 108,124 
Mucosal biomarkers
In the previous chapters we chose to study the systemic effects of a local viral infection, 
because it is difficult to obtain material from the lower respiratory tract from young 
children. Analysis of parameters in peripheral blood provides a reflection of disease 
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severity as was shown in the preceding part of this thesis. However, it is thought that the 
local inflammatory response may initiate the development of severe disease. We 
therefore further explored the inflammatory response at the mucosal level. A 
nasopharyngeal aspirate (NPA) is relatively easy to obtain and can be a source for 
potential biomarkers. 
In Chapter 12 we show that we can successfully perform microarray analysis on NPA 
(containing epithelial cells and immune cells). This analysis revealed several genes, 
such as TSPAN 8, MUC13, MSP and CCL7 that were differently expressed between 
patients with mild or moderate and severe disease. These results were validated with 
qPCR in an independent cohort and delivered similar results. We believe that transcrip-
tional analysis of NPA specimens is a promising approach for diagnostic procedures, 
which can relatively easy be combined with pathogen detection. This technology 
platform also offers the opportunity to establish a microbiological diagnosis and at the 
same time provide the clinician with insight in (the prognosis of) severity of disease. 
Mucosal immune responses
Viral infections of the respiratory tract always occur in the presence of colonizing 
bacteria (microbiome). Bacterial co-infection cannot always be excluded in patients 
with severe viral disease.125 In our studies on viral RTIs routine cultures did not reveal 
many bacterial co-infections. Most children with viral RTIs that were not admitted to the 
ICU did not receive antibiotics, indicating that in non-mechanically ventilated children 
bacterial co-infections do not play an important role. The effect of the colonizing 
bacteria on the anti-viral host response in the respiratory tract has not yet been studied 
extensively. However, interactions between enteric viruses, antiviral immunity and the 
gut microbiome receive increasing interest.126-128 
In Chapter 13 we found that the presence and density of Streptococcus pneumoniae 
and Haemophilus influenzae in the nasopharynx of patients with RSV infections did not 
correlate with viral load, inflammation or severity of disease. However, when patients 
were colonized with Streptococcus pneumoniae, the bacterial density correlated with 
an increased RSV load, higher MMP 9 levels and a decreased disease severity, 
indicating that the presence of bacteria can indeed affect the anti-viral host-response. 
Recently De Steenhuijsen Piters et al. reported that the nasopharyngeal microbiome 
interacts with the immune response during RSV infection and may influence disease 
severity. 129 They demonstrated that an upper respiratory tract microbiome enriched for 
H. influenzae or S. pneumoniae was associated with an increased disease severity 
defined as a need for hospitalization. In modular gene expression analysis of peripheral 
blood from patients with these enriched microbiomes, the responses related to 
TLR-signaling and neutrophil recruitment were more pronounced. This confirms the 
hypothesis that colonization is associated with modulation of the immune response 
during RSV infections. This phenomenon has also been reported during influenza virus 
infections and may indicate that microbiota regulate immune defense during respiratory 
viral infections and calibrate the activation threshold for (innate) immune responses.128,130 
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Suarez-Arrabal et al. demonstrated that colonization with Gram-negative bacteria 
(Moraxella catarrhalis and H. Influenzae) results in increased numbers of mucosal and 
systemic inflammatory cells, higher pro-inflammatory cytokine levels and a trend 
towards increased disease severity.131 This is in agreement with the study from De 
Steenhuijsen Piters et al., but in contrast with the results presented in Chapter 13. This 
may be due to differences in study protocols and detection methods. We used a 16S 
qPCR specific for Streptococcus pneumoniae while in the other studies 16S rRNA gene 
amplicon sequencing was used, by which the different streptococcal species cannot 
be distinguished. In addition, inflammation was in our study defined by protein levels, 
whereas De Steenhuijsen Piters et al., used gene expression. As shown in chapters 8 
and 9 these do not always correlate.
The respiratory mucosa and the mucus contain antibodies. In general, immunoglobu-
lins directed against RSV are thought to be protective, as reflected by the reduction of 
disease severity by passive immunization with palivizumab and protection against RSV by 
high maternal antibodies.132-135 The RSV vaccination trial in the sixties, where immunization 
led to more severe disease and mortality, illustrates that levels of antibodies do not 
always correlate with protection, because a strong antibody responses upon vaccination 
were measured. 136 Although the exact mechanism of ‘antibody enhanced disease’ has 
not yet been clarified, titers of non-neutralizing antibodies and the level of avidity of 
antibodies seem to play an important role in RSV disease. 
In Chapter 14 we show that there is no correlation between the plasma levels and 
mucosal levels of IgG in children with viral RTI’s. Levels of mucosal IgG correlate better 
with viral load and mucosal inflammation than levels of plasma immunoglobulin. This 
finding can be of importance for the evaluation of future vaccination studies in children. 
It may also be an argument for intranasal vaccination in children. A relation between 
better local CD8+ T cell responses after nasal vaccination compared to intraperitoneal 
vaccination has already been demonstrated by Morabito et al. in mice.137 
Conclusions and future perspectives on part II of this thesis
The clinical value of biomarkers which we have identified should be assessed in 
prospective studies that include serial measurements and should ideally start from an 
earlier time point in the course of disease, preferably at the initial visit to the general 
practitioner. Thus far only a restricted number of analyses could be performed per 
patient due to a limited amount of blood that can be taken from young infants. Due to 
improved techniques the amount of blood per test is dramatically reduced (we used 3 
ml blood for a micro-array analysis while this test is now possible with 1.0 ml).138 In this 
way, more markers can be tested simultaneously, reducing the ethical and safety 
arguments against the assessment of different time points. When validation studies 
show similar results, also at earlier time points, the markers can be used in a clinical 
trial. At that point most of the criteria for a good biomarker as proposed by Morrow and 
de Lemos have been fulfilled.139 These criteria state that a good biomarker should be 
easy to measure and add information to the clinical decision progress. Importantly, a 
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good biomarker should have an impact on clinical management.139 Sequential testing 
can have additional value, since study of the kinetics of biomarkers may provide 
additional useful information. Furthermore, the use of a combination of biomarkers may 
increase the sensitivity and the specificity of these tests as described in Chapter 6. 
Once an optimal gene set or protein panel is established it should be converted to a 
point-of-care test. Techniques for bed-side PCR and protein measurement in plasma 
are already available.140,141
Future studies should assess whether expression profiling of a limited number of genes 
can also be used to reflect distance to health and assess the potential of implementation 
of this maker in clinical practice. In addition, the modular analysis developed by 
Chaussabel et al. can be used to gain more insight into the pathophysiology of severe 
RSV infections, but may also be applied to other (infectious) diseases. The combined 
measurement of genomic data, microbiome analysis and expression profiling, may 
enhance the understanding of the interaction between the bacterial microbiome and 
the human immune response, especially when used in a human experimental challenge 
model. Integration with other ‘omic’ techniques, such as metabolomics and proteomics, 
will facilitate in-depth analysis of the host-pathogen interaction and offers the opportunity 
to decipher individual susceptibility for severe RSV-infections.142
Several antivirals are currently under investigation. At this moment only ribavirin is 
approved for the treatment for RSV.143 The use of ribavirin in severe RSV infections is 
controversial and not recommended. It is difficult to administer ribavirin in ventilated 
patients in the ICU and the drug is expensive.143,144 Potential new antivirals can be 
divided into three groups based on their mechanism of action, 1.) nucleocapsid protein 
inhibitors (RSV604), 2.) RNA-dependent RNA polymerase inhibitors (YM-52403, BI-DD 
and ALS-8176) and 3.) fusion inhibitors (TMC-353121, BMS-433771, VP-14637 and GS-
5805).145-149 Currently, only ALS-8176 and GS-5806 are tested in clinical trials. 150,151 
By revealing the crystal structure of the F-glycoprotein of RSV in its pre-triggered 
(prefusion) conformation the RSV vaccine development has exhilarated.152,153 
Neutralizing antibodies mainly bind to the prefusion form of the F protein (preF).154,155 
This preF is highly unstable and easily switches to its postfusion form (postF), which 
has no function in fusion of membranes and viral entry into a host cell.156,157 Therefore, 
antibodies directed against the postF offer limited protection. The development of 
monoclonal antibodies targeting preF is more effective in reducing viral infection.155,158 
Once the half-life of these antibodies can be increased they could be used for passive 
immunization of which only one administration of these antibodies will be enough to 
reduce disease severity in the first 6 months of life. 
Intranasally administered live-attenuated vaccines or chimeric live vector vaccines, are 
currently tested in clinical trials and seem to be safe for children older than 6 months of 
age.159-162 Further, gene-based replication-defective vaccines with viral vectors or 
nucleic acid are considered safe and are in early phases of clinical testing in adults.159,160 
Subunit proteins and protein based nanoparticles are proposed for maternal vaccination 
purposes to protect the youngest children.160 Other vaccine strategies, such as virus-like 
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particles and virosomes, have been tested in animal studies, but not yet in clinical 
trials.159 The current clinical trials on antivirals and vaccines offer the potential for future 
generations to change the epidemiology of RSV disease. Availability of validated 
biomarkers to predict disease severity of viral RTI will help to design studies to assess 
antivirals and vaccines and thus will contribute to decrease the number of patients with 
severe RSV disease.
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Introductie
Acute lage luchtweginfecties (LLWI’s) zijn de meest voorkomende oorzaak van ziekte 
bij kinderen en de belangrijkste oorzaak van sterfte in de leeftijdsgroep van twee 
maanden tot vijf jaar. Mortaliteit ten gevolge van onderste luchtweginfecties (OLWI) is 
zeldzaam in de westerse wereld, maar nog steeds aanzienlijk in delen van Afrika, Azië 
en Zuid-Amerika. Elke 35 seconden sterft er ergens op de wereld een kind aan een lage 
luchtweginfectie, de 3FM Serious Request actie van 2016 zamelde geld in en bracht dit 
onderwerp onder de aandacht van het grote publiek. Virussen werden voorheen als 
minder relevant beschouwd in vergelijking met bacteriën als veroorzakers van ernstige 
lage luchtweginfecties. Tegenwoordig worden virussen gezien als belangrijke pathogenen 
bij deze aandoening bij volwassenen als kinderen. Meer dan 90% van de kinderen met 
bronchiolitis, ruim 50% van de kinderen met longontsteking en astma exacerbaties 
wordt veroorzaakt door een virus. 1-6 De ziektelast bij volwassenen is eveneens hoog: 
virussen zijn aanwezig bij 30-50% van de patiënten met een in de gemeenschap 
verworven pneumonie (CAP) en in meer dan 80% van de astma-exacerbaties.5
Influenza virus pH1N1
Influenza is het enige respiratoire virus waarvoor effectieve antivirale medicatie en 
vaccinatie beschikbaar is. Doordat de genetische samenstelling van het influenza virus 
telkens verandert door “antigene drift”, moeten de vaccins jaarlijks aangepast worden. 
Dit is de reden waarom er geen goede immuniteit bij de mens ontstaat. Antigene drift 
ontstaat doordat bij elke replicatie van het virus gemiddeld 1 fout gemaakt wordt door 
het RNA-afhankelijke RNA-polymerase. Aangezien het influenza virus geen correctie 
enzymen heeft die deze fout kunnen corrigeren, verandert het virus bij elke deling een 
beetje en ontstaat er uiteindelijk een virus dat niet meer herkend wordt door de 
aangemaakte antilichamen na een vaccin of ziekteperiode.7,8 Als meerdere influenza 
stammen een zelfde host (mens, vogel, varken) infecteren, kan herschikking van 
hemaggluttinin (H) en soms neuraminidase (N) genen optreden. Dit is mogelijk doordat 
het genoom van het influenza A virus gesegmenteerd is. Een dergelijke abrupte en 
grote verandering in het genetisch materiaal heet een ‘antigene shift’. 8-10 Elke antigene 
shift heeft de potentie om een pandemie te veroorzaken.8,10,11
In hoofdstuk 2 van dit proefschrift zijn de nieuw ontdekte respiratoire virussen van de 
afgelopen twee decennia besproken. Door de invoering van PCR- en sequencing 
technieken worden er veel meer virussen ontdekt dan voorheen. Met de traditionele 
technieken, zoals o.a. viruskweek, was dit moeilijker en tijdrovender en niet alle virussen 
kunnen zo ontdekt worden. De meeste van de recent geïdentificeerde virussen zijn 
echter nog niet volledig gekarakteriseerd volgens de (gemodificeerde) Koch’s 
postulaten. 12,13 In sommige gevallen, zoals bij het bocavirus, is de pathogeniciteit van 
het virus niet volledig vastgesteld, aangezien dit virus ook wordt aangetroffen bij 
asymptomatische kinderen. 15-12 Sinds onze publicatie in Hot Topics in Infection and 
Immunity bij kinderen IX zijn verschillende nieuwe respiratoire virussen ontdekt. 16 
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Voorbeelden zijn MERS coronavirus (Middle East Respiratory Syndrome-coronavirus’ 
(MERS-CoV) in 2012, het nieuwe influenza A H7N9-virus in 2013 en nieuwe uitbraken 
van enterovirus (EV) D68 infecties in 2014. 16 MERS-CoV wordt veroorzaakt door een 
RNA-β-coronavirus dat in 2012 voor het eerst werd ontdekt bij een zieke patiënt. 17-19 
Dromedarissen lijken de verspreiders van het virus. 20 Een infectie kan asymptomatisch 
of mild verlopen, maar kent ook vaak een ernstig beloop leidend tot acute respiratory 
distress syndrome en multi-orgaanfalen. 21-24 De letaliteit is 40% in de algemene 
bevolking en oplopend tot 60% bij (oudere) patiënten met co-morbiditeiten, zoals 
diabetes of hart- en vaatziekten. De gemiddelde leeftijd van patiënten is 50 jaar [range 
1 -94 jaar]. In 2% van de gerapporteerde infecties betreft het kinderen, vaak met een 
relatief mild ziekteverloop. 21-25 Van mens op mens overdracht is beschreven, vooral 
tijdens ziekenhuisuitbraken. 23 Het virus is (nog) niet aangepast aan de menselijke 
gastheer, hierdoor is de efficiëntie van verspreiding laag en de kans op een pandemie 
beperkt. 19 Preventie van infectie is de belangrijkste interventie, omdat er geen 
behandeling of vaccin tegen de ziekte is. 25 
In 2013 ontstond een nieuwe Influenza A H7N9 virus in China. 19 Infectie met dit virus is 
geassocieerd met typische influenza symptomen, zoals koorts, hoesten, pijn op de 
borst en longontsteking. Ernstige gevallen ervaren respiratoire insufficiëntie, acute 
respiratory distress syndrome, multi-orgaanfalen en/of encefalopathie. Influenza A 
H7N9 heeft een letaliteit van 39%, vooral bij patiënten ouder dan 60 jaar. 19,26 Bij 
patiënten jonger dan 60 jaar lijken infecties een kortere duur te hebben en verlopen ze 
vaak minder ernstig. 27 De wijze van overdracht is nog onduidelijk. Vogels zijn een 
potentiële bron van besmetting aangezien vermindering van het aantal nieuwe gevallen 
samen viel met sluiting van pluimvee markten. 19 Mens op mens overdracht kan niet 
worden uitgesloten.28 Enterovirus D68 (EVD68) is een lid van de familie Picornaviridae. 
Het werd voor het eerst geïsoleerd in 1962 bij kinderen met een longontsteking en 
bronchiolitis. 29 Sinds 1962 werd EVD68 zo nu en dan gedetecteerd als een oorzaak 
van ernstige ziekte van de luchtwegen. 30,31 EVD68 verspreidt zich door nauw contact 
met besmette patiënten. In 2014 werden clusters van (ernstige) aandoeningen van de 
luchtwegen en astma exacerbaties gerapporteerd, deze vielen samen met berichten 
over kinderen met een acute slappe verlamming. Het bleek dat de ademhalings- en 
neurologische problemen beide veroorzaakt werden door EVD68. 32-34 Sindsdien wordt 
EVD68 wereldwijd vaker waargenomen. 31,35 
Screenen op nieuwe zoönotische virussen (dromedaris MERS-Cov, aviaire influenza A 
H7N9, aviaire influenza A H10N8, varkens influenza A H3N2) is moeilijk omdat infecties 
door deze virussen bij dieren meestal geen waarneembare gezondheidsproblemen 
veroorzaken. De beperkte kennis van de pathogenese en de transmissie van deze 
nieuwe pandemie en dodelijke virussen maakt wereldwijde alertheid noodzakelijk in 
combinatie met intensief toezicht om vroege opsporing mogelijk te maken. 36 
Surveillancenetwerken hebben bijgedragen tot een snelle detectie en identificatie van 
de pandemische influenza A H1N1-virus in 2009 en de preventie van deze infectie door 
vaccinatie.
Processed on: 1-3-2017
508516-L-bw-Ahout
279
Nederlandse samenvatting
16
In hoofdstuk 3 beschrijven we de klinische symptomen en het beloop van ziekte bij 
Nederlandse kinderen die opgenomen werden vanwege de pandemische influenza A 
H1N1 infectie in het academisch ziekenhuis in Nijmegen. De meeste patiënten waren 
ouder dan 5 jaar en hadden een onderliggende medische aandoening. Echter, de 
meest ernstige en acute presentaties vonden plaats bij voorheen gezonde kinderen 
jonger dan 3 jaar waren. Het Europees Centrum voor ziektepreventie en -bestrijding 
(ECDC) heeft erop gewezen dat aanvullende studies naar risicogroepen voor ernstige 
griep nodig zijn alvorens routinematige vaccinatie van kinderen kan worden aanbevolen. 42,43 
In hoofdstuk 4 zijn de klinische symptomen van (bijna) alle gehospitaliseerde kinderen 
met een PCR bewezen H1N1 influenza A-virus infectie beschreven in een Nederlands 
retrospectief onderzoek. De risicogroepen voor een ernstig beloop zijn op basis hiervan 
geïdentificeerd. Er bleken sterke overeenkomsten tussen deze risico -groepen tijdens 
de H1N1 pandemie en de risicogroepen van de gewone seizoensgriep. 37-39 In het 
bijzonder kinderen met neurologische aandoeningen en psychomotore retardatie 
hadden een hoog risico op een ernstig beloop. Het H1N1-influenza A-virus dat deze 
pandemie veroorzaakte, blijft wereldwijd circuleren en blijft een belangrijke reden voor 
IC opname bij zowel volwassenen als kinderen met en zonder risicofactoren. 40,41 Een 
plotseling begin en een ernstig verloop van de ziekte bij voorheen gezonde kinderen 
zijn gedocumenteerd, zowel tijdens de pandemie als bij de seizoensgebonden influenza- 
infecties. Deze waarneming is opvallend, aangezien ernstige ziekte vooral wordt 
verwacht in een hoog risico groepen die in aanmerking komen voor vaccinatie.
In hoofdstuk 5 zijn de criteria die de Nederlandse Gezondheidsraad hanteert voor 
toelating van vaccins tot het Rijksvaccinatieprogramma (RVP) gebruikt om te analyseren 
of influenzavaccinatie in het RVP moet worden ingevoerd. 44 In dit review uit 2013 
hebben we geconcludeerd dat het onderzoek naar influenza vaccinatie nog niet aan 
alle criteria voldoet. Recentelijk hebben Cromer et al. laten zien dat patiënten uit 
risicogroepen ondanks vaccinatie nog steeds at risk zijn voor een ernstig ziektebeloop. 
45 Ook blijkt dat 40% van de doktersbezoeken en ziekenhuisopnames in verband met 
influenza infecties voorkomt bij kinderen onder de 15 jaar. Dit geeft aan dat de huidige 
risico-groep-gebaseerde vaccinatie strategie deze leeftijdsgroep van gezonde kinderen 
onvoldoende beschermd. 45 Er zijn verschillende argumenten ten gunste van algemene 
vaccinatie van kinderen: kinderen zijn de belangrijkste bron voor de verspreiding van 
influenza, enerzijds door het intensieve contact wat zij met elkaar hebben op scholen 
en anderzijds door immunologische factoren, zoals een onrijpe adaptief immuunsysteem 
waardoor zij langdurig het virus blijven uitscheiden. 46-49 Vaccinatie van alle kinderen 
tegen influenza in plaats van alleen risicogroepen heeft ook voordelen voor niet- 
gevaccineerde personen via het fenomeen van groepsimmuniteit. 50-52 Wiskundige 
modellen op basis van gegevens van 14 influenza seizoenen in Engeland tonen aan dat 
vaccinatie van alle kinderen tussen 5-16 jaar gunstig en kosteneffectief is. 53 Vooral de 
combinatie van leeftijdsgroepen (lage en middelbare school) blijkt in deze statistische 
analyse kosten effectief. 54 Op dit moment maakt seizoensgebonden griepvaccinatie 
met een quadrivalent nasaal en levend verzwakt griepvaccin (LAIV) al deel uit van het 
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RVP in Engeland. 42,43,55 De eerste berichten zijn bemoedigend. Er is zowel directe als 
indirecte bescherming opgetreden, wat resulteert in een verminderde incidentie van 
influenza-achtige ziekte en van zowel de bovenste en onderste luchtwegen. 56-58 De 
griepvaccinatie voor kinderen wordt geleidelijk uitgerold over meerdere delen van het 
Verenigd Koninkrijk.
Er is geen influenzavaccin beschikbaar voor kinderen die jonger dan 6 maanden zijn, 
hoewel de ziektelast juist het hoogst is bij kinderen in deze leeftijdsgroep. 45,59,60 
Maternale vaccinatie zou in dit geval de ziektelast kunnen verminderen. Deze methode 
is veilig en wordt aanbevolen door de WHO sinds 2012. 61 Een recent gepubliceerde 
studie op de maternale vaccinatie in het seizoen 2013/2014 liet een effectiviteit van 71% 
qua aantal influenza infecties bij zuigelingen jonger dan 6 maanden en een effectiviteit 
van 64% ten aanzien van het aantal ziekenhuisopname. 62 Dit is in overeenstemming 
met een eerder gepubliceerde gerandomiseerde trial: 63% effectiviteit van het vaccin 
en 29% vermindering in periodes van ziekte van de luchtwegen met koorts. 63
Conclusies en toekomstperspectieven van deel I van dit proefschrift
Kinderen met een risico op seizoensgriep lopen ook het risico op besmetting met 
ernstige influenza A H1N1-infecties. Een groot deel van de gehospitaliseerde kinderen 
met een ernstig beloop waren voorheen gezond. Het bewijs dat vaccinatie van kinderen 
zou leiden tot bescherming van de hele bevolking en ook kosteneffectief was, vonden 
wij in 2013 niet sterk genoeg. Echter, nieuwe gegevens over de druk van influenza bij 
zuigelingen en de medische sector, de kosteneffectiviteit van vaccinatie van gezonde 
kinderen en de voorlopige resultaten van influenza vaccinatie van kinderen in het 
Verenigd Koninkrijk suggereren nu dat Nederland opnieuw moet overwegen om het 
griepvaccin aan te bieden aan alle kinderen.
Alvorens dit te doen, zal het nodig zijn om de publieke perceptie met betrekking tot 
(griep)vaccinatie in Nederland te onderzoeken. Daarnaast is informatieverstrekking 
over de voor- en nadelen van het gebruik van dit vaccin bij kinderen noodzakelijk. Dit 
kan bezorgdheid over de veiligheid met betrekking tot griepvaccinatie, die een reden 
voor de weigering kan zijn, verminderen. 64-66 Nederland heeft momenteel een hoge 
respons bij griepvaccinatie bij risicogroepen (81%). 67,68 Echter, na de invoering van de 
HPV-vaccinatie bij jonge meisjes ontstond er veel discussie in de sociale media, de 
politiek en de wetenschappelijke gemeenschap ten aanzien van de veiligheid, de duur 
van de bescherming en de leeftijd waarop het vaccin werd gegeven. Dit illustreert het 
belang van informatie en voorlichting voor en tijdens de introductie van nieuwe 
vaccins.69,70 Daarnaast is de logistiek van een uitgebreid influenzavaccin programma 
uitdagend, omdat er jaarlijkse een nieuw vaccin moet worden gegeven dat bescherming 
biedt tegen de voorspelde circulerende influenzastam. Studies uit het Verenigd 
Koninkrijk en de Verenigde Staten laten zien dat de school geïnitieerde vaccinatie het 
meest succesvol is en resulteert in een hoger percentage gevaccineerde mensen in 
vergelijking met vaccinatie door huisartsen en gezondheidscentra. 56,57 Daarnaast is 
maternale vaccinatie een effectieve manier om de ziektelast bij kinderen jonger dan 6 
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maanden te verminderen. Maternale vaccinatie wordt al geadviseerd in verschillende 
Europese landen. 71,72 Studies zijn nodig om te beoordelen of de jaarlijkse griepvaccina-
tie van gezonde kinderen ook de ziektelast bij kinderen onder de 6 maanden vermindert. 
Als dit aangetoond is, raden wij aan om een hogere prioriteit te geven aan de invoering 
van maternale vaccins tegen Bordetella pertussis en RSV omdat daar nog geen goed 
alternatief voor is.
Respiratoir syncytieel virus (RSV)
RSV werd zestig jaar geleden ontdekt. Infecties door dit virus worden wereldwijd 
beschouwd als een zware last voor kinderen en de maatschappij. 73,74 Tot nu toe is er 
geen behandeling beschikbaar en vaccins tegen RSV zijn nog in ontwikkeling. 
Toediening van palivizumab, een profylactisch monoklonaal antilichaam, biedt passieve 
bescherming voor hoog risico groepen, maar het is niet beschikbaar voor alle kinderen 
vanwege de hoge kosten. Bovendien werkt palivizumab toediening niet bij patiënten 
die al zijn besmet met RSV en veranderd ook het ziektebeloop niet als het gegeven 
wordt aan kinderen met een ernstige RSV-infectie. 75,76 Tot op heden is de behandeling 
van RSV infecties beperkt tot ondersteunende zorg, bestaande uit ademhalingsonder-
steuning en adequate vocht- en voedingstoestand.
De pathofysiologie van RSV infecties is complex en nog niet volledig bekend. Directe 
cytopathische effecten van het virus en versterkte ontstekingsreacties spelen een 
belangrijke rol bij de pathogenese van de ziekte. 77 Opname is bij RSV bronchiolitis 
noodzakelijk bij ongeveer 1-3% van zuigelingen en kinderen. 78 De ernst van de ziekte 
kan variëren van een milde verkoudheid tot respiratoir falen met de noodzaak tot 
kunstmatige beademing. De onderliggende oorzaak voor deze verschillen in ernst van 
ziekte is nog niet opgehelderd. 79-81 Risicofactoren voor een ernstig verloop van de 
ziekte, zoals prematuriteit, immuundeficiënties en aangeboren hart- en longaandoenin-
gen zijn goed beschreven. 82 Meer dan de helft van de jonge kinderen op de intensive 
care was voorheen gezond. 83 Artsen gebruiken klinische parameters en de bekende 
risicofactoren om de ernst van de ziekte in te schatten en te oordelen of opname nodig 
is. Deze beoordeling heeft echter beperkingen aangezien ongeveer een derde van de 
gehospitaliseerde patiënten achteraf geen ondersteunende behandeling nodig had, 
terwijl 4,6-6,8% van de kinderen die vanaf de eerste hulp naar huis mochten later alsnog 
opgenomen moesten worden. 84-86
Zoektocht naar biomarkers 
In de hoofdstukken 6-10 beschrijven we biomarkers die onderscheid kunnen maken 
tussen de groepen van ernst van de ziekte bij kinderen met virale lage luchtweginfec-
ties (LLWI’s). In de hoofdstukken 6-8 bestudeerden we of de biomarkers die zijn 
beschreven in de context van (chronische) longziekte en bacteriële luchtweginfecties 
ook kunnen worden gebruikt om bij virale LLWI ernst van de ziekte te bepalen. In 
hoofdstuk 6 toonden we aan dat een combinatie van inflammatoire eiwitten PTX3, 
CRP, SAA en Properdin patiënten met een ernstig ziekteverloop kunnen onderscheiden 
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van kinderen met een mild ziektebeloop van virale ziekte. De oppervlakte onder de 
curve (AUC) van deze combinatie van eiwitniveaus was 0,89. 87,88 In een validatie cohort 
van kinderen met virale LLWI had de test een sensitiviteit en specificiteit van respectie-
velijk 71% en 87%. Deze studie toont aan dat de strategie waarbij meerdere ontste-
kingsfactoren gecombineerd worden een aantrekkelijke benadering is voor het 
identificeren van biomarkers die ernst van ziekte voorspellen. Meting van PTX3, CRP, 
SAA en Properdin in een eerder stadium van de ziekte moet hun werkelijke voorspellende 
waarde aan het licht brengen. Bovendien is het interessant om te kijken hoe deze 
markers functioneren als voorspellers bij andere pediatrische infectieziekten. 
In hoofdstuk 7 bestudeerden we de expressie van oppervlaktemarkers op circulerende 
monocyten tijdens RSV-infectie en correleerden we de uitkomsten met ernst van ziekte. 
Monocyten zijn belangrijke aangeboren immuuncellen voor antivirale immuniteit. 89-91 
Circulerende monocyten kunnen worden onderverdeeld in drie groepen (klassiek, 
intermediate- en niet-klassiek) op basis van hun CD14 en CD16 expressie. 92 We hebben 
aangetoond dat er significante verschuivingen in monocyten subpopulaties opgetreden 
tijdens acute RSV infecties. Veranderingen omvatten de expressie van oppervlakte- 
eiwitten CD14 en CD16, een verhoogde expressie van HLA-ABC en verminderde 
expressie van HLA-DR. Verminderde expressie van HLA-DR op monocyten correleert 
met de ernst van de ziekte. Dit verschijnsel is eerder waargenomen tijdens bacteriële 
infecties. 93-95 Of dit van prognostische waarde is, zoals werd aangetoond voor septische 
pasgeborenen is nog niet duidelijk.93 Daarnaast werden in-vitro cytokineresponsen op 
endotoxine (LPS) gemeten bij gezonde controles en RSV geïnfecteerde patiënten met 
een ernstig en niet ernstig ziekteverloop. Patiënten met een ernstige RSV-infectie 
hadden normale TNF productie, maar vertoonde een lagere IL-10 productie vergeleken 
met de respons van gezonde controles. Dit komt niet overeen met ‘immuun paralyse’, 
een verschijnsel wat wordt gezien bij ernstige bacteriële infecties. Immuun paralyse 
wordt gekenmerkt door lage HLA-DR expressie en verlaagde TNF reacties. 93-95 Ernstige 
RSV infecties geven dus geen klassieke immuun paralyse, hoewel een onevenwichtige 
immuunreactie een belangrijke rol bij ernstige ziekte kan spelen.
Verhoogde serum concentraties van MMP8 en MMP9 zijn tijdens acute longbeschadiging 
en longontsteking bij volwassenen en kinderen aanwezig. 96-98 MMP8 en MMP9 eiwitten 
kunnen de extracellulaire matrix degraderen, helpen celmigratie van ontstekingscellen 
en hebben immunomodulerende capaciteiten. 99.100 MMP 9 niveaus zijn gecorreleerd 
met de ernst van astma en longontsteking. 96,97 In hoofdstuk 8 hebben we MMP8 en 
MMP 9 eiwitniveaus en genexpressie gemeten in plasma en nasofaryngeale aspiraten 
om te zien of ze als een biomarker voor de ernst van RSV-ziekte kunnen dienen. 100 
We zagen enkele verschillen in plasmaspiegels van MMP8 en MMP9 tussen kinderen 
met een milde en ernstige ziekte. De klinische waarde van MMP8 en MMP9 metingen 
als biomarker voor ernst van RSV ziekte is beperkt door een brede overlap tussen de 
groepen. Daarentegen heeft de meting van genexpressie niveaus van MMP 8 en MMP9 
in zowel PBMC en granulocyten meer potentie om te worden gebruikt als een biomarker. 
Ook in een andere studie werd de potentie van MMP9 als biomarker voor de ernst van 
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RSV-infectie bij kinderen aangetoond. 101 In vitro studies met humane epitheelcellen 
tonen aan dat RSV een krachtige stimulans is voor MMP9 genexpressie en vrijlating. 
Bovendien kan MMP9 RSV infectie van humane epitheelcellen voorkomen in vitro, maar 
ook bij muizen longen. 101-103 In MMP9 knock-out muizen is de neutrofielen werving en 
cytokine productie aanzienlijk versterkt bij RSV-infectie. 103 Kong et al. tonen dat MMP9 
knock-out muizen of muizen behandeld met siRNA om MMP9 genen onderdrukken 
minder inflammatie en verminderde neutrofiel influx hadden tijdens RSV-infectie. Ook 
was er verminderde virale replicatie van RSV. 102 Zij stellen dat overtollige MMP9 activiteit 
een nieuw doelwit voor therapieën kan zijn. 102
Microarray studies
In hoofdstuk 9 voerden we microarray analyse op PBMC’s van kinderen met een 
primaire RSV-infectie uit. Door gebruik te maken van de Prediction Analysis of Microarray 
(PAM) analyse, werd Olfactomedin 4 geïdentificeerd als marker die patiënten met een 
ernstige ziekte herkent. Deze bevinding werd bevestigd in een cohort van kinderen met 
virale LLWI (zowel RSV positieve als negatieve kinderen). Het relatieve risico op de 
ontwikkeling van ernstige ziekte was, na correctie voor leeftijd en prematuriteit, bij 
kinderen met een hoog OLMF4 niveau 6,1. Ook nu bleken plasmaspiegels van 
Olfactomedin 4 minder discriminerend dan genexpressie niveaus, hetgeen overeenkomt 
met de data in hoofdstuk 8. Dit geeft aan dat de analyse van genexpressie in perifeer 
bloed soms gevoeliger en meer geschikt is als biomarker om ernst van ziekte te 
bepalen dan de meting van eiwitconcentraties. Verder concluderen wij, op grond van 
gegevens van andere microarray studies bij kinderen met virale infecties, dat de 
Olfactomedin 4 reactie niet RSV-specifiek is. Olfactomedin 4 kan dus ook een marker 
voor ernst van de ziekte zijn bij infecties veroorzaakt door andere virussen en bacteriën. 
Tot dusver is de biologische functie van OLFM4 nog niet volledig opgehelderd. Studies 
zijn vooral gericht op de rol van OLFM4 bij kanker, maar het blijkt dat OLFM4 ook een 
rol in de aangeboren immuniteit speelt. Bij infecties met H. pylori kan OLFM4 de NF-k B 
pathway downreguleren. 104.105 Daarnaast vertonen OLFM4 deficiënte muizen verbeterde 
immuniteit tegen sepsis en infectie door Escherichia coli en Staphylococcus aureus. 106 
Die studie toonde aan dat OLFM4 een belangrijke negatieve regulator is van de bacterie-
dodende werking van neutrofielen door het beïnvloeden van cathepsine C-activiteit. 
106.107 OLFM4 is een eiwit dat wordt opgeslagen in specifieke granules van een subset 
van circulerende humane neutrofielen (20-25%), tot nu toe is er geen verschil in functi-
onaliteit tussen OLFM4-positieve en negatieve neutrofielen aangetoond. 108. Opvallend 
is dat OLFM4 ook wordt uitgeworpen in neutrophil extracellular traps (NET), maar het 
gevolg ervan is niet bekend. 108.109
Genexpressiestudies op PBMC’s vereist een cel isolatie stap, die tijdrovend is en 
toepassing in de klinische setting belemmert. Daarom hebben we de protocollen 
aangepast om genexpressie op volbloed te meten. Eerst onderzochten we of een gen 
signatuur in volbloed kan worden vastgesteld dat het verloop van RSV-infectie bij 
kinderen met hoge nauwkeurigheid voorspelt.
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In hoofdstuk 10 werd de genexpressie data van volbloed van kinderen met een virale 
LLWI gecorrigeerd voor leeftijd en geslacht (confounders voor ernst van de ziekte) en 
geanalyseerd met verschillende bioinformatische benaderingen, met inbegrip van 
machine learning. Zo wilden we de ontdekking van biomarkers optimaliseren. Hiermee 
werd een expressieprofiel van 84 genen geïdentificeerd waarmee de patiënten met een 
ernstige RSV-infectie goed te onderscheiden waren van kinderen met een minder 
ernstig beloop. Deze set van 84-genen werd gevalideerd in een onafhankelijke cohort 
(dat gebruik maakte van een ander (Illumina) microarray platform, wij gebruikten 
Affymetrix) en toonde een AUC van 0.856 voor het identificeren van patiënten met een 
ernstig beloop van ziekte. De exacte klinische waarde moet in toekomstige studies 
worden geëvalueerd. Transcriptionele profilering kan worden gebruikt om bacteriële 
infecties te onderscheiden van virale ziekte. De groep van O. Ramilo was de eersten die 
verschillen in de gastheerrespons van kinderen aantoonde ten tijde van virale en 
bacteriële infecties, er bleken ook verschillen in genexpressie tussen de verschillende 
virussen en bacteriën onderling. 110.111 De groep van M. Levin publiceerde onlangs een 
gevalideerde set van maar twee genen waarmee op basis van expressie onderscheid 
gemaakt kan worden tussen bacteriële en virale oorzaken van ziekte bij kinderen met 
koorts. 112 Deze twee transcript RNA signatuur (FAM89A en IFI44L) heeft een hoge 
sensitiviteit en specificiteit (≥90%). 112 Een soortgelijk onderzoek werd gelijktijdig 
gepubliceerd met als doelgroep kinderen onder de 60 dagen met koorts, waarbij een 
gen set van 10 genen (inclusief MMP9) werd gebruikt. In een validatie cohort konden 
kinderen met ernstige bacteriële infecties worden geïdentificeerd met een sensitiviteit 
en specificiteit van> 90%. 113
Een andere methode om transcriptoom data te analyseren is door alle expressie data 
van een ziek persoon bij elkaar op te tellen en deze uitkomst te vergelijken met het 
gemiddelde getal van een groep gezonde personen. Dit geeft het verschil in afstand tot 
de gezonde situatie aan (molecular distance to health). 111 In hoofdstuk 11 laten we zien 
dat de molecular distance to health van kinderen met RSV correleert met de ernst van 
de ziekte, de duur van de ziekenhuisopname en de duur van extra zuurstof. Deze 
methode wordt ook gebruikt in andere studies en lijkt een goede marker te zijn om ernst 
van ziekte te ‘kwantificeren’ bij infectieziekten, zoals tuberculose en bij kinderen met 
RSV of Staphylococcus aureus infecties. 111.114.115 De analyse van molecular distance to 
health lijkt een veelbelovende conceptuele benadering van ernst van de ziekte in infec-
tieziekten bestuderen bieden. Het is interessant om te onderzoeken of dit ook geldt 
voor andere niet-infectieuze ziekten.
Chaussabel et al. ontwikkelde een modulaire analysemethode voor microarray studies, 
met deze methode wordt gekeken naar co-expressie van genen in plaats van één gen 
tegelijk. Op deze manier is het mogelijk om gedrag van celtypen en processen tijdens 
infecties te bestuderen. 116 In hoofdstuk 11 werd deze werkwijze aangepast aan een 
Affymatrix microarray platform en toegepast op volbloed transcriptoom profielen om 
het inzicht in de pathofysiologie van ernstige RSV-infectie te verbeteren. Er werden zes 
modules geïdentificeerd die significante verschillen in genexpressie tussen de ernst -
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groepen. De module van de neutrofielen had de meeste evidente verschillen tussen de 
ernstgroepen, met statistisch significant hogere waarden bij kinderen met een ernstig 
beloop van ziekte in vergelijking met kinderen die een mild en matig beloop van de RSV 
infectie hadden. Genexpressie in de modules van cytotoxische T-cellen en NK-cellen 
waren laag tijdens ernstige RSV-infecties. Dit is meest waarschijnlijk een gevolg van het 
lagere aantal cellen van dit type in volbloed zoals eerder al door onze groep werd 
getoond. 117 De modules inflammatie, bloedplaatjes en erytrocyten werden opgereguleerd. 
Vergelijkbare resultaten werden waargenomen in een andere uitgebreidere studie die 
de immuunrespons tegen verschillende virussen vergeleek, maar zich ook richtte op de 
verschillen in immuunresponsen bij patiënten met in RSV ziekte ernst. 111
De rol van neutrofielen bij virale infecties is intrigerend en niet goed begrepen. Bij 
zuigelingen met een ernstig beloop van RSV wordt een sterke instroom van neutrofielen 
in bronchoalveolaire spoelingen waargenomen. Bij autopsies van zuigelingen die 
overleden aan een RSV infectie wordt een opeenstapeling van neutrofielen in het 
longweefsel gezien en slijmpluggen in de luchtwegen. 118.119 Het lijkt dat neutrofielen een 
belangrijke rol spelen bij deze luchtwegobstructie. 76 Onlangs hebben diverse studies 
aangetoond dat neutrofielen antivirale capaciteiten hebben. 120.121 Neutrophil extracellular 
traps (NETs) kunnen door RSV uitgelokt worden en deze NETs verhinderen dat RSV 
nieuwe cellen infecteren. Dit is echter niet alleen maar voordelig, want een overmaat 
aan deze NETs kan bijdragen aan een ernstiger beloop van ziekte. 121 Iversen et al. 
toonden aan dat een innate antiviraal pathway al kan worden geactiveerd door het 
epitheel, waardoor neutrofielen al vóór de interferon respons gerekruteerd worden. 120 
NETs blijken ook bij andere virale infecties van belang, zoals influenzavirus, en lijken 
een rol te spelen bij de beheersing en preventie van virale infectie. 122 123 Het is intrigerend 
dat de biomarkers MMP8, MMP9 en OLFM4 uit onze studies allen kunnen worden 
opgeslagen in de granulae van neutrofielen. 108.124
Mucosale biomarkers
In de voorgaande hoofdstukken kozen we ervoor om de systemische effecten van een 
lokale virale infectie te bestuderen. Het is moeilijk is om materiaal te verkrijgen uit de 
lagere luchtwegen van jonge kinderen. Analyse van parameters in perifeer bloed bleek 
toch een weerspiegeling te geven van de ernst van de ziekte zoals is besproken in het 
voorgaande deel van dit proefschrift. Het is reëel om aan te nemen dat de lokale ont-
stekingsreactie essentieel is in de ontwikkeling van ernstige ziekte. Daarom wordt in dit 
deel gekeken naar de immuunrespons in de neus-keelholte (nasofarynx). Een 
nasofaryngeale aspiraat (NPA) is relatief gemakkelijk te verkrijgen en is mogelijk een 
bron van potentiële biomarkers.
In hoofdstuk 12 laten we zien dat het mogelijk is om een microarray te doen op 
materiaal wat verkregen is met een NPA (neusspoeling) (bevat epitheel en immuuncellen). 
Uit de analyse bleek dat een aantal genen, zoals tspan 8, MUC13, MSP en CCL7 
significant verschilden in genexpressie niveaus tussen patiënten met milde tot matige 
en ernstige ziekte. Deze resultaten werden bevestigd met qPCR in een onafhankelijk 
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cohort. Transcriptie analyse van NPA lijkt een veelbelovende methode om prognostische 
testen te combineren met diagnostische procedures. Deze technologie biedt de 
mogelijkheid om de clinicus naast een microbiologische diagnose (RSV infectie) ook 
meteen een inzicht te geven in de ernst van de ziekte (de prognose).
Mucosale immuunrespons
Virale infecties van de luchtwegen ontstaan altijd in aanwezigheid van koloniserende 
bacteriën (microbioom). Bacteriële co-infectie kan niet altijd uitgesloten worden bij 
patiënten met een ernstige virusziekte. 125 In onze studies naar virale LWI konden routine - 
matig kweken op de intensive care maar zelden een bacteriële co-infectie aantonen. 
De meeste kinderen met virale LLWI die niet op de IC opgenomen worden krijgen geen 
antibiotica, wat aangeeft dat bij niet-beademde kinderen bacteriële co-infecties geen 
belangrijke rol lijkt te spelen. De invloed van het respiratoire microbioom op de antivirale 
immuunrespons is nog niet uitgebreid bestudeerd. Interacties tussen enterale virussen, 
antivirale immuniteit en het darmmicrobioom krijgen toenemende belangstelling. 126-128
In hoofdstuk 13 bleek dat zowel de aanwezigheid als de dichtheid van Streptococcus 
pneumoniae en Haemophilus influenzae in de nasofarynx niet correleerden met de viral 
load, mate van ontsteking of ernst van de ziekte bij patiënten met RSV infecties. Echter, 
bij patiënten die gekoloniseerd waren met Streptococcus pneumoniae, was de 
bacteriële dichtheid gecorreleerd met een hogere RSV load, hogere MMP 9 niveaus en 
een verminderde ernst van de ziekte. Dit impliceert dat de aanwezigheid van bacteriën 
inderdaad de antivirale gastheerreactie kan beïnvloeden. Onlangs publiceerde De 
Steenhuijsen Piters et al. dat het nasofaryngeale microbioom interactie heeft met de 
immuunrespons tijdens RSV-infecties en op deze manier mogelijk ernst van de ziekte 
kan beïnvloeden. 129 Zij toonden aan dat een bovenste luchtweg microbioom dat veel 
H. influenzae of S. pneumoniae geassocieerd is met een toegenomen ernst van de 
ziekte gedefinieerd als noodzaak tot ziekenhuisopname. In het modulaire genexpressie 
analyse op perifeer bloed van patiënten met deze verrijkte microbiomen, waren de 
genexpressies in genen met betrekking tot TLR-signalering en neutrofielen werving 
meer uitgesproken. Dit bevestigt de hypothese dat kolonisatie geassocieerd is met 
modulatie van de immuunrespons tijdens RSV infecties. Dit fenomeen werd ook gezien 
tijdens influenzavirus infecties. Deze studie gaf aan dat de resultaten impliceren dat het 
microbioom de immuunrespons tijdens respiratoire virale infecties reguleert en tevens 
de activatie drempel voor (innate) immuunresponsen kalibreert.128.130 Suarez-Arrabal et 
al. beschrijven dat kolonisatie met Gram-negatieve bacteriën (Moraxella catarrhalis en 
H. influenzae) resulteert in verhoogde aantallen mucosale en systemische inflammatoire 
cellen, hogere pro-inflammatoir cytokine niveaus en een trend naar toenemende ernst 
van ziekte. 131 Dit is in overeenstemming met de studie van De Steenhuijsen Piters et 
al.,maar in tegenstelling tot de in hoofdstuk 13 beschreven resultaten. Dit kan te wijten 
zijn aan verschillen in onderzoekprotocollen en detectiemethoden. We gebruikten een 
16S qPCR specifiek voor Streptococcus pneumoniae, terwijl in de andere studies 16s 
rRNA gen amplicon sequencing werd gebruikt, waarbij de verschillende soorten 
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streptokokken niet te onderscheiden zijn. Bovendien, ontsteking was in onze studie 
gedefinieerd als eiwitniveaus, terwijl De Steenhuijsen Piters et al., genexpressie 
gebruikte. Zoals in hoofdstuk 8 en 9 al aangetoond is correleren plasma eiwitniveaus 
en gen expressie niet altijd.
De respiratoire mucosa en het slijm in de luchtwegen bevatten antilichamen. In het 
algemeen wordt gedacht dat immunoglobulines gericht tegen RSV een beschermend 
effect hebben, zoals weergegeven door de vermindering van ernst van de ziekte door 
passieve immunisatie met palivizumab en een beschermend effect van veel maternale 
antilichamen tegen ernstige RSV infecties bij kinderen in epidemiologische studies. 
132-135 De RSV vaccinatietrial uit de jaren zestig, waarbij vaccinatie tegen RSV resulteerde 
in een ernstiger beloop van ziekte en zelfs tot meer sterfte bij kinderen met een goede 
antilichaamrespons, illustreert echter dat de antilichamen titer niet altijd correleert met 
de mate van bescherming. 136 Hoewel het exacte mechanisme van «antilichaam versterkte 
ziekte” nog niet duidelijk is, lijken de titers van niet-neutraliserende antilichamen en de 
mate van de aviditeit van antilichamen een belangrijke rol te spelen bij RSV-ziekte.
In hoofdstuk 14 laten we zien dat er geen correlatie is tussen de titers in het plasma en 
de mucosale titers van IgG bij kinderen met virale LLWI’s. Titers van mucosaal IgG 
correleren beter met de virale load en inflammatoire respons op de mucosa dan de titer 
van plasma IgG. Deze bevinding kan van belang zijn voor de evaluatie van toekomstige 
vaccinatiestudies bij kinderen. Ook kan dit een argument voor intranasale vaccinatie bij 
kinderen zijn. In muizen is het al aangetoond dat de mucosale CD8+ T cel respons na 
nasale vaccinatie beter is dan na intraperitoneale vaccinatie. 137
Conclusies en toekomst perspectieven van deel II van dit proefschrift
De klinische waarde van de biomarkers die wij geïdentificeerd hebben moet nog 
bepaald worden in prospectieve studies met seriële metingen. Bij voorkeur moet er al 
op een eerder tijdstip, zoals bij het eerste contact met de huisarts gemeten worden. Tot 
nu toe kon slechts een beperkt aantal analyses worden uitgevoerd per patiënt vanwege 
een beperkte hoeveelheid bloed die veilig kan worden afgenomen bij jonge kinderen. 
Door verbeterde technieken is de hoeveelheid bloed per test drastisch verminderd (we 
gebruikten 3 ml bloed voor een micro-array analyse, dit kan nu al met 1,0 ml). 138 
Hierdoor kunnen er meerdere analyses gedaan worden in een minimale hoeveelheid 
bloed, waardoor de ethische en veiligheidsargumenten tegen de seriële bepalingen 
afnemen. Zodra onze resultaten gevalideerd zijn kan een klinische studie opgezet worden. 
Op dat moment is aan het grootste deel van de criteria voor een goede biomarker, 
zoals voorgesteld door Morrow en de Lemos, voldaan. 139 Deze criteria stellen dat een 
goede biomarker gemakkelijk te meten moet zijn en informatie toe moet voegen aan 
klinische besluitvorming. De marker moet dan ook een impact hebben op het klinische 
besluitvorming. 139 Sequentieel testen kan hierbij ook een toegevoegde waarde hebben, 
omdat de kinetiek in de tijd mogelijk een betere prognose geeft. Het gebruik van een 
combinatie van biomarkers zou de gevoeligheid en de specificiteit van deze tests ook 
kunnen verhogen, zoals beschreven in hoofdstuk 6. Zodra een ideale combinatie van 
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genen of eiwitpanel is vastgesteld, kan een point-of-care test ontwikkeld worden. De techniek 
voor bedside PCR en eiwitmeting in plasma is al beschikbaar. 140.141
Toekomstige studies moeten uitwijzen of het aantal genen om de molecular distance of 
health te meten ook gereduceerd kan worden tot een beperkt aantal genen, dit zou het 
gebruik van deze maat in de kliniek reëler maken. De modulaire analyse van Chaussabel 
et al. kan niet alleen worden gebruikt om meer inzicht te krijgen in de pathofysiologie van 
ernstige RSV-infecties, maar kan ook worden toegepast op andere (infectie) ziekten. De 
gecombineerde analyse van genomische data, microbioom analyse en RNA sequencing, 
kan het inzicht omtrent de wisselwerking tussen het microbioom en de humane 
immuunrespons verhogen, vooral bij gebruik in een experimenteel humaan challenge 
model. Integratie met andere ‘omic’ technieken, zoals metabolomics en proteomics, zal 
een grondige analyse van de gastheer-pathogeen interactie vergemakkelijken en biedt 
de mogelijkheid om individuele gevoeligheid ontcijferen voor ernstige RSV-infecties. 142
Op dit moment is alleen ribavirine goedgekeurd voor de behandeling van RSV. 143 Het 
gebruik van ribavirine bij ernstige RSV-infecties is controversieel en wordt niet aanbevolen. 
Het is moeilijk om ribavirine te dienen in beademde patiënten op de intensive care en 
het geneesmiddel is duur. 143.144 Verschillende antivirale middelen worden momenteel 
onderzocht. Potentiële nieuwe antivirale middelen kunnen worden onderverdeeld in 
drie groepen op basis van hun werkingsmechanisme, 1) nucleocapside eiwit remmers 
(RSV604), 2) RNA-afhankelijk RNA polymerase inhibitoren (YM-52403, BI-DD en 
ALS-8176) en 3.) fusie-remmers (TMC-353121, BMS-433771, VP-14637 en GS-5805). 
145-149 Momenteel worden alleen ALS-8176 en GS-5806 getest in klinische studies. 150.151
Door de ontrafeling van de kristalstructuur van het F-glycoproteïne van RSV in zijn pre- 
geactiveerd (prefusion) conformatie heeft de vaccinontwikkeling een boost gekregen. 
152.153 Neutraliserende antilichamen binden hoofdzakelijk aan de prefusion vorm van het 
F-eiwit (PREF). 154.155 Dit PreF is zeer instabiel en eenvoudig schakelaars zijn postfusion 
vorm (postF), die geen functie in de fusie van membranen en virale intrede heeft in een 
gastheercel. 156.157 Daarom bieden antilichamen gericht tegen de postF vorm enkel 
beperkte bescherming. De ontwikkeling van monoklonale antilichamen specifiek gericht 
tegen de preF is zeer effectief in het verminderen van virale infectie. 155.158 Zodra de 
halfwaardetijd van deze antilichamen is verhoogd kan dit worden gebruikt voor passieve 
immunisatie. Dan is slechts één toediening nodig om ernst van RSV-ziekte te verminderen 
in de eerste 6 maanden van het leven. 
Intranasaal toegediend levend-verzwakte vaccins of chimerische levende vector 
vaccins worden momenteel getest in klinische trials en lijken veilig te zijn voor gebruik 
bij kinderen ouder dan 6 maanden. 159-162 Verder worden gen-gebaseerde replicatie- 
defecte vaccins met virale vectoren of nucleïnezuren als veilig beschouwd. De vaccines 
zitten nu in de vroege fase van klinische onderzoek bij volwassenen. 159.160 Subunit eiwit 
en eiwitten op basis van nanodeeltjes zullen waarschijnlijk voor maternale vaccinatie 
doeleinden gebruikt gaan worden om de jongste kinderen te beschermen. 160 Andere 
vaccinatiestrategieën zoals virus-like partikels en virosomen zijn inmiddels getest in 
dierstudies, maar nog niet toegepast in klinische studies. 159 
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De huidige klinische trials met antivirale middelen en vaccins bieden de mogelijkheid 
voor toekomstige generaties om de epidemiologie van RSV ziekte te veranderen. De 
beschikbaarheid van gevalideerde biomarkers om ernst van virale ziekte te voorspellen 
kan ook van nut zijn voor het ontwerp van toekomstige studieprotocollen bij onderzoek 
naar de werkzaamheid van antivirale middelen en vaccins. Ook op deze manier kan 
een biomarker een bijdrage leveren aan het verminderen van een ernstig beloop van 
een RSV infectie.
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Processed on: 1-3-2017
508516-L-bw-Ahout
290
Chapter 16
Processed on: 1-3-2017
508516-L-bw-Ahout
291
Curriculum Vitae
16
Curriculum Vitae
Inge Maria Leonie Ahout werd op 17 februari 1984 geboren in Apeldoorn. Toen ze zes 
jaar was verhuisde ze naar Vaassen. Zij behaalde haar VWO diploma aan het Stedelijk 
Gymnasium in Apeldoorn, zij volgde het profiel Natuur en Gezondheid met de extra 
vakken natuurkunde-2 en scheikunde-2. Van 2002 tot 2008 studeerde zij geneeskunde 
aan de Universiteit van Maastricht. Daarna heeft zij gedurende ruim 1 jaar als arts- 
assistent niet in opleiding gewerkt in het Canisius Wilhelmina Ziekenhuis te Nijmegen. 
In februari 2010 begon zijn aan haar promotietraject “Determinants of disease severity 
in children with viral lower respiratory tract infections” onder de begeleiding van dr. J.G. 
Ferwerda, dr. M.I. de Jonge, Prof. dr. R. de Groot en Prof. dr. P.W.M. Hermans binnen 
het Laboratorium Kinderinfectieziekten van het Radboudumc. Zij participeerde in het 
VIRGO-consortium, hierbinnen was ze verantwoordelijk voor het includeren van patiënten 
met acute virale luchtweginfecties op de eerste hulp, polikliniek en de kinderafdeling van 
het CWZ en het Amalia kinderziekenhuis, en van de intensive care afdelingen van het 
Radboudumc Nijmegen en Sophia kinderziekenhuis Rotterdam. Ook werden hiervoor 
door bijna heel het land huisbezoeken afgelegd. Voor de studie naar de griep epidemie 
met H1N1 in 2009 werden (bijna) alle ziekenhuizen met een kinderafdeling bezocht. 
Hiervoor werkte ze intensief samen met Mariëtte Las (RSV) en Ria Philipsen (H1N1) die 
nauw betrokken waren met de logistiek en inclusie van de patiënten. Ook begeleidde 
ze diverse studenten geneeskunde tijdens hun wetenschappelijke stage. De resultaten 
van haar onderzoek zijn grotendeels beschreven in dit proefschrift. In mei 2014 startte zij 
haar opleiding tot kinderarts met een perifere stage in het Canisius Wilhelmina Ziekenhuis 
in Nijmegen (opleider dr. B.A. Semmekrot). Momenteel vervolgd ze haar opleiding binnen 
het Amalia kinderziekenhuis Radboudumc te Nijmegen (opleider dr. J.M.T Draaisma en 
later dr. A.A.E.M. van Alfen - van der Velzen). 
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Dankwoord
Wat een heerlijk gevoel! Mijn proefschrift is goedgekeurd en het is nog maar een 
kwestie van weken of ik heb mijn proefschrift in handen. Een mooi moment om terug te 
kijken op die bijzondere tijd. Divers is denk ik wel een goede beschrijving van de 
afgelopen jaren. Het was rennen om alle patiënten te includeren en de materialen op 
tijd op te slaan. Het hele land werd doorkruist voor huisbezoeken of voor statusonder-
zoek in (bijna) alle Nederlandse ziekenhuizen. Dit werd afgewisseld met inspirerende 
gesprekken, een niet te beschrijven spanning bij interessante ontdekkingen, leuke 
borrels en gezellige etentjes.
Beste prof. R. de Groot, Ronald, ik weet nog precies waar ik zat toen ik je mail kreeg 
waarin je me uitnodigde voor een gesprek. Dat gesprek was bijzonder en bleek ook 
typerend voor het enthousiasme en de passie van jou en de groep! Bedankt voor je 
bevlogenheid, onuitputtelijke kennis en kritische blik. Voor jou is werkelijk geen brug 
te ver, zoals wel blijkt uit je volle agenda als gepensioneerd hoogleraar en kinderarts. 
Dat heeft mede gezorgd voor vele hoofdstukken in mijn proefschrift. Ook dank voor 
je vaak humorvolle commentaar en je geduld bij de correctie van mijn teksten! Prof. 
P.W.M. Hermans, Peter, jij zat als hoofd van het LKI ook bij dat zeer luidruchtige kennis-
makingsgesprek. Je werkt alweer een tijdje elders, maar met name in het begin hebben 
we regelmatig samen gebrainstormd over mijn vraagstukken. Ik zal je nuttige lessen 
in onderhandelen niet vergeten! De barbecue voor het lab in Huissen was een jaarlijks 
feestje! Dr. M.I. de Jonge, Marien, ooit begonnen we als kamergenoten. Ik ben je 
ontzettend dankbaar voor je inzet voor het lab, mede dankzij jou kan ik promoveren bij 
het LKI! Daarnaast ben ik je dankbaar voor je betrokkenheid bij mij als persoon en bij 
het onderzoeksproject. Dr. J.G. Ferwerda, Gerben, jouw enthousiasme en creativiteit 
waren al duidelijk in dat kennismakingsgesprek, maar ook in de jaren die erop volgden! 
Jij ziet de obstakels in een context of ziet juist dat ene detail wat alles veranderd. 
Ik bewonder jouw manier van (om)denken en kansen zien. Je hebt mij geïntroduceerd 
in de lab- en onderzoekswereld en dat ging van het vasthouden van een pipet tot het 
verfraaien van een poster. Ondanks dat het jammer is dat je die walkie talkie niet bij je 
droeg, vind ik het fantastisch hoe je er voor me was. 
Mariëtte, wij gaan ooit ons eigen tijdschrift uitgeven! Wat hebben wij veel meegemaakt 
en voor elkaar gekregen. Ik ben je ontzettend dankbaar voor al je hulp, steun en 
gezelligheid. Samen met Jos en je collega’s hebben wij twee mooie studies afgerond. 
Dank voor jullie expertise en inzet om de studies op alle fronten goed te maken. Ria, 
jij bent de drijvende kracht achter de H1N1 studie! Ik ben je heel dankbaar voor je 
doortastendheid, creativiteit en inzet. Zonder jou was dit niet gelukt, want de klus was 
heel wat groter dan gedacht! Ada, Marieke en Sandra, jullie aandeel in mijn promotie 
wordt niet onderschat. Secretariële- en projectondersteuning dekt bij lange na de lading 
niet. Hartelijk dank voor alles!
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De leden van de manuscriptcommissie, prof. dr. A.J.A.M. van de Ven, prof. dr. 
A.D.M.E. Osterhaus en prof. dr. P. Pickkers, jullie wil ik bedanken voor jullie bereidheid 
om mijn proefschrift te beoordelen. Marloes en Amelieke, mede Angels! Met mijn 
promotie is de cirkel rond. Drie promotietrajecten doorlopen en drie maal paranimfen 
bij elkaars promotie. Dank voor alle hulp, adviezen, gedwongen pauzes, zorgen, 
bijzondere gesprekken en gezelligheid. Het begin is al lang gemaakt, maar ik hoop nog 
heel veel speciale momenten met jullie te delen.
Dit type onderzoek kun je niet uitvoeren zonder patiënten. Op deze plek wil ik alle 
ouders/verzorgers en kinderen bedanken die meegedaan hebben aan dit onderzoek! 
Jullie reacties maakten dat ik nog meer overtuigd raakte van het belang ervan. De huis- 
 bezoeken hebben mij een onverwachte les geleerd, de impact die de ziekenhuisopname 
(veelal in de kraamtijd) had op jullie gezin werd tijdens deze contacten duidelijk. Jullie 
ervaringen en feedback zal ik voor mijn verdere carrière als arts onthouden! 
Naast het team om mij heen was mijn studie nooit van de grond gekomen zonder de 
hulp van de kinderafdelingen en de intensive care. Beste Marianne Brouwer, dank 
voor alles wat je mogelijk hebt gemaakt in het CWZ! Ben Semmekrot, jij hebt vanuit 
eigen ervaring en als opleider op vele manieren geholpen aan de totstandkoming van 
dit proefschrift. Ik wil op deze plek het hele team van kinderartsen, assistenten, poli 
medewerkers en iedereen van de kinderafdeling hartelijk danken voor alle hulp, toewijding 
en tijd! De samenwerking is 3 jaar lang heel intensief geweest. Chris Neeleman, 
jouw hulp op de IC is heel waardevol geweest. Niet alleen jij, maar heel het team van 
IC artsen, assistenten/fellows en verpleegkundigen waren betrokken bij de studie. Mijn 
bezoekjes aan de IC waren daardoor vaak net iets langer dan nodig. Dank voor alle 
interesse, steun en inspiratie! 
Jos Draaisma, jij hebt meegeholpen om mijn proefschrift vlotter te kunnen afronden 
als opleider van de kindergeneeskunde, dank voor je ondersteuning! 
Je werk kan inhoudelijk nog zo leuk zijn, ik ben er van overtuigd dat je werkvreugde 
sterk bepaald wordt door je collega’s. De roomies van 2.58A: Marloes, Corné, Jeroen, 
Erika en Marrit bedankt voor alle gezelligheid, afleiding en hulp! Samen hebben we 
ook buiten het werk veel leuke dingen gedaan. Ook alle collega PhD’s en post docs; 
Kim Brand, Kim Stol, Stefanie, Daan, Stefan, Stan, Lilly, Fredrick, Jop, Kirsten, 
Amelieke en Dimitri, Aldert, Hester, Peter en Saskia wil ik bedanken. Mede door 
jullie voelde ik mij direct welkom op het lab, al duurde het even voordat ik inhoudelijk 
alles begreep van wat jullie me vertelden! Kim, als voorgangster heb jij voor mij al wat 
paden gebaand en wist je me te behoeden voor enkele valkuilen. Dank voor je hulp in 
de afgelopen jaren en de fijne samenwerking. Kirsten, als roomie was jij een hele steun 
bij de (gedeelde) eindsprint. Je luisterend oor, humor en de relaxmomentjes waren een 
goede mix!
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Team RSV dat begon met ons, Marloes, Corné en Gerben. Jop, jij volgde al snel. Dat 
onderzoek hebben we maar mooi opgebouwd met zijn allen! Dank voor alle discussies, 
de fijne samenwerking en mooie artikelen die we gemaakt hebben. Aldert, jouw brede 
kennis en gave om ingewikkelde zaken duidelijk uit te leggen heeft mij bij heel wat 
artikelen geholpen! Ik ben je dankbaar voor je kritische houding, humor en begeleiding. 
LKO collega’s, jullie maken de ervaring compleet. Op de werkvloer kunnen we soms 
nog meer van elkaar leren, maar op de borrels zijn we 1 team! Veel van mijn artikelen 
zouden nog niet af zijn zonder hulp van jullie, Christa, Elles en Marc! Dank voor jullie 
ondersteuning in het lab, bij analyses, administratie en al mijn vragen. Samen met Fred 
en de onco-analisten zorgen jullie voor een fantastische sfeer, een schat aan kennis en 
een soepel lopend lab. 
Tijdens mijn promotie hebben meerdere studenten als stagiair meegewerkt aan mijn 
project. Velen hebben zo ook een bijdrage geleverd aan de artikelen in dit proefschrift. 
Dank jullie wel Kioa, Fabian, Lian, Marieke, Lilid en Meryem.
Team Rotterdam: Pieter, Ab en Arno bedankt voor de samenwerking en inspirerende 
meetings van de afgelopen jaren! Arno, jij hebt je heel erg voor VIRGO ingezet, dank 
hiervoor. Zonder VIRGO geen promotie! Pieter en Ab, ook in het H1N1 werk hebben 
jullie bijgedragen aan een mooi resultaat. Bedankt voor jullie expertise, kritische blik en 
bereidheid om regelmatig op korte termijn waardevolle input te geven. 
Ik vond de samenwerking met de virologie afdeling (Janette, Willem, Foekje en Jan) erg 
leerzaam. We hadden hele interessante virologie besprekingen en we schreven als kers 
op de taart een prachtig artikel! 
Nel Roeleveld, dank voor het aanvullen van mijn statistiek kennis en je expertise bij de 
diverse artikelen! 
Ik wil op deze plek alle co-auteurs bedanken die ik nu nog niet bij naam genoemd 
heb. We hebben fijn overleg gehad en goede discussies en zodoende mooie artikelen 
gecreëerd. 
Mijn collega’s van de kliniek zorgen voor heel wat afleiding en gezelligheid, maar 
hebben mij ook ondersteund in het hele proces. Dank voor al jullie interesse en soms 
bewust niet-vragen de afgelopen jaren! 
Er is meer dan werk en onderzoek en mijn vrienden en familie mogen dan ook niet 
ontbreken in dit dankwoord. Jullie hebben mijn enthousiaste verhalen gehoord en 
soms ook het zwoegen gezien. Bij deze is het dan écht afgerond! Straks verzin ik 
natuurlijk weer iets nieuws, maar voor nu is het even rustig. Ik wil jullie heel erg bedanken 
voor jullie steun, interesse en begrip. Door jullie weet ik altijd weer mijn prioriteiten bij te 
stellen en besef ik wat écht belangrijk is. Een paar mensen wil ik graag bij naam noemen:
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Daniëlle, wij kennen elkaar inmiddels al lang en goed. Alle hoogte- en dieptepunten 
maken onze vriendschap sterk. Vanaf nu heb ik meer tijd om vaker met jou en Coen af 
te spreken! Henneke en Annet, als wij samen zijn is het allemaal weer goed! Bijzonder 
hoe wij altijd overal een feestje van maken en genieten. Lianne en Germano, dank 
voor jullie interesse, de top avonden en de mooie gesprekken van de afgelopen jaren. 
Lieve meiden uit Maastricht, Linda, Marlien, Renée, Veerle, Gerdien en Sanne, 
bedankt voor alle gezelligheid, etentjes en borrels! Ik zit vol goede voornemens om die 
voort te zetten. ;-) Anne, collega, vriendin en sportmaatje, bedankt voor je luisterend 
oor en alle leuke momenten samen. Succes met je eigen onderzoeksavontuur. Else, 
dank voor je wijze raad en gezelligheid tijdens de avonden waarbij we samen met 
Anne de wereld redden! Nijmeegse vrienden, Emmi, Lindy en de andere ‘chica’s van 
het goede leven’, dank voor alle topavonden tijdens het laatste deel van het onderzoek. 
En mij meeslepen naar die tennislessen was een top idee!   
Lieve Paul en Frank, jullie zijn de beste broertjes! Wij zijn er voor elkaar en dat vind ik 
heel bijzonder. Dank voor jullie interesse, nuchterheid en natuurlijk de gezelligheid, samen 
met Chantal. Lieve pap en mam, Jan Gerard en Ina, ik ben jullie ontzettend dankbaar 
voor jullie liefde, steun en vertrouwen. Het is fijn om te merken hoe jullie er onvoorwaardelijk 
voor mij zijn. Een beter thuis kan ik me niet indenken!
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